TOHOKU UNIVERSITY Researchers

Details of the Researcher

Home

日本語 English

Noriko Fukuhara

Section

Graduate School of Medicine

Job title

Associate Professor

Degree

博士（医学）（東北大学）

researchmap

https://researchmap.jp/7000006876

J-GLOBAL ID

201401083723738971

Education 2

Tohoku University　Graduate School, Division of Medical Sciences

- 2008/09
Tohoku University　Faculty of Medicine

- 1999/03/31

Professional Memberships 12

日本腫瘍循環器学会
日本癌治療学会
日本人類遺伝学会
日本輸血・細胞治療学会
日本造血・免疫細胞療法学会
日本癌学会
日本リンパ腫学会
米国血液学会
日本臨床腫瘍学会
米国臨床腫瘍学会
日本血液学会
日本内科学会

︎Show all ︎Show first 5

Research Areas 1

Life sciences / Hematology and oncology /

Papers 252

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL).

Koji Izutsu, Noriko Fukuhara

International journal of hematology　121　(5)　577-585　2025/05

DOI： 10.1007/s12185-025-03922-4 　
High FCGR2B Expression Can Identify Low-tumor-burden Follicular Lymphoma Patients Who Do Not Require Any Antilymphoma Therapy for a Long Term. International-journal

Shotaro Watanabe, Hiroki Kato, Tohru Fujiwara, Shunsuke Hatta, Yasuo Tomiya, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Hisayuki Yokoyama, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae, Noriko Fukuhara

The American journal of surgical pathology　2025/04/07

DOI： 10.1097/PAS.0000000000002397 　

More details Close

Spontaneous regression or a long-term lack of obvious progression is often observed in patients with low-tumor-burden (LTB) follicular lymphoma (FL). However, conventional prognostic risk models are unable to precisely identify the patients who will not require any antilymphoma treatment for a long term, especially at diagnosis. In this study, we identified genes whose expression levels were associated with the clinical outcome of LTB FL and verified their prognostic value using immunohistochemistry. Because the tumor microenvironment may influence FL pathogenesis, we used digital expression profiling to quantify the expression of 730 immune-related genes extracted from tumor tissue specimens collected from 55 untreated patients with LTB FL. Five genes were identified as potential transcriptomic predictive markers. Among these, FCGR2B, an inhibitory FC gamma receptor, was immunohistochemically stainable and identified as a reliable immunohistochemical prognostic marker mainly expressed in tumor cells but not in the surrounding reactive cells. Our findings could help identify patients with LTB FL who do not require any antilymphoma treatment for the long term.
Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. International-journal

Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata, Yasuo Ejima, Dai Maruyama, Nobuko Kubota, Takeshi Maeda, Jun Takizawa, Nobuhiro Hiramoto, Masahiro Takeuchi, Rika Sakai, Noriko Fukuhara, Senzo Taguchi, Naoko Asano, Motoko Yamaguchi, Ritsuro Suzuki

Leukemia　39　(4)　909-916　2025/04

DOI： 10.1038/s41375-025-02527-4 　

More details Close

A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19-90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014-2017 vs. 50.7% for 2018-2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.
Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study. International-journal

Yuma Nato, Kana Miyazaki, Dai Maruyama, Hiroyuki Takahashi, Kazutaka Sunami, Satsuki Murakami, Eiju Negoro, Yuri Miyazawa, Ilseung Choi, Takahiro Okada, Nobuyuki Takayama, Naoto Tomita, Shuji Momose, Yuto Kaneda, Masahiro Yoshida, Hiroshi Gomyo, Kohtaro Toyama, Momoko Nishikori, Akio Saito, Junji Hiraga, Taro Masunari, Naoki Takahashi, Junya Makiyama, Tomotaka Suzuki, Hiroko Tsunemine, Jun Takizawa, Takeharu Kato, Yasufumi Masaki, Noriko Fukuhara, Masataka Okamoto, Isao Tawara, Naoko Asano, Koichi Ohshima, Koji Izutsu, Koji Kato, Ritsuro Suzuki, Motoko Yamaguchi

Hematological oncology　43　(2)　e70047　2025/03

DOI： 10.1002/hon.70047 　

More details Close

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and high-dose methotrexate (HD-MTX) (DA-EPOCH-R/HD-MTX) showed excellent efficacy and manageable safety in a phase II study of patients diagnosed with stage II-IV CD5+ DLBCL. To validate the results of that study and elucidate the current state of treatment for CD5+ DLBCL, we retrospectively analyzed the outcomes of patients with CD5+ DLBCL diagnosed between 2016 and 2021 who received anthracycline-containing chemotherapy with rituximab. Among the 346 patients evaluated, 62 (18%) received DA-EPOCH-R/HD-MTX. The median follow-up time was 43 months. In 55 patients with stage II-IV disease treated with DA-EPOCH-R/HD-MTX, the 2-year overall survival (OS), progression-free survival, and cumulative incidence of CNS relapse were 87% (95% CI, 73%-94%), 76% (95% CI, 61%-86%), and 7.3% (95% CI, 2.4%-16%), respectively. There were no treatment-related deaths. Febrile neutropenia occurred in 18 (33%) patients. Multivariate analysis of the 346 patients identified elevated serum lactate dehydrogenase levels, multiple extranodal involvement, no intrathecal MTX (IT-MTX), and no DA-EPOCH-R/HD-MTX as independent risk factors for OS. Only one CNS relapse event was observed in 28 patients who received both HD-MTX and IT-MTX. Our study provides real-world data on the treatments and outcomes of a large number of patients. The favorable survival and manageable toxicity of DA-EPOCH-R/HD-MTX have been validated in clinical settings. The use of HD-MTX and IT-MTX might be effective for preventing CNS relapse in patients with CD5+ DLBCL.
Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study) International-journal

Tsutomu Kobayashi, Kenichi Ishizawa, Ryunosuke Machida, Ryo Sadachi, Keita Sasaki, Haryoon Kim, Keisuke Kataoka, Wataru Munakata, Noriko Fukuhara, Hirokazu Nagai

Japanese Journal of Clinical Oncology　2025/02/25
Publisher: Oxford University Press (OUP)
DOI： 10.1093/jjco/hyaf038 　

eISSN： 1465-3621

More details Close

Abstract Maintenance therapy with monoclonal anti-CD20 antibody is the standard approach in patients with follicular lymphoma who initially treated and achieved response to immunochemotherapy. Maintenance therapy reduces the risk of lymphoma progression, but the risk of late or delayed fatal treatment-emergent adverse events is a clinically important issue. The aim of this randomized phase III study is to confirm the non-inferiority of observation compared to obinutuzumab maintenance therapy in patients with untreated high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy (JCOG2008, MAIN study). The first registration is performed before obinutuzumab plus bendamustine administration. Those who achieved complete metabolic response at the end of induction are included in the second registration and randomized to an obinutuzumab maintenance arm or observation only. This study has been registered in the Japan Registry for Clinical Trials as jRCT1031210379.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. International-journal

Kazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Akinao Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Akiko Meguro, Yoshihiro Kin, Yosuke Minami, Daigo Hashimoto, Takahiro Nishiyama, Satoko Shimada, Yasufumi Masaki, Masataka Okamoto, Yoshiko Atsuta, Hitoshi Kiyoi, Ritsuro Suzuki, Shigeo Nakamura, Tomohiro Kinoshita

EClinicalMedicine　80　103078-103078　2025/02

DOI： 10.1016/j.eclinm.2025.103078 　

More details Close

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi). METHODS: We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165). FINDINGS: With a median follow-up of 7.1 years (interquartile range 5.6-8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%-80%) and OS was 78% (95% CI 61%-89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1). INTERPRETATION: Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients. FUNDING: This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). International-journal

Masaki Ri, Shinsuke Iida, Kosuke Saito, Yoshiro Saito, Dai Maruyama, Arisa Asano, Suguru Fukuhara, Hideki Tsujimura, Kana Miyazaki, Shuichi Ota, Noriko Fukuhara, Eiju Negoro, Junya Kuroda, Shinichiro Yoshida, Eiichi Ohtsuka, Tsukamoto Norifumi, Takayuki Tabayashi, Nobuyuki Takayama, Toko Saito, Yasuhiro Suzuki, Yasuhiko Harada, Ishikazu Mizuno, Isao Yoshida, Masaki Maruta, Yasushi Takamatsu, Hiroo Katsuya, Makoto Yoshimitsu, Yosuke Minami, Keisuke Kanato, Wataru Munakata, Hirokazu Nagai

Cancer chemotherapy and pharmacology　95　(1)　29-29　2025/01/24

DOI： 10.1007/s00280-025-04752-1 　

More details Close

PURPOSE: A comprehensive analysis of metabolites (metabolomics) has been proposed as a new strategy for analyzing liquid biopsies and has been applied to identify biomarkers predicting clinical responses or adverse events associated with specific treatments. Here, we aimed to identify metabolites associated with bortezomib (Btz)-related toxicities and response to treatment in newly diagnosed multiple myeloma (MM). METHODS: Fifty-four plasma samples from transplant-ineligible MM patients enrolled in a randomized phase II study comparing two less-intensive regimens of melphalan, prednisolone and Btz (MPB) were subjected to the lipidomic profiling analysis. The amount of each lipid metabolite in plasma obtained prior to MPB therapy was compared to toxicity grades and responses to MPB therapy. RESULTS: High levels of 7 phospholipids (4 lysophosphatidylcholines and 3 phosphatidylcholines) were observed in cases with Btz-induced ≥ grade 2 peripheral neuropathy (BiPN) (n = 11). In addition, low levels of 3 fatty acids (FAs)-FA (18:2), FA (18:1), and FA (22:6)-were observed in patients who developed severe skin disorders ≥ grade 2 (n = 10). No metabolite significantly associated with treatment response was identified. CONCLUSION: We conclude that levels of specific plasma lipid metabolites are associated with the severity of BiPN and skin disorders in patients with MM. These metabolites may serve as candidate biomarkers to predict Btz-induced toxicity in patients with MM before initiating Btz-containing therapy.
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. International-journal

Wataru Munakata, Takahiro Kumode, Hideki Goto, Noriko Fukuhara, Tatsu Shimoyama, Masahiro Takeuchi, Toshiro Kawakita, Kohmei Kubo, Masashi Sawa, Toshiki Uchida, Yuko Mishima, Michiko Ichii, Miyoko Hanaya, Asuka Matsumoto, Masaaki Kuriki, Toshihiro Seike, Koji Izutsu, Kenichi Ishizawa

British journal of haematology　206　(2)　541-550　2025/01/08

DOI： 10.1111/bjh.19994 　

More details Close

Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity. Objective and complete response rates were 75.4% (95% confidence interval [CI], 62.7%-85.5%) and 24.6% (95% CI, 14.5%-37.3%) respectively. Median time to response was 58 days; 70.5% (43/61) of patients achieved their first response by Week 8. At least one Grade ≥ 3 treatment-emergent adverse event (TEAE) occurred in 55.7% of patients: transaminase elevation (8.2%); cutaneous reactions (3.3%); and diarrhoea, enterocolitis and lung infection (1.6% each), defined as adverse events of special interest. The discontinuation rate due to any TEAE was 14.8%. No zandelisib-related death occurred. Zandelisib showed favourable efficacy and tolerability in Japanese patients with relapsed or refractory indolent non-Hodgkin B-cell lymphoma. This unique dosing schedule may maintain efficacy while mitigating the safety issues observed with other PI3Kδ inhibitors (ClinicalTrials.gov number, NCT04533581).
Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation. International-journal

Ryuta Kubo, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hideo Harigae

Annals of hematology　104　(1)　841-845　2025/01

DOI： 10.1007/s00277-024-06150-8 　

More details Close

Follicular lymphoma (FL) may undergo histological transformation (HT) into a more aggressive lymphoma. Although rituximab for B-cell non-Hodgkin lymphomas (B-NHL) has greatly improved the overall survival (OS) of patients with transformed FL (tFL), relapse after anthracycline-based chemoimmunotherapy has a poor prognosis. CD19-targeting chimeric antigen receptor-modified T-cell (CAR-T) therapy is a promising treatment for relapsed or refractory (r/r) large B-cell lymphoma (LBCL), including tFL. However, lymphopenia and reduced T-cell fitness caused by bendamustine exposure for treatment of underlying FL may impair the feasibility and reduce the efficacy of CAR-T therapy. Herein, we report the case of a 44-year-old woman with tFL who relapsed following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and received CAR-T therapy. The patient could not initially undergo CAR-T therapy due to lymphopenia caused by bendamustine exposure, but CAR-T therapy became feasible following allo-HSCT. Although CAR-T therapy using T cells harvested from an allo-HSCT recipient may theoretically cause alloreactivity, the patient did not experience graft versus host disease (GVHD) or serious complications specific to CAR-T therapy, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and she has remained in complete response (CR) for >18 months. CAR-T therapy following allo-HSCT for patients with r/r tFL may be a safe and effective treatment option. Allo-HSCT may enhance the efficacy of CAR-T therapy.
Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration. International-journal

Satoshi Ichikawa, Hiroki Kato, Naoya Morota, Hiroaki Abe, Akihisa Kawajiri, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Satoko Sato, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　104　(1)　835-840　2024/12/18

DOI： 10.1007/s00277-024-06148-2 　

More details Close

Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for several years because of asymptomatic pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) was admitted to our hospital because of poor general condition and hypotension. Blood tests revealed thrombocytopenia and elevated serum lactate dehydrogenase levels, whereas computed tomography revealed systemic lymphadenopathy and splenomegaly. An inguinal lymph node biopsy precipitated a diagnosis of angioimmunoblastic T-cell lymphoma (AITL). Shortly after admission, the patient experienced spontaneous intestinal perforation and hemorrhage caused by multiple intestinal infiltrations of the AITL. Although chemotherapy was administered, the patient died several weeks after admission. A 46,XY,t(8;14)(q24;q11.2) karyotype was identified, and fluorescence in situ hybridization analyses showed split signals for the MYC and T-cell receptor (TCR) alpha genes, by which a TCR::MYC translocation was confirmed. Pathological autopsy analysis revealed systemic infiltration of the AITL and no MALToma lesions. Only a few cases of mature T-cell lymphoma harboring MYC-R have been reported in the literature thus far. To the best of our knowledge, this is the first reported case of AITL with TCR::MYC rearrangement. This condition could be associated with refractoriness to chemotherapy and aggressive clinical course with systemic infiltration that included the intestine.
Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.

Satoshi Ichikawa, Hiroaki Abe, Hiroka Komatsu, Kenta Takenaka, Hiroshi Nakamura, Naoya Morota, Kazuki Sakurai, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

Internal medicine (Tokyo, Japan)　64　(8)　1235-1239　2024/09/27

DOI： 10.2169/internalmedicine.4221-24 　

More details Close

A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3+, CD7+, CD33+, CD34dim, CD56+/-, HLA-DR+, cyMPO+, and TdT- immunophenotypes. Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism. He had been in good health without relapse for over nine months since transplantation. Timely allogeneic hematopoietic stem cell transplantation using an available donor source may be a promising treatment strategy for MNKPL.
Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma.

Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, Yoshiko Tamai, Yoshihiro Kameoka, Naoto Takahashi, Yasuro Miyairi, Kazunori Murai, Kenji Shimosegawa, Kozue Yoshida, Kyoko Inokura, Noriko Fukuhara, Hideo Harigae, Ryo Sato, Kenichi Ishizawa, Katsushi Tajima, Souichi Saitou, Masahiko Fukatsu, Takayuki Ikezoe, Saburo Tsunoda, Masayuki Mita, Jinichi Mori, Shugo Kowata, Shigeki Ito

Journal of clinical and experimental hematopathology : JCEH　64　(3)　191-202　2024/07/31

DOI： 10.3960/jslrt.24021 　

More details Close

Immune checkpoint inhibitors (ICI) are promising therapeutic agents for relapsed or refractory classical Hodgkin's lymphoma (RRcHL). This retrospective study evaluated patients with RRcHL registered in the clinical research program Tohoku-Hematology-Forum-26, between 2016 and 2020, and treated with ICI in 14 centers in Northeast Japan. We analyzed the usage, efficacy, and safety of ICI therapy (ICIT). Among a total of 27 patients with RRcHL, 21 and nine were treated with nivolumab and/or pembrolizumab, respectively. The best response was complete response (CR), partial response (PR), stable disease (SD), and progressive disease in 11 (40.8%), seven (25.9%), eight (29.6%), and one (3.7%) patient, respectively. In all patients undergoing ICIT, the 2-year progression-free survival and 2-year overall survival (OS) were 48.6% and 87.4%, respectively. The 2-year OS for patients with CR, PR, and SD were 100%, 68.6%, and 87.5%, respectively. A total of 36 events of immune-related adverse events (irAEs) or immune-related like adverse events (irlAEs) were observed in 19 of the 27 patients (70.4%). Two thirds of these irAEs or irlAEs were grade 1-2 and controllable. During the observation period, ICIT was discontinued in 22 of 27 (81.4%) patients due to CR, inadequate response, irAE and patient circumstances in five (22.7%), seven (31.8%), eight (36.4%) and two patients (9.1%), respectively. Therapy-related mortality-associated irAE were observed in only one patient during ICIT. These results suggest that ICIT for RRcHL is effective and safe in real-world settings. The optimal timing of induction and duration of ICIT remains to be established.
Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305) International-journal

Shigeru Kusumoto, Wataru Munakata, Ryunosuke Machida, Takashi Terauchi, Hiroaki Onaya, Masahiko Oguchi, Shinsuke Iida, Kisato Nosaka, Yasuhiro Suzuki, Yasuhiko Harada, Kana Miyazaki, Masaki Maruta, Noriko Fukuhara, Tomomi Toubai, Nobuko Kubota, Ken Ohmachi, Toko Saito, Shinya Rai, Ishikazu Mizuno, Suguru Fukuhara, Mai Takeuchi, Ukihide Tateishi, Dai Maruyama, Kunihiro Tsukasaki, Hirokazu Nagai

Cancer Science　115　(10)　3384-3393　2024/07/22
Publisher: Wiley
DOI： 10.1111/cas.16281 　

ISSN： 1347-9032

eISSN： 1349-7006

More details Close

Abstract This single‐arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)‐guided therapy for newly diagnosed advanced‐stage classic Hodgkin lymphoma (cHL). Patients aged 16–60 years with cHL received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and then underwent an iPET scan (PET2), which was centrally reviewed using a five‐point Deauville scale. PET2‐negative patients continued an additional four cycles of ABVD, whereas PET2‐positive patients switched to six cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). The co‐primary endpoints were 2‐year progression‐free survival (PFS) among all eligible and PET2‐positive patients. Ninety‐three patients were enrolled between January 2016 and December 2019. One patient was ineligible because of a diagnostic error. The median age of the 92 eligible patients was 35 (interquartile range, 28–48) years. Forty (43%) patients had stage III disease, and 43 (47%) had stage IV disease. The remaining nine (10%) patients had stage IIB disease with risk factors. Nineteen PET2‐positive (21%) patients received eBEACOPP, 18 completed six cycles of eBEACOPP, 73 PET2‐negative (79%) patients continued ABVD, and 70 completed an additional four cycles of ABVD. With a median follow‐up period of 41.1 months, the 2‐year PFS of 92 eligible patients and 19 PET2‐positive patients were 84.8% (80% confidence interval [CI], 79.2–88.9) and 84.2% (80% CI, 69.7–92.1), respectively. Both primary endpoints were met at the prespecified threshold. This study demonstrates that iPET‐guided therapy is a useful treatment option for younger patients with newly diagnosed advanced‐stage cHL. Registration number: jRCTs031180218.
Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan.

Motoko Yamaguchi, Noriko Fukuhara, Jun Takizawa, Kenji Ishitsuka, Akihiko Yokohama, Kana Miyazaki, Yuma Nato, Satoshi Ichikawa, Masaki Mitobe, Kodai Shima, Yuri Miyazawa, Koji Izutsu, Ritsuro Suzuki, Hirokazu Nagai, Naoya Nakamura

Journal of clinical and experimental hematopathology : JCEH　64　(3)　216-222　2024/07/02

DOI： 10.3960/jslrt.24028 　

More details Close

Alemtuzumab is recommended as first-line and second-line therapies for T-cell prolymphocytic leukemia (T-PLL). This study retrospectively evaluated the efficacy and safety of alemtuzumab in nine Japanese patients with T-PLL at five participating institutions who were treated between January 2015 and August 2023. The median age at first administration of alemtuzumab was 72 years (range, 39 to 78). Two patients were treatment naïve, and seven had been treated with a median of one (range, 1 to 3) prior systemic therapy. Six patients were refractory to their most recent therapy. Three patients completed 12 weeks of treatment. The overall response rate and the complete response (CR) rate were 78% and 11%, respectively. Among the six patients who achieved a partial response, two achieved clinical CR but did not undergo bone marrow examination. One patient also achieved clinical CR but did not undergo CT or bone marrow examination for response evaluation. The median progression-free survival time was 8.1 months (95% confidence interval, 0.9 to 18.6). Three patients received readministration of alemtuzumab monotherapy after disease progression. There were no treatment-related deaths. The grade 3 or 4 nonhematologic adverse events included infusion reaction (grade 3, n = 2), cytomegalovirus reactivation (grade 3, n = 2), and pulmonary edema (grade 3, n = 1). One patient experienced Epstein‒Barr virus-positive diffuse large B-cell lymphoma 15 months after the last dose of alemtuzumab. These results confirm that the efficacy and safety of alemtuzumab monotherapy in Japanese patients are comparable to those previously reported.
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. International-journal

Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara, Nicolas Daguindau, René-Olivier Casasnovas, Sylvia Snauwaert, Remy Gressin, Christopher P Fox, Francesco Annibale d'Amore, Philipp B Staber, Olivier Tournilhac, Krimo Bouabdallah, Catherine Thieblemont, Marc André, Shinya Rai, Daisuke Ennishi, Argyrios Gkasiamis, Mitsufumi Nishio, Luc-Matthieu Fornecker, Marie-Helene Delfau-Larue, Nouhoum Sako, Sebastien Mule, Laurence de Leval, Philippe Gaulard, Kunihiro Tsukasaki, François Lemonnier

The Lancet. Haematology　11　(6)　e406-e414　2024/06

DOI： 10.1016/S2352-3026(24)00102-9 　

More details Close

BACKGROUND: Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with relapsed or refractory TFHL. METHODS: Patients older than 18 years with relapsed or refractory TFHL (angioimmunoblastic T-cell lymphoma, follicular lymphoma, or nodal T-cell lymphoma with phenotype, ie, positive with two or more markers among CD10, BCL6, CXCL13, PD1, or ICOS) based on the 2017 WHO classification of haematological neoplasms, with an Eastern Cooperative Oncology Group performance status score of 0-3, were recruited in university hospitals from five European countries and from Japan. Patients were randomly assigned 1:1 to treatment with either azacitidine given at a dose of 300 mg once a day (200 mg in Japanese patients) for 14 days in a 28-day cycle or gemcitabine, bendamustine, or romidepsin according to the investigator's choice. Random assignment was stratified by the number of previous lines of therapy and by the presence of previous or concomitant myeloid malignancy. The primary endpoint was investigator-assessed progression-free survival, presented in the intention-to-treat population. This Article is the final analysis of this trial, registered at ClinicalTrials.gov (Europe NCT03593018 and Japan NCT03703375). FINDINGS: 86 patients (median age 69 years [IQR 62-76], 50 patients were male, 36 were female) were enrolled between Nov 9, 2018, to Feb 22, 2021; 42 in the azacitidine group and 44 in the ICT group. With a median follow-up of 27·4 months (IQR 20·2-32·9), the median progression-free survival was 5·6 months (95% CI 2·7 -8·1) in the azacitidine group versus 2·8 months (1·9-4·8) in the ICT group (hazard ratio of 0·63 (95% CI 0·38-1·07); 1-sided p=0·042). Grade 3-4 adverse events were reported in 32 (76%) of 42 patients in the azacitidine group versus 42 (98%) of 43 patients in the ICT group. The most adverse grade 3 or worse adverse events were haematological (28 [67%] of 42 patients vs 40 [93%] of 43 patients), infection (8 [19%] and 14 [33%]), and gastrointestinal (5 [12%] vs 1 [2%] for azacitidine and ICT, respectively). There were two treatment-related deaths in the azacitidine group (one endocarditis and one candidiasis) and three in the ICT group (one heart failure, one COVID-19, and one cause unknown). INTERPRETATION: Although the pre-specified primary outcome of the trial was not met, the favourable safety profile suggests that azacitidine could add to the treatment options in these difficult to treat diseases especially in combination with other drugs. Trials with combination are in preparation in a platform trial. FUNDING: Bristol-Myers Squibb. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
T細胞前リンパ球性白血病(T-PLL)に対するアレムツズマブ日本リンパ網内系学会診療保険委員会による国内使用実態調査(ATP study)

山口素子, 宮崎香奈, 名藤佑真, 市川聡, 福原規子, 鈴木隆晴, 瀧澤淳, 島晃大, 石塚賢治, 宮澤悠里, 横濱章彦, 伊豆津宏二, 鈴木律朗, 永井宏和, 中村直哉

日本リンパ網内系学会会誌　64　91-91　2024/05
Publisher: (一社)日本リンパ腫学会
ISSN： 1342-9248

eISSN： 1883-681X
Diffuse large B-cell lymphoma of the skull vault.

Satoshi Ichikawa, Hisayuki Yokoyama, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　119　(3)　215-216　2024/03

DOI： 10.1007/s12185-024-03717-z 　
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Shinichi Makita, Shuichi Ota, Yuko Mishima, Kensuke Usuki, Daisuke Ennishi, Masamitsu Yanada, Noriko Fukuhara, Ryusuke Yamamoto, Atsushi Takamine, Go Nohara, Koji Izutsu

International journal of hematology　119　(2)　156-163　2024/02

DOI： 10.1007/s12185-023-03689-6 　

More details Close

This phase Ib, open-label, single-arm, multicenter study assessed the efficacy and safety of duvelisib, an oral dual inhibitor of phosphatidylinositol 3-kinase-δ and -γ, in Japanese patients with relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Duvelisib was administered orally at 25 mg twice a day (BID) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) and all responses were assessed by an independent review committee. Nine CLL patients and 1 SLL patient were enrolled. ORR was 80% (95% confidence interval 44.4, 97.5) for all 10 patients. All 6 patients previously treated with a Bruton's tyrosine kinase (BTK) or BCL2 inhibitor achieved a partial response. The most common adverse events were neutropenia (50%), diarrhea (40%), anemia, hypokalemia, constipation and rash (30% each). The most common grade ≥ 3 adverse events were neutropenia (50%), anemia (30%) and thrombocytopenia (20%). Duvelisib 25 mg BID showed favorable efficacy and a manageable safety profile in selected Japanese patients with r/r CLL/SLL, including patients previously treated with BTK or BCL2 inhibitors (Clinical trial registration: jRCTs2080224791).
Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T/NK-cell Lymphoma

Satoshi Ichikawa, Hiroaki Abe, Naoya Morota, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Shunsuke Hatta, Yuna Katsuoka, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Internal Medicine　2024
Publisher: Japanese Society of Internal Medicine
DOI： 10.2169/internalmedicine.4672-24 　

ISSN： 0918-2918

eISSN： 1349-7235

More details Close

Nodal Epstein-Barr virus-positive T/NK-cell lymphoma (EB-nTNKL) is an extremely rare disease characterized by an aggressive clinical course and poor prognosis, for which treatment strategies have not yet been established. We herein report a young man with EB-nTNKL. Although initial chemotherapies, including L-asparaginase, failed to produce a good response, subsequent myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT) resulted in favorable disease control and a long-term disease-free survival. The prompt performance of alloHSCT using an available donor source at that time, regardless of whether or not the initial chemotherapy was effective, could be critical to saving patients with this otherwise fatal disease.
[Multiple myeloma with IgH::MYC and multiple extramedullary lesions].

Yuto Sasaki, Satoshi Ichikawa, Kazuki Sakurai, Hiroshi Nakamura, Kyoko Inokura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

[Rinsho ketsueki] The Japanese journal of clinical hematology　65　(3)　147-152　2024

DOI： 10.11406/rinketsu.65.147 　

ISSN： 0485-1439

More details Close

A 41-year-old woman with right shoulder pain was found to have multiple tumors with osteolysis and M-proteinemia. Abnormal plasma cells (CD38+, CD138+, Igλ≫κ) were detected in 1.4% of bone marrow nucleated cells, and G-banding analysis revealed a 46,XX,t (8;14), (q24;q32) karyotype in 4 of 20 cells analyzed. A biopsy specimen from an extramedullary lesion had a packed proliferation of aberrant plasmacytoid cells with positive IgH::MYC fusion signals on fluorescence in situ hybridization. The patient was diagnosed with symptomatic multiple myeloma and treated with the BLd regimen, which significantly reduced M protein levels. Extramedullary lesions were initially reduced, but increased again after four cycles. The lesions disappeared with subsequent EPOCH chemotherapy and radiation, and complete remission was confirmed. The patient was then treated with high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Complete remission was maintained for over one year with lenalidomide maintenance therapy. A solitary IgH::MYC chromosomal translocation is extremely rare in multiple myeloma and may be associated with high tumor proliferative capacity, multiple extramedullary lesions, and poor prognosis. Combined therapeutic modalities with novel and conventional chemotherapy and radiation might be a promising treatment strategy for patients with this type of multiple myeloma.
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. International-journal

Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa

Neuro-oncology advances　6　(1)　vdae037　2024

DOI： 10.1093/noajnl/vdae037 　

More details Close

BACKGROUND: The ONO-4059-02 phase 1/2 study showed favorable efficacy and acceptable safety profile of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, for relapsed/refractory primary central nervous system lymphoma (PCNSL). Here, we report the long-term efficacy and safety after a 3-year follow-up. METHODS: Eligible patients were aged ≥ 20 years with histologically diagnosed PCNSL and KPS of ≥ 70. Patients received oral tirabrutinib once daily at 320 or 480 mg, or 480 mg under fasted conditions. RESULTS: Between October 19, 2017, and June 13, 2019, 44 patients were enrolled: 33 and 9 had relapsed and refractory, respectively. The 320, 480, and 480 mg fasted groups included 20, 7, and 17 patients, respectively. The median follow-up was 37.1 months. The overall response rate was 63.6% (95% CI: 47.8-77.6) with complete response (CR), unconfirmed CR, and partial response in 9, 7, and 12 patients, respectively. The median duration of response (DOR) was 9.2 months, with a DOR rate of 19.8%; the median progression-free survival (PFS) and median overall survival (OS) were 2.9 months and not reached, respectively, with PFS and OS rates of 13.9% and 56.7%, respectively. Adverse events occurred in 38 patients (86.4%): grade ≥ 3 in 23 (52.3%) including 1 patient with grade 5 events. KPS and quality of life (QoL) scores were well maintained among patients receiving long-term treatment. CONCLUSIONS: The results demonstrated the long-term clinical benefit of tirabrutinib, with deep and durable response in a subset of patients and acceptable safety profile, while KPS and QoL scores were maintained.
Plasma Venetoclax Concentrations in Patients with Acute Myeloid Leukemia Treated with CYP3A4 Inhibitors.

Ayaka Otsuki, Masaki Kumondai, Daisuke Kobayashi, Masafumi Kikuchi, Yugo Ueki, Yuji Sato, Nagomi Hayashi, Ayaka Yagi, Yasushi Onishi, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Masamitsu Maekawa, Nariyasu Mano

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan　144　(7)　775-779　2024

DOI： 10.1248/yakushi.24-00018 　

ISSN： 1347-5231

More details Close

Venetoclax (VEN) is used in patients with acute myeloid leukemia (AML) and is primarily metabolized by CYP3A4, a major drug-metabolizing enzyme. Patients with AML simultaneously administered VEN and CYP3A4 inhibitors require a more appropriate management of drug-drug interactions (DDIs). Here, we report two cases of patients with AML (54-year-old man and 22-year-old woman) administrated VEN and CYP3A4 inhibitors, such as posaconazole, cyclosporine, or danazol. In the first case, we evaluated the appropriateness of timing for adjusting VEN dosage subsequent to the cessation of posaconazole. Consequently, modifying the VEN dosage in conjunction with the cessation of Posaconazole simultaneously may result in elevated plasma VEN levels. In the second case, plasma VEN concentrations were markedly elevated when co-administered with several CYP3A4 inhibitors. Additionally, in vitro assays were conducted for reverse translational studies to analyze CYP3A4 inhibition. CYP3A4 inhibition by combinatorial administration of cyclosporine A and danazol was demonstrated in vitro, which potentially explains the increasing plasma VEN concentrations observed in clinical settings. Although the acquisition of therapeutic effects is a major priority for patients, frequent therapeutic drug monitoring and dosage adjustments considering DDIs would be important factors in chemotherapy.
Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine. International-journal

Jun Nomura, Masafumi Seki, Syori Abe, Tadahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Shinichiro Takahashi, Hideo Harigae, Junichi Kameoka

Human vaccines & immunotherapeutics　19　(1)　2165381-2165381　2023/12/31

DOI： 10.1080/21645515.2023.2165381 　

More details Close

Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine 'BNT162b2 Pfizer-BioNTech.' The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 'Pfizer-BioNTech.'
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Hideki Goto, Satoshi Ito, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara, Koji Kato, Toko Saito, Yasuhito Terui, Sumiko Okubo, Tomomi Soshin, Jiewei Zeng, Hideyuki Honda, Mohamed Badawi, Jeremy A Ross, Koji Izutsu

International journal of clinical oncology　29　(2)　232-240　2023/12/29

DOI： 10.1007/s10147-023-02443-6 　

More details Close

BACKGROUND: Despite high response rates to initial therapy, most patients with mantle cell lymphoma (MCL) experience relapsed or refractory (R/R) disease. Here, we report the efficacy, safety, and pharmacokinetics of the Phase 2, single-arm M20-075 study (NCT04477486) of ibrutinib and venetoclax combination therapy in Japanese patients with R/R MCL. METHODS: Patients received 560 mg ibrutinib and 400 mg venetoclax (after a 5-week ramp-up from 20 mg) once daily for up to 104 weeks. Primary endpoint was complete response (CR) rate by independent review committee (IRC). Secondary endpoints included overall response rate (ORR), duration of response (DOR), undetectable minimal residual disease (uMRD) rate, progression-free survival (PFS), overall survival (OS), safety including dose-limiting toxicity (DLT) assessment in the first six patients, and pharmacokinetic parameters. Full analysis set (FAS) comprised all treated patients. Per protocol set (PPS) excluded treated patients with non-evaluable disease at baseline by IRC. RESULTS: Thirteen patients were treated (FAS n = 13; PPS, n = 12). Median age was 71 years, patients had a median of two prior treatments. After a median follow-up of 9.6 months, IRC-assessed CR rate and ORR were both 83% (PPS). All six MRD-evaluable patients had uMRD. Median DOR, PFS, and OS were unreached. The most common Grade ≥ 3 treatment-emergent adverse event (TEAE) was neutropenia (23%); 1 patient discontinued due to squamous cell carcinoma of the lung. No DLTs, tumor lysis syndrome, or deaths related to TEAEs were observed. CONCLUSION: Ibrutinib plus venetoclax exhibited high response rates and a well-tolerated safety profile in Japanese patients with R/R MCL.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. International-journal

Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara

Cancer science　114　(12)　4643-4653　2023/12

DOI： 10.1111/cas.15996 　

More details Close

Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Ab that showed deep, durable responses with a manageable safety profile in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the global multicenter pivotal phase II trial EPCORE NHL-1. Here, we present results from the similar EPCORE NHL-3 phase I/II trial evaluating epcoritamab monotherapy in Japanese patients with R/R CD20+ B-cell non-Hodgkin's lymphoma previously treated with two or more lines of therapy. Epcoritamab was dosed subcutaneously in 28-day cycles; once weekly during cycles 1-3, every 2 weeks during cycles 4-9, and every 4 weeks from cycle 10 until disease progression or unacceptable toxicity. Step-up dosing and cytokine release syndrome (CRS) prophylaxis were used during treatment cycle 1. As of January 31, 2022, 36 patients received treatment with 48 mg epcoritamab monotherapy. At a median follow-up of 8.4 months, overall response and complete response rates by independent review committee were 55.6% and 44.4%, respectively. The median duration of response, duration of complete response, and overall survival were not reached at the time of data cut-off. The most common treatment-emergent adverse events of any grade were CRS (83.3%), injection-site reactions (69.4%), infections (44.4%), neutropenia (38.9%), hypokalemia (27.8%), and decreased lymphocyte count (25.0%). Cytokine release syndrome occurrence was predictable; events were primarily low grade (grade 1-2), all resolved, and none led to treatment discontinuation. These encouraging results are consistent with previous findings and support the ongoing clinical evaluation of epcoritamab for the treatment of R/R DLBCL, including in earlier treatment lines.
悪性リンパ腫へのtisagenlecleucelの治療効果に関するPET/CTで評価されたMTHとDmaxのインパクト

後藤秀樹, 北脇年雄, 加藤光次, 藤井伸治, 大西康, 福原規子, 山内拓司, 虎谷和則, 下茂雅俊, 小林宏紀, 小野寺晃一, 吉田匠汰, 千丈創, 小野澤真弘, 平田健司, 横田勲, 豊嶋崇徳

日本血液学会学術集会　85回　1193-1193　2023/10
Publisher: (一社)日本血液学会
再発難治性低悪性度B細胞性非ホジキンリンパ腫を対象としたザンデリシブの第2相臨床試験

後藤秀樹, 棟方理, 口分田貴裕, 福原規子, 下山達, 武内正博, 河北敏郎, 久保恒明, 澤正史, 内田俊樹, 三嶋裕子, 一井倫子, 花屋美代子, 松本明日香, 栗城正朗, 伊豆津宏二, 石澤賢一

日本血液学会学術集会　85回　806-806　2023/10
Publisher: (一社)日本血液学会
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Sumiko Okubo, Natsumi Ogawa, Mizu Sakai, Yasuko Nishimura, Brenda Chyla, Yan Sun, Dai Maruyama

International journal of hematology　118　(4)　526-528　2023/10

DOI： 10.1007/s12185-023-03646-3 　
臍帯血移植後の深在性真菌感染症抗糸状菌活性を有する抗真菌薬の有効性

橋本和貴, 大西康, 福原規子, 横山寿行, 市川聡, 小野寺晃一, 猪倉恭子, 川尻昭寿, 中村嘉詞, 櫻井一貴, 諸田直哉, 久保龍大, 安倍宇明, 張替秀朗

日本血液学会学術集会　85回　72-72　2023/10
Publisher: (一社)日本血液学会
進行胃癌に対するニボルマブ投与後に発症した後天性血小板減少性紫斑病の一例

渡邉樹也, 小野寺晃一, 鳴海善洋, 橋本和貴, 内堀雄介, 小松弘香, 竹中健人, 中村嘉詞, 櫻井一貴, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　192-192　2023/10
Publisher: (一社)日本血液学会
同種移植前微小残存病変がNPM1変異陽性急性骨髄性白血病の移植予後に及ぼす影響

横山寿行, 鈴木千恵, 真山晃史, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 藤巻慎一, 張替秀郎

日本血液学会学術集会　85回　203-203　2023/10
Publisher: (一社)日本血液学会
当院における再発難治性の濾胞性リンパ腫に対するCAR-T療法の後方視的検討

内堀雄介, 福原規子, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　412-412　2023/10
Publisher: (一社)日本血液学会
正常造血及び白血病におけるヘム合成の役割

燕艶, 加藤浩貴, 佐野沙矢香, 古川瑛次郎, 藤原亨, 大西康, 福原規子, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　934-934　2023/10
Publisher: (一社)日本血液学会
AML with RNUX1::RUNX1T1における血縁者間HLA一致同種移植と非血縁臍帯血移植成績の比較

櫻井一貴, 横山寿行, 小松弘香, 鳴海善洋, 竹中健太, 渡邉樹也, 中村嘉詞, 橋本和貴, 内堀雄介, 猪倉恭子, 市川聡, 小野寺晃一, 福原規子, 大西康, 齋藤慧, 八田俊介, 勝岡優奈, 斎藤陽, 鎌田真弓, 原崎頼子, 遠宮靖雄, 和泉透, 佐々木治, 張替秀郎

日本血液学会学術集会　85回　1247-1247　2023/10
Publisher: (一社)日本血液学会
ICC基準により分類したMDSの移植成績

小野寺晃一, 安部宇明, 久保龍大, 諸田直哉, 中村嘉詞, 橋本和貴, 川尻昭寿, 猪倉恭子, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　1252-1252　2023/10
Publisher: (一社)日本血液学会
症候性貧血(ACD)の原因、検査学的特徴およびアウトカム

亀岡淳一, 小林匡洋, 沖津庸子, 野村順, 阿部正理, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原実名美, 高橋伸一郎, 張替秀郎

日本血液学会学術集会　85回　1453-1453　2023/10
Publisher: (一社)日本血液学会
EBV関連節性細胞障害性T細胞リンパ腫は極めてアグレッシブな臨床経過を辿る

市川聡, 福原規子, 横山寿行, 八田俊介, 沖津庸子, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

日本血液学会学術集会　85回　1472-1472　2023/10
Publisher: (一社)日本血液学会
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.

Yusuke Uchibori, Koichi Onodera, Yasushi Onishi, Hiroka Komatsu, Kenta Takenaka, Yoshihiro Narumi, Tatsuya Watanabe, Hiroshi Nakamura, Kazuki Sakurai, Kazuki Hashimoto, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

The Tohoku journal of experimental medicine　261　(2)　123-127　2023/08/10

DOI： 10.1620/tjem.2023.J063 　

More details Close

The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) against anti-HLA-A, -B, -C, and -DRB1 in HLA-mismatched hematopoietic stem cell transplantation (HSCT) is associated with graft failure. DSAs against HLA-A, -B, -C, and -DRB1 with a mean fluorescence intensity (MFI) of greater than > 1,000 was shown to increase the risk of graft failure in single-unit umbilical cord blood transplantation (UCBT). Nevertheless, the impact of DSAs against HLA-DP or -DQ on transplantation outcomes is not fully understood. In this report, we present a case of UCBT in a patient with myelodysplastic syndrome who was positive for DSAs against HLA-DP with MFI of 1,263 before UCBT but successfully achieved neutrophil engraftment. If HLA-DP or -DQ is mismatched in UCBT, evaluating DSAs against HLA-DP or -DQ is crucial to avoid graft failure. However, the criteria for DSAs against HLA-A, -B, -C, and -DRB1 may not be directly applicable to those against HLA-DP or -DQ.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. International-journal

Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki, Kisato Nosaka, Norifumi Tsukamoto, Tatsu Shimoyama, Noriko Fukuhara, Yoshihiro Yakushijin, Kazunori Ohnishi, Kana Miyazaki, Yoshihiro Kameoka, Nobuyuki Takayama, Ichiro Hanamura, Hirofumi Kobayashi, Kensuke Usuki, Naoki Kobayashi, Kazuma Ohyashiki, Takahiko Utsumi, Kyoya Kumagai, Dai Maruyama, Ken Ohmachi, Yoshihiro Matsuno, Shigeo Nakamura, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai

Cancer science　114　(8)　3461-3465　2023/05/26

DOI： 10.1111/cas.15849 　

More details Close

Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed.
Severe Bone Marrow Aplasia Following Macrophage Activation Syndrome in Systemic Lupus Erythematosus.

Hirona Ichimura, Satoshi Ichikawa, Koya Ono, Kyoko Inokura, Yosuke Hoshi, Tsuyoshi Shirai, Noriko Fukuhara, Hisayuki Yokoyama, Hiroshi Fujii, Hideo Harigae

The Tohoku journal of experimental medicine　260　(4)　301-304　2023/05/11

DOI： 10.1620/tjem.2023.J037 　

More details Close

Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases, characterized by activated macrophages with hemophagocytosis and multiple organ damage. We report a case of MAS associated with systemic lupus erythematosus that initially presented with severe liver dysfunction. Although it was improved with steroids and plasmapheresis, severe pancytopenia was subsequently experienced, and the bone marrow showed severe aplasia similar to aplastic anemia. Nevertheless, the administration of immunosuppressants resulted in the recovery of blood counts within two weeks. When severe MAS results in cytokine overproduction, bone marrow aplasia may occur, for which immunosuppressive therapy may be highly effective.
Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis International-journal

Kazuaki Kameda, Ryo Yanagiya, Yuji Miyatake, Joaquim Carreras, Hiroshi Higuchi, Hiromichi Murayama, Takashi Ishida, Asahi Ito, Shinsuke Iida, Noriko Fukuhara, Hideo Harigae, Yuki Fujioka, Naoto Takahashi, Hidenori Wada, Fumihiro Ishida, Hideyuki Nakazawa, Rei Ishihara, Yuki Murakami, Hiroyuki Tagawa, Tadashi Matsuura, So Nakagawa, Sadahiro Iwabuchi, Shinichi Hashimoto, Ken-Ichi Imadome, Naoya Nakamura, Kenichi Ishizawa, Yoshinobu Kanda, Kiyoshi Ando, Ai Kotani

Blood Journal　142　(4)　352-364　2023/05/05
Publisher: American Society of Hematology
DOI： 10.1182/blood.2022018597 　

ISSN： 0006-4971

eISSN： 1528-0020

More details Close

Aggressive natural killer cell leukemia (ANKL) is a rare lymphoid neoplasm frequently associated with Epstein-Barr virus, with a disastrously poor prognosis. Owing to the lack of samples from patients with ANKL and relevant murine models, comprehensive investigation of its pathogenesis including the tumor microenvironment (TME) has been hindered. Here we established three ANKL-patient-derived xenograft mice (PDXs), which enabled extensive analysis of tumor cells and their TME. ANKL cells primarily engrafted and proliferated in the hepatic sinusoid. Hepatic ANKL cells were characterized by an enriched Myc-pathway and proliferated faster than those in other organs. Interactome analyses and in vivo CRISPR-Cas9 analyses revealed transferrin (Tf)-transferrin receptor 1 (TfR1) axis as a potential molecular interaction between the liver and ANKL. ANKL cells were rather vulnerable to iron deprivation. PPMX-T003, a humanized anti-TfR1 monoclonal antibody, showed remarkable therapeutic efficacy in a preclinical setting using ANKL-PDXs. These findings indicate that the liver, a non-canonical hematopoietic organ in adults, serves as a principal niche for ANKL, and that inhibition of the Tf-TfR1 axis is a promising therapeutic strategy for ANKL.
骨髄異形成症候群に対する同種造血幹細胞移植後に発症したノカルジア症の1例

竹中健太, 市川聡, 横山寿行, 小松弘香, 鳴海善洋, 渡邊樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 福原規子, 大西康, 張替秀郎

臨床血液　64　(5)　432-432　2023/05
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.

Hideki Goto, Toshio Kitawaki, Nobuharu Fujii, Koji Kato, Yasushi Onishi, Noriko Fukuhara, Takuji Yamauchi, Kazunori Toratani, Hiroki Kobayashi, Shota Yoshida, Masatoshi Shimo, Koichi Onodera, Hajime Senjo, Masahiro Onozawa, Kenji Hirata, Isao Yokota, Takanori Teshima

International journal of clinical oncology　28　(6)　816-826　2023/04/18

DOI： 10.1007/s10147-023-02334-w 　

More details Close

BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). RESULTS: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4-19.65; P < 0.05] into a high-risk group). CONCLUSION: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel.
【造血器腫瘍に対する新しい展開-Choosing Wisely-】びまん性大細胞型B細胞リンパ腫全ての患者に初期治療でPola-R-CHP療法を適用すべきか?

市川聡, 福原規子

腫瘍内科　31　(4)　444-451　2023/04
Publisher: (有)科学評論社
ISSN： 1881-6568
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.

Wataru Munakata, Kiyoshi Ando, Masahiro Yokoyama, Noriko Fukuhara, Kazuhito Yamamoto, Suguru Fukuhara, Ken Ohmachi, Yuko Mishima, Satoshi Ichikawa, Daisuke Ogiya, Arata Aoi, Masahiro Hatsumichi, Kensei Tobinai

International journal of hematology　117　(4)　553-562　2023/04

DOI： 10.1007/s12185-022-03514-6 　

More details Close

Tirabrutinib is a Bruton's tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160 mg, 320 mg, or 480 mg once daily, or 300 mg twice daily (N = 3, 3, 4, and 7, respectively). Three patients continued tirabrutinib until study completion (November 30, 2020). Adverse events (AEs) occurred in all 17 patients, with Grade 3-4 AEs in 8 (47.1%), serious AEs in 7 (41.2%), drug-related AEs in 16 (94.1%), and Grade 3-4 drug-related AEs in 6 (35.3%). Drug-related AEs reported in 3 or more patients were rash, vomiting, neutropenia, arthralgia, and malaise. One additional serious AE (benign neoplasm of the lung, unrelated to tirabrutinib) occurred after the previous data cutoff (January 4, 2018). Tirabrutinib administration and response assessment were continued for over 4 years in 4 patients. The overall response rate was 76.5% (13/17 patients). The median (range) time to response and duration of response were 0.9 (0.9-5.9) months and 2.59 (0.08-5.45) years, respectively. These findings demonstrate the long-term safety and efficacy of tirabrutinib in Japanese patients with B-cell malignancies.Clinical trial registration: JapicCTI-142682 ( http://www.clinicaltrials.jp/ ).
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. International-journal

Kana Miyazaki, Rika Sakai, Noriko Iwaki, Go Yamamoto, Kayoko Murayama, Momoko Nishikori, Kazutaka Sunami, Isao Yoshida, Hiroki Yano, Naoki Takahashi, Akinao Okamoto, Saori Munemoto, Aiko Sawazaki, Youko Suehiro, Noriko Fukuhara, Atsushi Wake, Ayako Arai, Yasufumi Masaki, Kohtaro Toyama, Akihiro Yokoyama, Hiroko Tsunemine, Yuichi Hasegawa, Kenji Matsumoto, Tomomi Yamada, Yuki Nishimura, Satoshi Tamaru, Naoko Asano, Kohta Miyawaki, Koji Izutsu, Tomohiro Kinoshita, Ritsuro Suzuki, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi

Cancer science　114　(6)　2689-2691　2023/03/16

DOI： 10.1111/cas.15784 　
Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of an Asian Phase 2 Study. International-journal

Won-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, Kazuhito Yamamoto, Toshiki Uchida, Eiju Negoro, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam L Kwong, Kensei Tobinai

Blood advances　7　(17)　4903-4912　2023/01/20

DOI： 10.1182/bloodadvances.2022008615 　

More details Close

Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase II, nonrandomized, single-arm, open-label study evaluated the efficacy and safety of intravenous darinaparsin (300 mg/m2 over 1 hour, once daily for five consecutive days, per 21-day cycle) and its pharmacokinetics at multiple doses in 65 Asian patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The primary endpoint was the overall response rate (ORR). The ORR based on central assessment was 19.3% (90% confidence interval: 11.2-29.9%), which was significantly higher than the predefined threshold of 10% (p = 0.024). The ORR was 16.2% in patients with PTCL-not otherwise specified and 29.4% in patients with angioimmunoblastic T-cell lymphoma. The tumor size decreased in 62.3% of patients. Treatment-emergent adverse events (TEAEs) were observed in 98.5% of patients. Grade ≥3 TEAEs with an incidence rate ≥5% included anemia (15.4%), thrombocytopenia (13.8%), neutropenia (12.3%), leukopenia (9.2%), lymphopenia (9.2%), and hypertension (6.2%). Darinaparsin is effective and well tolerated, with TEAEs that were clinically acceptable and manageable with symptomatic treatment and dose reductions (ClinicalTrials.gov: NCT02653976).
マントル細胞リンパ腫に対する最新の治療戦略

市川聡, 福原規子

血液内科　86　(1)　113-118　2023/01
Publisher: (有)科学評論社
ISSN： 2185-582X
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Eiju Negoro, Takahiro Yamauchi, Noriko Fukuhara, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Dai Maruyama, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Ilseung Choi, Nobuhiro Kanemura, Nobuhiko Nakamura, Go Yamamoto, Yoshinobu Maeda, Hirohiko Shibayama, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Won-Seog Kim, Kensei Tobinai

Journal of clinical and experimental hematopathology : JCEH　63　(2)　108-120　2023

DOI： 10.3960/jslrt.23005 　

More details Close

A Japanese subgroup analysis from the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) was performed to evaluate the efficacy and safety outcomes of the Japanese population. In this Asian phase II study, darinaparsin was administered to 65 patients, including 37 Japanese patients. In the Japanese population, the histopathological type of PTCL was PTCL, not otherwise specified in 26 patients (70.3%), angioimmunoblastic T-cell lymphoma in 9 patients (24.3%) and anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK) -negative in 2 patients (5.4%), and the median patient age was 70.0 (range: 43-85). 94.6% and 35.1% of the Japanese population had previously received multi-agent and single-agent regimen, respectively. The efficacy and safety were summarized and compared between the overall and Japanese populations. Based on central assessment, the overall response rate was 22.2% (8/36; 90% confidence interval [CI]: 11.6-36.5) in the Japanese population and 19.3% (11/57; 90% CI: 11.2-29.9) in the overall population. There were no essential differences in the safety profile of darinaparsin between the Japanese population and the overall population. The results of this subgroup analysis indicate that the efficacy and safety profiles of the Japanese subpopulation were broadly consistent with that of the overall population, and that darinaparsin is potentially an effective treatment with a manageable safety profile in Japanese patients with relapse or refractory PTCL.
[Treatment strategies for follicular lymphoma].

Noriko Fukuhara

[Rinsho ketsueki] The Japanese journal of clinical hematology　64　(9)　1019-1025　2023

DOI： 10.11406/rinketsu.64.1019 　

ISSN： 0485-1439

More details Close

Follicular lymphoma (FL) is the most common indolent lymphoma, benefits from anti-CD20 monoclonal antibody therapy, and has a median overall survival of over 15 years. However, it remains incurable in the majority of patients despite the current standard therapeutic strategy. For advanced-stage cases with a low tumor burden, watchful waiting remains the standard treatment. The optimal timing of rituximab monotherapy is a clinical question. For advanced-stage cases with a high tumor burden, the standard of care includes anti-CD20 monoclonal antibody and chemotherapy, followed by maintenance therapy for 2 years in responding cases. The significance of maintenance therapy after bendamustine administration has not been confirmed. Even within the early relapse group, histological transformation is the most important prognostic factor. For refractory FL, anti-CD19 chimeric antigen receptor T-cell therapy and CD20/CD3-bispecific antibodies have shown promising results. This review presents the current FL treatment strategy and prognostic factors.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib. International-journal

Yoshiki Arakawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa

Neuro-oncology advances　5　(1)　vdad109　2023

DOI： 10.1093/noajnl/vdad109 　

More details Close

BACKGROUND: Tirabrutinib, a second-generation inhibitor of Bruton's tyrosine kinase, was approved in March 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (r/r PCNSL) based on phase I/II studies in Japan. We previously reported the overall response rate and safety profile. We describe Karnofsky Performance Status (KPS) and the quality of life (QoL) in patients with r/r PCNSL receiving tirabrutinib based on more than 1-year follow-up data. METHODS: Patients with r/r PCNSL, age ≥20 years, and KPS ≥70 were treated with tirabrutinib once daily at a dose of 320, 480, or 480 mg under fasted conditions. QoL was assessed using questionnaires issued by the European Organization for Research and Treatment of Cancer (EORTC), namely EORTC QLQ-C30, EORTC QLQ-BN20, and EuroQol 5 dimensions 3-level (EQ-5D-3L) along with KPS. RESULTS: Forty-four patients (mean age, 60 years [range 29-86]) were enrolled. The median follow-up period was 14.9 months (range, 1.4-27.7). The median KPS of the patients at baseline was 80.0 (range, 70-100), and this remained constant during the treatment. The global health status/QoL in the QLQ-C30 showed significant improvements from baseline through cycles 3-17 and remained relatively constant thereafter until cycle 23. Improvements were also seen in emotional functioning and constipation in the QLQ-C30 segments. Other items of QLQ-C30 and QLQ-BN20, EQ-5D visual analog scales, and EQ-5D index were maintained during the treatment. CONCLUSIONS: Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL items in patients with r/r PCNSL.
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.

Noriko Fukuhara, Koji Kato, Hideki Goto, Tajima Takeshi, Mayu Kawaguchi, Kota Tokushige, Koichi Akashi, Takanori Teshima, Hideo Harigae, Stephen J Schuster, Catherine Thieblemont, Martin Dreyling, Nathan Fowler

International journal of hematology　117　(2)　251-259　2022/11/21

DOI： 10.1007/s12185-022-03481-y 　

More details Close

BACKGROUND: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from ELARA. METHODS: ELARA (NCT03568461) is a global single-arm trial of tisagenlecleucel in patients with r/r FL who received ≥ 2 prior lines of therapy. The primary endpoint was the complete response rate (CRR), and the secondary endpoints were the overall response rate, duration of response, progression-free survival, overall survival, safety, and cellular kinetics. RESULTS: As of March 29, 2021, nine Japanese patients were enrolled and received tisagenlecleucel with a median follow-up of 13.6 months (range, 10.5‒19.3). Per independent review committee, CRR was 100% (95% CI 63.1‒100). Within 8 weeks of infusion, cytokine release syndrome (CRS) of any grade was reported in 6 patients (66.7%); however, no grade ≥ 3 CRS or any grade serious neurological events or treatment-related deaths were observed. CONCLUSION: Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.
Elucidation of the Role of FAM210B in Mitochondrial Metabolism and Erythropoiesis. International-journal

Chie Suzuki, Tohru Fujiwara, Hiroki Shima, Koya Ono, Kei Saito, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Molecular and cellular biology　42　(12)　e0014322　2022/11/14

DOI： 10.1128/mcb.00143-22 　

More details Close

Mitochondria play essential and specific roles during erythroid differentiation. Recently, FAM210B, encoding a mitochondrial inner membrane protein, has been identified as a novel target of GATA-1, as well as an erythropoietin-inducible gene. While FAM210B protein is involved in regulate mitochondrial metabolism and heme biosynthesis, its detailed function remains unknown. Here, we generated both knockout and knockdown of endogenous FAM210B in human induced pluripotent stem-derived erythroid progenitor (HiDEP) cells using CRISPR/Cas9 methodology. Intriguingly, erythroid differentiation was more pronounced in the FAM210B-depleted cells, and this resulted in increased frequency of orthochromatic erythroblasts and decreased frequencies of basophilic/polychromatic erythroblasts. Comprehensive metabolite analysis and functional analysis indicated that oxygen consumption rates and the NAD (NAD+)/NADH ratio were significantly decreased, while lactate production was significantly increased in FAM210B deletion HiDEP cells, indicating involvement of FAM210B in mitochondrial energy metabolism in erythroblasts. Finally, we purified FAM210B-interacting protein from K562 cells that stably expressed His/biotin-tagged FAM210B. Mass spectrometry analysis of the His/biotin-purified material indicated interactions with multiple subunits of mitochondrial ATP synthases, such as subunit alpha (ATP5A) and beta (ATP5B). Our results suggested that FAM210B contributes prominently to erythroid differentiation by regulating mitochondrial energy metabolism. Our results provide insights into the pathophysiology of dysregulated hematopoiesis.
著明な血小板減少を伴った血管免疫芽球性T細胞リンパ腫の1例

渡邉樹也, 市川聡, 鳴海善洋, 中村嘉詞, 櫻井一貴, 猪倉恭子, 小松弘香, 竹中健太, 橋本和貴, 内堀雄介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

臨床血液　63　(11)　1588-1588　2022/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
高感度デジタルPCR法を用いて中枢神経再発を診断し得たMYD88 L265P変異陽性B細胞性リンパ腫の1例

小松弘香, 小野寺晃一, 竹中健太, 橋本和貴, 内堀雄介, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

臨床血液　63　(11)　1589-1589　2022/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. International-journal

Kana Miyazaki, Ritsuro Suzuki, Masahiko Oguchi, Senzo Taguchi, Jun Amaki, Takeshi Maeda, Nobuko Kubota, Dai Maruyama, Yasuhito Terui, Nodoka Sekiguchi, Jun Takizawa, Hiroyuki Tsukamoto, Tohru Murayama, Toshihiko Ando, Hiroshi Matsuoka, Masatoshi Hasegawa, Hideho Wada, Rika Sakai, Yoshihiro Kameoka, Norifumi Tsukamoto, Ilseung Choi, Yasufumi Masaki, Kazuyuki Shimada, Noriko Fukuhara, Takahiko Utsumi, Nobuhiko Uoshima, Yoshitoyo Kagami, Naoko Asano, Yasuo Ejima, Naoyuki Katayama, Motoko Yamaguchi

Hematological oncology　40　(4)　667-677　2022/10

DOI： 10.1002/hon.2977 　

More details Close

To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 and 2013 in a nationwide retrospective study in Japan were updated and analyzed. At a median follow-up of 8.4 years, the 5-year overall survival (OS) and progression-free survival (PFS) were 71% and 64%, respectively, in 140 localized ENKTL patients who received radiotherapy-dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) in clinical practice. Nine (6.4%) patients experienced second malignancies. In 155 localized ENKTL patients treated with RT-DeVIC, 10 (6.5%) experienced CNS relapse (median, 12.8 months after diagnosis). In five of them, the events were confined to the CNS. Nine of the 10 patients who experienced CNS relapse died within 1 year after CNS relapse. Multivariate analysis identified gingival (hazard ratio [HR], 54.35; 95% confidence interval [CI], 8.60-343.35) and paranasal involvement (HR, 7.42; 95% CI, 1.78-30.89) as independent risk factors for CNS relapse. In 80 advanced ENKTL patients, 18 received steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment. Patients who received SMILE as their first-line treatment tended to have better OS than those who did not (p = 0.071). Six (7.5%) advanced ENKTL patients experienced isolated CNS relapse (median, 2.6 months after diagnosis) and died within 4 months of relapse. No second malignancies were documented in advanced ENKTL patients. In the entire cohort, the median OS after first relapse or progression was 4.6 months. 12 patients who survived 5 years after PFS events were disease-free at the last follow-up. Of those, 11 (92%) underwent hematopoietic stem cell transplantation. Our 8-year follow-up revealed the long-term efficacy and safety of RT-DeVIC and SMILE. The risk of CNS relapse is an important consideration in advanced ENKTL.
[The Evolution of the Treatment of Chronic Myelogenous Leukemia].

Koichi Onodera, Noriko Fukuhara

Gan to kagaku ryoho. Cancer & chemotherapy　49　(10)　1035-1039　2022/10

ISSN： 0385-0684

More details Close

Chronic myelogenous leukemia(CML)is a myeloproliferative neoplasm caused by a reciprocal translocation (t 9 ; 22) (q34 ; q11). The finding that the constitutive tyrosine kinase activity of the BCR-ABL1 fusion protein, which is produced by fusing the ABL1 and BCR genes, is involved in the pathogenesis of CML has led to the development of drugs targeting the BCR-ABL1 fusion protein. Imatinib, a first-generation tyrosine kinase inhibitor(TKI), was introduced in 2001 as a treatment for CML, dramatically changing CML therapy. With the advent of imatinib, disease progression is largely prevented and the prognosis of CML patients is markedly improved, allowing a substantial proportion of patients to remain in the chronic phase for an extended period of time. In the TKI-era, it is no longer the primary disease that defines the long-term prognosis of CML patients, but rather comorbidities other than CML and adverse events(AEs), including cardiovascular events, and management to avoid AEs associated with long-term TKI use has become increasingly important. In recent years, treatment-free remission(TFR)is becoming a new therapeutic goal, as many reports have shown that some patients who have achieved deep molecular response with TKIs can maintain long-term TFR without relapsing after TKI discontinuation.
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma.

Satsuki Murakami, Masaki Ri, Masato Ito, Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Yuichiro Inagaki, Junya Kuroda, Makoto Yoshimitsu, Akinao Okamoto, Noriko Fukuhara, Hirofumi Taji, Hiroatsu Iida, Hirokazu Nagai, Ichiro Hanamura, Hideki Tsujimura, Miyuki Okura, Mio Kurata, Yachiyo Kuwatsuka, Yoshiko Atsuta, Shinsuke Iida

International journal of hematology　116　(4)　563-569　2022/10

DOI： 10.1007/s12185-022-03379-9 　

More details Close

The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1-14, and 20 mg Dex on days 1-2 and 8-9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6-77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8-99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.

Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, Hirokazu Nagai, Shinichi Makita, Kenjiro Kamezaki, Toshiki Uchida, Shigeru Kusumoto, Junya Kuroda, Chisako Iriyama, Masamitsu Yanada, Norifumi Tsukamoto, Youko Suehiro, Hironobu Minami, Jose Garcia-Vargas, Barrett H Childs, Masanobu Yasuda, Shigeo Masuda, Toshiaki Tsujino, Yui Terao, Kensei Tobinai

International journal of hematology　117　(1)　100-109　2022/09/29

DOI： 10.1007/s12185-022-03455-0 　

More details Close

The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival. In phase Ib, patients received copanlisib 45 mg intravenously on days 1, 8, and 15 of a 28-day cycle, and when tolerated, consecutive patients received copanlisib 60 mg. As no dose-limiting toxicities occurred at the 45 mg (n = 3) or 60 mg (n = 7) dose in phase Ib, the recommended dose for Japanese patients was determined to be 60 mg, and this dose was used in phase II (n = 15). Although all patients experienced at least one treatment-emergent adverse event (TEAE), with hyperglycemia being the most common AE, no AE-related deaths were reported. The ORR was 68.0% (17/25 patients), median PFS was 302 (95% CI 231-484) days, and the duration of response was 330 (range 65-659) days. The pharmacokinetic properties of copanlisib were similar between Japanese and non-Japanese patients. Overall, copanlisib 60 mg had an acceptable safety profile and showed promising antitumor activity in Japanese patients with relapsed/refractory indolent NHL.
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. International-journal

Tetsuro Ochi, Tohru Fujiwara, Koya Ono, Chie Suzuki, Maika Nikaido, Daichi Inoue, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

Scientific reports　12　(1)　14562-14562　2022/08/26

DOI： 10.1038/s41598-022-18921-2 　

More details Close

Acquired sideroblastic anemia, characterized by bone marrow ring sideroblasts (RS), is predominantly associated with myelodysplastic syndrome (MDS). Although somatic mutations in splicing factor 3b subunit 1 (SF3B1), which is involved in the RNA splicing machinery, are frequently found in MDS-RS, the detailed mechanism contributing to RS formation is unknown. To explore the mechanism, we established human umbilical cord blood-derived erythroid progenitor-2 (HUDEP-2) cells stably expressing SF3B1K700E. SF3B1K700E expressing cells showed higher proportion of RS than the control cells along with erythroid differentiation, indicating the direct contribution of mutant SF3B1 expression in erythroblasts to RS formation. In SF3B1K700E expressing cells, ABCB7 and ALAS2, known causative genes for congenital sideroblastic anemia, were downregulated. Additionally, mis-splicing of ABCB7 was observed in SF3B1K700E expressing cells. ABCB7-knockdown HUDEP-2 cells revealed an increased frequency of RS formation along with erythroid differentiation, demonstrating the direct molecular link between ABCB7 defects and RS formation. ALAS2 protein levels were obviously decreased in ABCB7-knockdown cells, indicating decreased ALAS2 translation owing to impaired Fe-S cluster export by ABCB7 defects. Finally, RNA-seq analysis of MDS clinical samples demonstrated decreased expression of ABCB7 by the SF3B1 mutation. Our findings contribute to the elucidation of the complex mechanisms of RS formation in MDS-RS.
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). International-journal

Dai Maruyama, Shinsuke Iida, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura, Kensuke Usuki, Takahiro Yamauchi, Takahiko Utsumi, Ishikazu Mizuno, Yasushi Takamatsu, Yasuyuki Nagata, Shuichi Ota, Eiichi Ohtsuka, Ichiro Hanamura, Yasuhiro Suzuki, Shinichiro Yoshida, Satoshi Yamasaki, Youko Suehiro, Yutaro Kamiyama, Suguru Fukuhara, Kunihiro Tsukasaki, Hirokazu Nagai

Cancer science　113　(9)　3267-3270　2022/07/31

DOI： 10.1111/cas.15484 　
【血液疾患における抗体医薬と免疫細胞療法の新たな展開】古典的ホジキンリンパ腫に対する抗体医薬の臨床的意義

市川聡, 福原規子

血液内科　85　(1)　14-21　2022/07
Publisher: (有)科学評論社
ISSN： 2185-582X
Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.

Masahiro Miyazaki, Satoshi Ichikawa, Yasushi Onishi, Noriko Fukuhara, Eijiro Furukawa, Koichi Onodera, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　62　(3)　164-168　2022/06/22

DOI： 10.3960/jslrt.22003 　

More details Close

ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) has a favorable prognosis in general; however, some cases are resistant to chemotherapy, which leads to a poor clinical outcome. We herein report the case of a 32-year-old male with aggressive ALK+ ALCL who presented with hemorrhage from a large tumor in the duodenum and multiple tumors in the lungs, mediastinum, and peritoneal cavity. Although induction chemotherapy resulted in a marked reduction of the tumor lesions, premature progression with massive pulmonary infiltration and central nervous system invasion occurred immediately after the completion of chemotherapy. The patient was then promptly treated with brentuximab vedotin (BV) and high-dose methotrexate, which resulted in complete remission. Subsequently, he successfully underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor and has been healthy and did not relapse for more than 3 years after transplantation without any additional therapy. Allo-HSCT may be a promising treatment option for ALK+ ALCL due to its graft-versus-lymphoma effect. In addition, molecular targeting agents, such as BV, may be promising as a bridging therapy before allo-HSCT to achieve disease remission.
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. International-journal

Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Cancer science　113　(6)　2085-2096　2022/06

DOI： 10.1111/cas.15344 　

More details Close

The phase II study of tirabrutinib monotherapy at a daily dose of 480 mg under fasting conditions for treatment-naïve and relapsed/refractory Waldenström's macroglobulinemia (ONO-4059-05 study) demonstrated a promising efficacy and tolerable safety profile. We conducted an unplanned analysis with a median follow-up of 24.8 months to update the efficacy and safety results and to report patient-reported quality of life. Of 27 enrolled patients, 22 patients continued receiving the study drug. The major response assessed by an independent review committee was observed in 25 patients (93%), including one and five patients who newly achieved complete response and very good partial response, respectively, after the primary analysis. The progression-free and overall survival rates at 24 months were 92.6% and 100%, respectively. Serum IgM levels in all patients except one declined and were maintained at low levels, although transient increases occurred after temporal interruption of the study drug. The disease-related symptoms including recurrent fever and hyperviscosity mostly disappeared. Health-related quality of life, assessed by cancer-specific questionnaires, was mostly maintained. Grade 3-4 neutropenia, lymphopenia, and leukopenia were newly recognized in three, two, and one patient, respectively. Grade 3 treatment-related hypertriglyceridemia was also recognized. Nine patients experienced grade 1-2 bleeding events (33%), one patient experienced grade 2 treatment-related atrial fibrillation, and one patient experienced grade 1 treatment-related hypertension. Treatment-related skin adverse events were observed in 14 patients (52%). Taken together, tirabrutinib has durable efficacy with an acceptable safety profile for treatment-naïve and refractory/relapsed Waldenström's macroglobulinemia.
Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis. International-journal

Koya Ono, Tohru Fujiwara, Kei Saito, Hironari Nishizawa, Noriyuki Takahashi, Chie Suzuki, Tetsuro Ochi, Hiroki Kato, Yusho Ishii, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Rie Yamada, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Scientific reports　12　(1)　9024-9024　2022/05/30

DOI： 10.1038/s41598-022-12940-9 　

More details Close

X-linked sideroblastic anemia (XLSA), the most common form of congenital sideroblastic anemia, is caused by a germline mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. In XLSA, defective heme biosynthesis leads to ring sideroblast formation because of excess mitochondrial iron accumulation. In this study, we introduced ALAS2 missense mutations on human umbilical cord blood-derived erythroblasts; hereafter, we refer to them as XLSA clones. XLSA clones that differentiated into mature erythroblasts showed an increased frequency of ring sideroblast formation with impaired hemoglobin biosynthesis. The expression profiling revealed significant enrichment of genes involved in ferroptosis, which is a form of regulated cell death induced by iron accumulation and lipid peroxidation. Notably, treatment with erastin, a ferroptosis inducer, caused a higher proportion of cell death in XLSA clones. XLSA clones exhibited significantly higher levels of intracellular lipid peroxides and enhanced expression of BACH1, a regulator of iron metabolism and potential accelerator of ferroptosis. In XLSA clones, BACH1 repressed genes involved in iron metabolism and glutathione synthesis. Collectively, defective heme biosynthesis in XLSA clones could confer enhanced BACH1 expression, leading to increased susceptibility to ferroptosis. The results of our study provide important information for the development of novel therapeutic targets for XLSA.
Peritoneal lymphomatosisによって腹部コンパートメント症候群を来したB細胞性リンパ腫の1例

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

臨床血液　63　(5)　491-492　2022/05
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.

Katsuyuki Sasaki, Tohru Fujiwara, Tetsuro Ochi, Koya Ono, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Toshio Miyata, Hideo Harigae

The Tohoku journal of experimental medicine　257　(3)　211-224　2022/04/28

DOI： 10.1620/tjem.2022.J036 　

More details Close

Chronic myeloid leukemia (CML) is triggered by t(9;22)(q34;q11.2) translocation, leading to the formation of the BCR-ABL1 fusion gene. Although the development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis of CML, the disease could often relapse, presumably because leukemic stem cell fraction of CML (CML-LSC) may reside in specific niches, and also acquire an ability to resist the cytotoxic agents. Recently a study indicated that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) would cause detachment of CML-LSCs from their niche by inducing maturation of membrane-type matrix metalloprotease-1 (MT1-MMP), leading to increased susceptibility of CML-LSCs against TKIs. However, the direct antitumor effect of PAI-1 inhibition in CML remains unclear. Because PAI-1 mRNA expression was lower in CML cell line (K562) than bone marrow mononuclear cells derived from CML patients, we established K562 cell clones stably expressing exogenous PAI-1 (K562/PAI-1). We found that TM5614 treatment significantly suppressed cell proliferation and induced apoptosis in K562/PAI-1 cells, accompanied by increased activity of Furin protease, which is a known target of PAI-1. Besides processing mature MT1-MMP, Furin is in charge of cleaving the NOTCH receptor to form a heterodimer before exporting it to the cell surface membrane. In K562/PAI-1 cells, TM5614 treatment increased NOTCH1 intracellular domain (NICD) protein expression as well as NOTCH1 target of HEY1 mRNA levels. Finally, forced expression of either Furin or NICD in K562/PAI-1 cells significantly inhibited cell proliferation and induced apoptosis. Collectively, PAI-1 inhibition may have an antitumor effect by modulating the Furin/NICD pathway.
Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.

Yasushi Onishi, Koichi Onodera, Noriko Fukuhara, Hiroki Kato, Satoshi Ichikawa, Tohru Fujiwara, Hisayuki Yokoyama, Minami Yamada-Fujiwara, Hideo Harigae

International journal of hematology　115　(6)　873-881　2022/03/10

DOI： 10.1007/s12185-022-03313-z 　

More details Close

Adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders (EBV-T/NK-LPDs) often progress rapidly, and require allogeneic stem cell transplantation early in the course of treatment. Unrelated cord blood transplantation (UCBT) is a readily available option for patients without HLA-matched donors. We retrospectively analyzed the outcomes of 12 UCBT in adult patients with chronic active EBV infection (CAEBV, n = 8), EBV-positive hemophagocytic lymphohistiocytosis following primary EBV infection (n = 2), hydroa vacciniforme-like lymphoproliferative disorder (n = 1), and systemic EBV-positive T-cell lymphoma of childhood (STCLC, n = 1). The median age at transplantation was 31.5 years (range 19-58). At the median follow-up time for survivors, which was 6.3 years (range 0.3-11.3), 3-year overall survival (OS) rates in all patients and 8 CAEBV patients were 68.2% (95% CI 28.6-88.9) and 83.3% (95% CI 27.3-97.5), respectively. Graft failure occurred in 4 of 8 CAEBV patients, requiring a second UCBT to achieve neutrophil engraftment. The cumulative incidence of grade II-IV acute GVHD was 33.3% (95% CI 9.1-60.4%). The EBV-DNA load became undetectable or very low after UCBT in all cases. UCBT may be a promising treatment option for adult-onset EBV-T/NK-LPDs.
Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study. International-journal

Noriko Fukuhara, Youko Suehiro, Harumi Kato, Shigeru Kusumoto, Cinthya Coronado, Erica Rappold, Wanying Zhao, Jia Li, Aidan Gilmartin, Koji Izutsu

Cancer science　113　(5)　1702-1711　2022/02/24

DOI： 10.1111/cas.15308 　

More details Close

Parsaclisib, a potent, selective, next-generation PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory B-cell lymphoma. We undertook a phase Ib study (CITADEL-111) evaluating safety, pharmacokinetics, and efficacy of parsaclisib in Japanese patients with relapsed or refractory B-cell malignancies. Patients received oral parsaclisib daily for 8 weeks then once weekly (10-mg dose, n = 3; 20-mg dose, n = 14). Pharmacokinetic samples were collected on days 1, 8, and 15, and efficacy was monitored according to Lugano criteria. At data cut-off (August 14, 2020), 6 patients (35.3%) remained on study treatment and 11 (64.7%) discontinued due to progressive disease (9 [52.9%]) or adverse events (2 [11.8%]). Median duration of treatment was 8.3 (range, 0.3-24.4) months. The most commonly reported nonhematologic adverse events were constipation (6 [35.3%]), nausea, and pyrexia (each 4 [23.5%]). Five patients (29.4%) experienced treatment-emergent new or worsening decreased neutrophils to grade 3 or 4. No treatment-emergent worsening in aminotransferase elevations to grade 3 or 4 were observed. Ten patients (58.8%) required dose interruption and 5 (29.4%) dose reduction. Body weight-normalized parsaclisib exposure was comparable between Japanese and Western patients. Objective response rate was 100% in follicular lymphoma (9 of 9 patients, including complete response in 2 patients [22.2%]) and marginal zone lymphoma (2 of 2 patients), and 16.7% in diffuse large B-cell lymphoma (1 of 6 patients). Results observed in Japanese patients with relapsed or refractory follicular or marginal zone lymphoma support further clinical development of parsaclisib in these patient populations.
Aleukemic T-lymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration

Ichikawa, S., Fukuhara, N., Doman, T., Kiba, D., Tanaka, Y., Inokura, K., Morota, N., Ono, K., Onodera, K., Onishi, Y., Yokoyama, H., Ichinohasama, R., Harigae, H.

Journal of Hematopathology　15　(2)　105-109　2022

DOI： 10.1007/s12308-022-00495-7 　

ISSN： 1865-5785 1868-9256

eISSN： 1865-5785
Anaplastic multiple myeloma with MYC rearrangement. International-journal

Satoshi Ichikawa, Noriko Fukuhara, Ko Hashimoto, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Leukemia research reports　17　100288-100288　2022

DOI： 10.1016/j.lrr.2021.100288 　

More details Close

A 52-year-old man with rapidly progressive paraplegia was presented to us with paravertebral tumors. Laminectomy with tumor resection was performed, and pathological analysis of the tumor revealed compact proliferation of anaplastic plasmacytoid cells. G-band analysis of the tumor revealed a complex karyotype, including IgH/MYC translocation. The patient was diagnosed with anaplastic multiple myeloma (AMM) with MYC arrangement, and cytotoxic chemotherapy followed by autologous hematopoietic stem cell transplantation resulted in long-term disease-free remission. This is the first report describing a case of de novo AMM with MYC rearrangement, suggesting that conventional chemotherapy could be a treatment option for this formidable disease.
Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells. International-journal

Fumiyoshi Fujishima, Noriko Fukuhara, Hiroki Katsushima, Yasuhiro Nakamura, Hideo Harigae, Hironobu Sasano, Ryo Ichinohasama

BMC cancer　21　(1)　1352-1352　2021/12/20

DOI： 10.1186/s12885-021-09098-4 　

More details Close

BACKGROUND: It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity. METHODS: We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). The PRIME-F notation was divided into five levels: notations starting with "-" followed by 3, 2, and 1 ">" correspond to level-I, level-II, or level-III; notations starting with "(dim)+" correspond to level-IV; and those starting with "+" or "(bright)+" correspond to level-V. RESULTS: The 52 cases of PRIME-F notation with "+" included 16 cases of peripheral T-cell lymphoma (PTCL/NOS), 3 of follicular T-cell lymphoma (FTL), 3 of angioimmunoblastic T-cell lymphoma (AITL), 6 of extranodal NK/T-cell lymphoma/nasal type (ENKL), 18 of adult T-cell lymphoma (ATL), and 6 cases of anaplastic large cell lymphoma (ALCL). Eight of the 52 cases were immunohistochemically CD30-negative. In the PRIME-F level-I to III group (excluding false-positive cases), 21.7% (5 out of 23 cases) were < 10% positive for CD30 upon immunohistochemistry (IHC). Contrarily, in the level-IV & -V group, no CD30 positivity rate of < 10% upon IHC was found (0%) (p = 0.0497). In level-IV, 42.9% of cases presented a CD30 negative rate > 1/3 upon IHC, while in level-V, only 7.1% (one out of 14 cases) did. The CD30 negative rate tended to be low (p = 0.0877) in level-V. CONCLUSIONS: To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.
Diffuse Large B-cell Lymphoma Presenting as Peritoneal Lymphomatosis: A Case Report and Literature Review.

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Internal medicine (Tokyo, Japan)　61　(13)　2057-2060　2021/12/11

DOI： 10.2169/internalmedicine.8793-21 　

More details Close

Peritoneal lymphomatosis (PL) is a rare presentation of malignant lymphoma cases, many of which are diagnosed as diffuse large B-cell lymphoma (DLBCL) and characterized by aggressive clinical courses. We herein report a 63-year-old woman presenting with the rapid development of abdominal distention due to bulky peritoneal tumors. The pathological evaluation of a needle biopsy sample, combined with flow cytometry, yielded the diagnosis of DLBCL. Prompt chemotherapeutic intervention resulted in favorable disease control and sustained complete remission. It is necessary to diagnose cases of DLBCL presenting as PL early to ensure prompt treatment and prevent mortality.
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). International-journal

Masaki Ri, Shinsuke Iida, Dai Maruyama, Aya Sakabe, Ryo Kamei, Takuto Nakashima, Masahiro Tohkin, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

Cancer science　112　(12)　5011-5019　2021/12

DOI： 10.1111/cas.15158 　

More details Close

Bortezomib (Btz) shows robust efficacy in patients with multiple myeloma (MM); however, some patients experience suboptimal responses and show specific toxicities. Therefore, we attempted to identify specific HLA alleles associated with Btz-related toxicities and response to treatment. Eighty-two transplant-ineligible patients with newly diagnosed MM enrolled in a phase II study (JCOG1105) comparing two less intensive melphalan, prednisolone, plus Btz (MPB) regimens were subjected to HLA typing. The frequency of each allele was compared between the groups, categorized based on toxicity grades and responses to MPB therapy. Among 82 patients, the numbers of patients with severe peripheral neuropathy (PN; grade 2 or higher), skin disorders (SD; grade 2 or higher), and pneumonitis were 16 (19.5%), 15 (18.3%), and 6 (7.3%), respectively. Complete response was achieved in 10 (12.2%) patients. Although no significant HLA allele was identified by multiple comparisons, several candidates were identified. HLA-B*40:06 was more prevalent in patients with severe PN than in those with less severe PN (odds ratio [OR] = 6.76). HLA-B*40:06 and HLA-DRB1*12:01 were more prevalent in patients with SD than in those with less severe SD (OR = 7.47 and OR = 5.55, respectively). HLA-DRB1*08:02 clustered in the group of patients with pneumonitis (OR = 11.34). Complete response was achieved in patients carrying HLA-DQB1*03:02, HLA-DQB1*05:01, and HLA-DRB1*01:01 class II alleles. HLA genotyping could help predict Btz-induced toxicity and treatment efficacy in patients with MM, although this needs further validation.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy International-journal

Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, Keith W Pratz, Kenichi Ishizawa, Toshihiro Miyamoto, Norio Komatsu, Yasuhiro Nakashima, Chikashi Yoshida, Noriko Fukuhara, Kensuke Usuki, Takahiro Yamauchi, Noboru Asada, Norio Asou, Ilseung Choi, Yasushi Miyazaki, Hideyuki Honda, Sumiko Okubo, Misaki Kurokawa, Ying Zhou, Jiuhong Zha, Jalaja Potluri, Itaru Matsumura

Japanese Journal of Clinical Oncology　52　(1)　29-38　2021/11/05
Publisher: Oxford University Press (OUP)
DOI： 10.1093/jjco/hyab170 　

eISSN： 1465-3621

More details Close

<title>Abstract</title> <sec> <title>Background</title> The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with placebo-azacitidine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy. Herein, efficacy and safety of venetoclax-azacitidine are analyzed in the Japanese subgroup of VIALE-A patients. </sec> <sec> <title>Methods</title> Eligible Japanese patients were randomized 2:1 to venetoclax-azacitidine (N = 24) or placebo-azacitidine (N = 13). Primary endpoints for Japan were overall survival and complete response (CR) + CR with incomplete hematologic recovery (CRi). Venetoclax (target dose 400 mg) was given orally once daily. Azacitidine (75 mg/m2) was administered subcutaneously or intravenously on Days 1–7 of each 28-day cycle. </sec> <sec> <title>Results</title> Median follow-up was 16.3 months (range, 1.0–20.3). Median overall survival was not reached with venetoclax-azacitidine (hazard ratio 0.409 and 95% confidence interval: 0.151, 1.109); overall survival estimate was higher with venetoclax-azacitidine than placebo-azacitidine at 12 (67 and 46%) and 18 months (57 and 31%), respectively. CR and CRi rates were 67% with venetoclax-azacitidine and 15% with placebo-azacitidine. Most common any-grade adverse events were febrile neutropenia (79 and 39%), thrombocytopenia (54 and 77%), constipation (54 and 54%) and decreased appetite (54 and 38%) in the venetoclax-azacitidine and placebo-azacitidine arms, respectively. Only 1 patient in the venetoclax-azacitidine arm, and no patients in the placebo-azacitidine arm, had grade 4 febrile neutropenia that led to treatment discontinuation. </sec> <sec> <title>Conclusions</title> This Japanese subgroup analysis of VIALE-A demonstrates comparable safety and efficacy outcomes compared with the global study and supports venetoclax-azacitidine as first-line standard-of-care for Japanese treatment-naive patients with acute myeloid leukemia who are ineligible for intensive chemotherapy. </sec>
2回目のSARS-CoV-2 mRNAワクチン接種後に溶血が進行した遺伝性球状赤血球症(HS)の1例

野村順, 関雅文, 阿部正理, 小林匡洋, 沖津庸子, 福原規子, 高橋伸一郎, 張替秀郎, 亀岡淳一

臨床血液　62　(9)　1415-1415　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
B細胞性悪性リンパ腫患者におけるリツキシマブの血中濃度の考察(Blood concentration of rituximab in malignant B cell lymphoma patients)

氷室真仁, 福原規子, 佐藤祥子, 猪倉恭子, 市川翼, 細川雅司, 佐藤諒, 柳谷稜, 山田茜, 相澤桂子, 伊藤巧, 山本雅一, 東梅友美, 石澤賢一

日本血液学会学術集会　83回　PS-5　2021/09
Publisher: (一社)日本血液学会
再発難治性ホジキンリンパ腫に対する免疫チェックポイント阻害薬治療の後方視的解析(Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26)

前田峻大, 小宅達郎, 久保恒明, 高畑武功, 玉井佳子, 亀岡吉弘, 高橋直人, 宮入泰郎, 村井一範, 下瀬川健二, 吉田こず恵, 菅原健, 猪倉恭子, 福原規子, 張替秀郎, 佐藤諒, 石澤賢一, 田嶋克史, 齊藤宗一, 深津真彦, 池添隆之, 角田三郎, 神林裕行, 三田正行, 森甚一, 古和田周吾, 伊藤薫樹

日本血液学会学術集会　83回　OS2-2　2021/09
Publisher: (一社)日本血液学会
Factors critical for the results of panel sequencing using DNA from FFPE samples in lymphoma(和訳中)

入山智沙子, 安田貴彦, 三好寛明, 大島孝一, 高橋直樹, 塚崎邦弘, 島田和之, 平賀潤二, 鏡味良豊, 福原傑, 伊豆津宏二, 鈴木律朗, 福原規子, 楫屋良子, 山本一仁, 石田高司, 小林幸夫, 眞田昌, 齋藤明子, 齋藤俊樹, 永井宏和, 堀部敬三, 冨田章裕

日本血液学会学術集会　83回　OS3-3　2021/09
Publisher: (一社)日本血液学会
BCR-ABL1陽性急性骨髄性白血病(AML with BCR-ABL1)の2例

櫻井一貴, 勝岡優奈, 横山寿行, 斎藤慧, 八田俊介, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 大西康, 和泉透, 張替秀郎

臨床血液　62　(9)　1417-1417　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
CRAB症候にて発症した骨髄原発B細胞リンパ腫の1例

道満剛之, 市川聡, 猪倉恭子, 櫻井一貴, 木葉大地, 田中悠也, 福原規子, 横山寿行, 小野寺晃一, 大西康, 張替秀郎

臨床血液　62　(9)　1418-1418　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
血球貪食症候群を伴い発症したTCR陰性末梢性T細胞リンパ腫、非特定型の1例

澤田拓実, 諸田直哉, 小野浩弥, 道又大吾, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　62　(9)　1418-1418　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
T-cell receptor-silent peripheral T-cell lymphoma complicated with hemophagocytic lymphohystiocytosis. International-journal

Koya Ono, Yasushi Onishi, Koichi Onodera, Daigo Michimata, Eijiro Furukawa, Kazuki Sakurai, Naoya Morota, Takumi Sawada, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hirofumi Watanabe, Chie Suzuki, Hideo Harigae

Annals of hematology　101　(4)　901-903　2021/08/30

DOI： 10.1007/s00277-021-04628-3 　
Advanced extramedullary hematopoiesis with a marked increase in reticulin fibers and hemorrhage on various organs: the first autopsy case report.

Hirofumi Watanabe, Fumiyoshi Fujishima, Noriko Fukuhara, Shinji Taniuchi, Kensuke Joh, Hironobu Sasano

Medical molecular morphology　55　(1)　68-75　2021/08/15

DOI： 10.1007/s00795-021-00300-x 　

More details Close

Myelofibrosis is characterized by stem cell-derived clonal proliferation potentially resulting in bone marrow fibrosis. As the disease progresses, extramedullary hematopoiesis is frequently detected in the spleen and the liver but rarely in other organs. We report a case of a 68-year-old woman with myelofibrosis with a JAK2 mutation, showing extramedullary hematopoiesis (EMH) in various organs with a marked increase in reticulin fibers, and myeloproliferative neoplasm (MPN)-related necrotizing crescent glomerulonephritis. She was admitted to our hospital owing to respiratory discomfort. Computed tomography revealed a mass in the anterior mediastinum. Ten days later, the patient died owing to respiratory distress. At autopsy, EMH were detected in the anterior mediastinum, heart, lung, spleen, and the kidney with a marked increase in reticulin fibers. We considered that respiratory distress was partially caused by EMH. In the kidney, necrotizing crescent glomerulonephritis was observed. Immunohistochemically, the glomerular basement and mesangial area were IgA- and C3d-positive. Ultrastructural examination revealed the presence of dense deposits in the subendothelial space and the mesangial and paramesangial areas. Thus, we suspected that MPN-related necrotizing crescentic glomerulonephritis harbored a pathogenesis similar to that of IgA-dominant post-infectious glomerulonephritis or IgA nephropathy. This case report could widen the spectrum of MPN- or EMH-related lesions.
Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report. International-journal

Koichi Onodera, Yasushi Onishi, Jun Inoue, Yuya Tanaka, Lee Yonha, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Kazunori Murai, Atsushi Masamune, Hideo Harigae

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　27　(8)　1230-1233　2021/08

DOI： 10.1016/j.jiac.2021.02.002 　

More details Close

Hepatitis C virus (HCV) infection has an adverse impact on outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). It is recommended that HSCT candidates infected with HCV receive the treatment prior to transplantation. Although the recent approval of direct-acting antivirals (DAAs) has led to great advances in the treatment of HCV infection, little information is available on the efficacy and safety of DAA therapy in patients receiving allogeneic HSCT. Herein, we report the clinical course of an umbilical cord blood (UCB) recipient treated with DAAs for HCV infection. The patient achieved HCV RNA negativity with glecaprevir and pibrentasvir after consolidation therapy for acute myeloid leukemia (AML), and underwent transplantation before confirming sustained virological response (SVR) at 12 weeks. The HCV viral load became detectable on day +28 after transplantation and second HCV treatment with sofosbuvir, velpatasvir, and ribavirin was required. It is important to confirm SVR prior to transplantation, but it is often difficult. If early transplantation is required, close monitoring of HCV RNA after transplantation is needed. Further investigation is required to clarify the optimal management of HCV infection for allogeneic HSCT recipients in the DAA era.
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. International-journal

Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano

Biomedical chromatography : BMC　35　(8)　e5124　2021/08

DOI： 10.1002/bmc.5124 　

More details Close

Recent studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKIs) could improve treatment efficacy and safety. A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma. Although these structures and physical properties are similar, owing to their different linear ranges, simultaneously determining the plasma levels of these five TKIs by applying optimal MS parameters remains difficult. A quantitative range exceeding 60,000-fold was required, and the linear dynamic ranges of imatinib, bosutinib, and nilotinib were limited because of the presence of a saturated detection signal. In this study, we applied the in-source collision-induced dissociation technique to control the ion amounts in mass spectrometry. This new method allowed rapid determination within 5 min with simple pretreatment. The method was validated according to the US Food and Drug Administration guidelines. Moreover, all samples of patients with chronic leukemia were successfully measured and their values were within the linear range of measurement. Therefore, our high-throughput analytical system is useful to measure the plasma concentrations of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in clinical practice.
Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review.

Yushi Inomata, Masatake Kuroha, Tomoyuki Handa, Yusuke Shimoyama, Rintaro Moroi, Hisashi Shiga, Yoichi Kakuta, Satoshi Ichikawa, Noriko Fukuhara, Yuichiro Sato, Taro Takahashi, Atsushi Masamune

Clinical journal of gastroenterology　14　(4)　1108-1114　2021/08

DOI： 10.1007/s12328-021-01389-4 　

More details Close

A 31-year-old man with Crohn's disease in remission after 6-year treatment with infliximab developed nasopharyngeal diffuse large B cell lymphoma. Infliximab was discontinued, and complete remission was achieved following chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, the patient subsequently experienced severely symptomatic Crohn's disease relapse. Therapy with adalimumab was initiated, and the patient attained remission. However, after 3 months, he suffered a recurrence of the lymphoma. Adalimumab was discontinued, and the patient received further chemotherapy (with rituximab, etoposide, cisplatin, methylprednisolone, and high-dose cytarabine) treatment and underwent allogeneic hematopoietic stem cell transplantation. Following the procedure, Crohn's disease and lymphoma have remained in complete remission for 5 years. There are limited reports on Crohn's disease remission after allogeneic hematopoietic stem cell transplantation. Therefore, we present this case report and a review of the existing literature on allogeneic stem cell transplantation for Crohn's disease.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. International-journal

Yasuhito Terui, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Hirohiko Shibayama

Cancer science　112　(7)　2845-2854　2021/07

DOI： 10.1111/cas.14937 　

More details Close

Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2 , rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography-computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT.
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. International-journal

Hidetsugu Kawai, Kiyoshi Ando, Dai Maruyama, Kazuhito Yamamoto, Eiji Kiyohara, Yasuhito Terui, Noriko Fukuhara, Tomomitsu Miyagaki, Yoshiki Tokura, Mamiko Sakata-Yanagimoto, Tadahiko Igarashi, Junya Kuroda, Jiro Fujita, Toshiki Uchida, Takayuki Ishikawa, Kentaro Yonekura, Koji Kato, Tadashi Nakanishi, Kenya Nakai, Risa Matsunaga, Kensei Tobinai

Cancer science　112　(6)　2426-2435　2021/06

DOI： 10.1111/cas.14906 　

More details Close

E7777 is a recombinant cytotoxic fusion protein composed of the diphtheria toxin fragments A and B and human interleukin-2. It shares an amino acid sequence with denileukin diftitox, but has improved purity and an increased percentage of active monomer. We undertook a multicenter, single-arm phase II study of E7777 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) to evaluate its efficacy, safety, pharmacokinetics, and immunogenicity. A total of 37 patients were enrolled, of which 17 and 19 patients had PTCL and CTCL, respectively, and one patient with another type of lymphoma (extranodal natural killer/T-cell lymphoma, nasal type), diagnosed by the Central Pathological Diagnosis Committee. Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36% (41% and 31%, respectively). The median progression-free survival was 3.1 months (2.1 months in PTCL and 4.2 months in CTCL). The common adverse events (AEs) observed were increased aspartate aminotransferase (AST) / alanine aminotransferase (ALT), hypoalbuminemia, lymphopenia, and pyrexia. Our results indicated that a 9 µg/kg/d dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression. The common AEs were manageable, but increase in ALT / AST, hypoalbuminemia, and capillary leak syndrome should be carefully managed during the treatment.
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. International-journal

Shuichi Taniguchi, Takahiro Yamauchi, Ilseung Choi, Noriko Fukuhara, Jalaja Potluri, Ahmed Hamed Salem, Wan-Jen Hong, Hideyuki Honda, Yasuko Nishimura, Sumiko Okubo, Kensuke Usuki

Japanese journal of clinical oncology　51　(6)　857-864　2021/05/28

DOI： 10.1093/jjco/hyab018 　

More details Close

BACKGROUND: Venetoclax plus azacitidine is indicated in the USA for the treatment of newly diagnosed acute myeloid leukaemia in older patients (≥75 years) or those ineligible for induction chemotherapy due to co-morbidities. METHODS: In this phase 1/2 study (NCT02265731), Japanese patients (≥60 years) with untreated (ineligible for induction chemotherapy) or relapsed/refractory acute myeloid leukaemia received oral venetoclax 400 mg/day (3-day ramp up in cycle 1) plus subcutaneous or intravenous azacitidine 75 mg/m2 on days 1-7 per 28-day cycle until disease progression or unacceptable toxicity. RESULTS: As of 10 December 2019, six patients were enrolled (median age: 75 years; untreated: n = 5; relapsed/refractory: n = 1); median treatment duration: 10.3 months (range, 0.7-29.4). Most common grade ≥ 3 adverse events were lymphopaenia and febrile neutropaenia (n = 4 each). Four patients reported serious adverse events; only an event of grade 3 fungal pneumonia was considered possibly related to both study drugs, requiring dose interruption of venetoclax and delay of azacitidine. Five (83%) patients had responses (complete remission: n = 3). Median time to first response of complete remission/complete remission with incomplete count recovery was 1.0 month (range, 0.8-5.5); median overall survival: 15.7 months (95% confidence interval: 6.2, not reached). CONCLUSIONS: Venetoclax plus azacitidine was well tolerated and showed high response rates in Japanese patients with acute myeloid leukaemia.
当科における臓器移植後リンパ増殖性疾患の経験

渡邊正太郎, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　61　98-98　2021/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Disseminated gonococcal infection in a patient with paroxysmal nocturnal haemoglobinuria receiving eculizumab. International-journal

Ikumi Niitsuma-Sugaya, Hajime Kanamori, Satoshi Ichikawa, Noriko Fukuhara, Issei Seike, Kentaro Takei, Hiroaki Baba, Kengo Oshima, Tetsuji Aoyagi, Hideo Harigae, Koichi Tokuda

The Lancet. Infectious diseases　21　(5)　741-741　2021/05

DOI： 10.1016/S1473-3099(20)30930-0 　
Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation.

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Kazuki Sakurai, Kyoko Inokura, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Junichi Kameoka, Hideo Harigae

Internal medicine (Tokyo, Japan)　60　(18)　3015-3019　2021/04/05

DOI： 10.2169/internalmedicine.6796-20 　

More details Close

Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia accompanied by an aggressive clinical course and dismal prognosis. We herein report a case of AMKL preceded by mediastinal germ cell tumor that relapsed early after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning but was successfully treated using salvage cord blood transplantation (CBT) with reduced-intensity conditioning. Although several serious complications developed, sustained remission with a favorable general condition was ultimately achieved. Although an optimal therapeutic strategy remains to be established, the graft-versus-leukemia effect of CBT may be promising, even for the treatment of refractory AMKL.
移植後早期再発した急性巨核芽球性白血病に対して臍帯血移植を行い長期寛解を達成した1例

櫻井一貴, 市川聡, 齋藤慧, 猪倉恭子, 福原規子, 横山寿行, 小野寺晃一, 大西康, 藤原亨, 亀岡淳一, 張替秀郎

臨床血液　62　(4)　323-323　2021/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Kathryn Humphrey, Su Young Kim, Sumiko Okubo, Natsumi Ogawa, Yasuko Nishimura, Ahmed Hamed Salem, Dai Maruyama

International journal of hematology　113　(3)　370-380　2021/03

DOI： 10.1007/s12185-020-03024-3 　

More details Close

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options. Venetoclax is a potent BCL-2 inhibitor that induces apoptosis in CLL cells. This open-label, phase 1/2 study (NCT02265731) evaluated the safety, pharmacokinetics, and efficacy of venetoclax in Japanese patients with R/R CLL/SLL. Patients enrolled in phase 1 received 400 mg/day venetoclax monotherapy. Patients enrolled in phase 2 received 400 mg/day venetoclax, plus rituximab. Venetoclax was administered with a weekly stepwise ramp-up in doses. In phase 2, efficacy was evaluated by objective response rate (ORR). Twelve patients were enrolled, six in each arm. The most common grade ≥ 3 adverse events were neutropenia (83%), lymphopenia (67%), leukopenia (33%), and thrombocytopenia (17%). Patients receiving venetoclax monotherapy achieved an ORR of 100%, including a complete remission (CR) rate of 17%. Patients receiving combination therapy had an ORR of 67% and a CR rate of 50%. The venetoclax pharmacokinetics profile in Japanese patients was similar to that of Western patients. Venetoclax 400 mg/day monotherapy or in combination with rituximab was well-tolerated and induced promising responses in Japanese patients with R/R CLL/SLL. Although patient numbers were small, the safety profile was largely consistent with other Western studies. Clinical trial registration: clinicaltrials.gov; NCT02265731.
A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. International-journal

Tetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, Shinichi Masuda, Yasuhiko Shibasaki, Tatsunori Goto, Noriko Fukuhara, Nobuharu Fujii, Kazuhiro Ikegame, Junichi Sugita, Takashi Ikeda, Yachiyo Kuwatsuka, Ritsuro Suzuki, Yuho Najima, Noriko Doki, Tomonori Kato, Yuichiro Inagaki, Yoshikazu Utsu, Nobuyuki Aotsuka, Masayoshi Masuko, Seitaro Terakura, Yasushi Onishi, Yoshinobu Maeda, Masaya Okada, Takanori Teshima, Makoto Murata

Annals of hematology　100　(3)　743-752　2021/03

DOI： 10.1007/s00277-020-04365-z 　

More details Close

To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 107/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0-85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 109/L on day 60 was 80.6% (68.2-88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L on day 100 were 75.8% (62.6-84.9%) and 72.6% (59.4-82.1%), respectively, with median time to platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. International-journal

Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Youko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Dai Maruyama, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai

Blood advances　5　(4)　984-993　2021/02/23

DOI： 10.1182/bloodadvances.2020002567 　

More details Close

Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (RW-CHOP) in patients with untreated DLBCL, we conducted a phase 2/3 study (JCOG0601, jRCTs031180139). Patients were randomly assigned to R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2]) or RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2]) groups. The primary end point of the phase 2 component was percent complete response (%CR) of the RW-CHOP arm, whereas that of the phase 3 component was progression-free survival (PFS). Between December 2007 and December 2014, 421 untreated patients were randomly assigned to R-CHOP (213 patients) or RW-CHOP (208 patients). The %CR in the RW-CHOP arm was 85.3% and therefore met the prespecified decision criteria for the phase 2 component. With a median follow-up of 63.4 months, the 3-year PFS and overall survival were 79.2% and 88.7% in the R-CHOP arm and 80.3% and 90.4% in the RW-CHOP arm, respectively. There was no significant difference in PFS (hazard ratio, 0.95; 90.6% confidence interval, 0.68-1.31). Although the safety profile and efficacy of RW-CHOP was comparable with R-CHOP and its tolerability was acceptable, weekly rituximab in combination with CHOP during the early treatment period did not improve PFS in untreated patients with DLBCL. This trial was registered at jrct.niph.go.jp as #jRCTs031180139.
Massive bone marrow infiltration of neuroendocrine carcinoma mimicking aggressive hematological malignancy

Ichikawa, S., Inokura, K., Kawamura, Y., Fukuhara, N., Yokoyama, H., Ouchi, K., Fujishima, F., Harigae, H.

Journal of Hematopathology　14　(4)　337-339　2021

DOI： 10.1007/s12308-021-00475-3 　

ISSN： 1865-5785 1868-9256

eISSN： 1865-5785
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. International-journal

Noriko Fukuhara, Tomohiro Kinoshita, Kazuhito Yamamoto, Hirokazu Nagai, Koji Izutsu, Go Yamamoto, Pankaj Bhargava, Nishan Rajakumaraswamy, Rita Humeniuk, Anita Mathias, Guan Xing, Masato Fukui, Kensei Tobinai

Japanese journal of clinical oncology　50　(12)　1395-1402　2020/12/16

DOI： 10.1093/jjco/hyaa153 　

More details Close

OBJECTIVE: Idelalisib is an orally administered, highly selective inhibitor of phosphatidylinositol 3-kinase-δ. In this phase 1b study, the safety, tolerability and pharmacokinetics of idelalisib, an oral inhibitor of phosphatidylinositol 3-kinase-δ, were evaluated in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. METHODS: In total, six patients (follicular lymphoma: n = 3, chronic lymphocytic leukemia: n = 3) were enrolled to receive idelalisib 150 mg twice daily. RESULTS: No dose-limiting toxicities were reported. The most common adverse events were diarrhea (n = 5), gastritis (n = 3), insomnia (n = 3) and pyrexia (n = 3). The most common ≥grade 3 adverse events were diarrhea (n = 2), increased transaminase levels (n = 2) and decreased appetite (n = 2). The maximum idelalisib plasma concentrations (Cmax) were achieved at 2.50 h (range: 1.50-4.00 h). The mean idelalisib plasma concentrations decreased over time but remained detectable in most patients at 12 h. All enrolled patients underwent efficacy evaluation by investigators, and five patients (follicular lymphoma: n = 2, chronic lymphocytic leukemia: n = 3) achieved partial response. The median duration of partial response was 14.5 months (range: 3.7-31.3 months). CONCLUSION: Idelalisib 150 mg twice daily was considered tolerable in Japanese patients with follicular lymphoma or chronic lymphocytic leukemia.(Clinical trial registration: NCT02242045).
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.

Shinichiro Matsuda, Ritsuro Suzuki, Tsutomu Takahashi, Youko Suehiro, Naoto Tomita, Koji Izutsu, Noriko Fukuhara, Yoshitaka Imaizumi, Kazuyuki Shimada, Tomonori Nakazato, Isao Yoshida, Kana Miyazaki, Motoko Yamaguchi, Junji Suzumiya

International journal of hematology　112　(6)　807-816　2020/12

DOI： 10.1007/s12185-020-02984-w 　

More details Close

CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) -/+ rituximab (R) is the standard chemotherapeutic regimen for aggressive lymphoma, but is insufficient for aggressive lymphoma with adverse prognostic factors. Dose-adjusted (DA)-EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisolone) -/+ R demonstrates excellent efficacy against some aggressive lymphoma. Thus, we conducted a retrospective study to evaluate the feasibility and efficacy of this therapy in clinical practice. We enrolled 149 patients from 17 institutions diagnosed between 2007 and 2015. The median follow-up period for survivors was 27 months (range 0.2-123). The complete response (CR) rate of newly diagnosed patients was 79% (95% CI 68-87%). All patients were hospitalized to receive this therapy and 94% of patients also received granulocyte-colony-stimulating factor support. There were no treatment-related deaths. Febrile neutropenia (FN) and grade 3 or 4 infection occurred in 55% and 28% of patients, respectively. There were no significant differences in FN or infection between young (≤ 65 years) and elderly patients (> 65 years). In newly diagnosed diffuse large B-cell lymphoma-not otherwise specified patients (n = 46), the CR rate was 80% (95% CI 64-91%) and the 2-year OS rate was 81% (95% CI 66-90%). In the present study, DA-EPOCH -/+ R exhibited excellent efficacy and feasibility for aggressive lymphoma.
臍帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の1例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　61　(11)　1631-1631　2020/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
臍帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の1例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　61　(11)　1631-1631　2020/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Successful Treatment of Primary Refractory Angioimmunoblastic T-cell Lymphoma With Cord Blood Transplantation. International-journal

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Eijiro Furukawa, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Clinical lymphoma, myeloma & leukemia　20　(11)　e926-e929　2020/11

DOI： 10.1016/j.clml.2020.07.009 　
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. International-journal

Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Noriko Fukuhara, Ilseung Choi, Junya Kuroda, Kiyoshi Ando, Akira Hattori, Kensei Tobinai

Japanese journal of clinical oncology　50　(11)　1265-1273　2020/10/22

DOI： 10.1093/jjco/hyaa117 　

More details Close

BACKGROUND: Many patients with classical Hodgkin lymphoma show increased programmed death-1 ligand expression in Reed-Sternberg cells. We report the final results of a phase II study of nivolumab, an anti-programmed death-1 monoclonal antibody, in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. METHODS: Japanese patients with previously treated classical Hodgkin lymphoma (aged ≥ 20 years) were administered nivolumab (3 mg/kg on Day 1 of 14-day cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason. Treatment could continue beyond progressive disease at the investigator's discretion in selected patients. RESULTS: Seventeen patients (median age: 63.0 years) were enrolled. The median follow-up was 38.8 months. One patient with non-Hodgkin lymphoma was excluded from efficacy analyses. The centrally assessed overall response rate in 16 classical Hodgkin lymphoma patients was 87.5% (95% confidence interval = 61.7-98.4%) and the disease control rate was 93.8% (95% confidence interval = 69.8-99.8%). The median (95% confidence interval) duration of response and progression-free survival were 8.5 (2.4-12.6) and 11.7 (1.8-42.3) months, respectively. The 3-year overall survival rate was 80.4% (95% confidence interval = 50.6-93.2%). Nivolumab was continued beyond progressive disease in seven patients; six were alive at the data cut-off. Adverse drug reactions occurred in all 17 patients with grades 3-4 adverse drug reactions in eight patients and no grade 5 adverse drug reactions. Pulmonary toxicities occurred in five patients; four of these occurred ≥17 months after starting nivolumab. CONCLUSION: Nivolumab is effective and tolerable in Japanese relapsed or refractory classical Hodgkin lymphoma patients. Continued monitoring may be necessary to detect late-onset pulmonary toxicities. CLINICAL TRIAL REGISTRATION: JapicCTI-142755 (Japan Pharmaceutical Information Center).
Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus.

Satoshi Ichikawa, Noriko Fukuhara, Tsuyoshi Shirai, Tomonori Ishii, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　112　(4)　592-596　2020/10

DOI： 10.1007/s12185-020-02914-w 　

More details Close

Increased incidence of lymphoproliferative disorders is reported in patients with autoimmune diseases, majority of which have a B-cell phenotype and are pathogenetically associated with the reactivation of Epstein-Barr virus (EBV). However, EBV-associated T/NK-cell lymphoma has hardly been reported. We present the case of a 68-year-old-woman, who had been diagnosed with systemic lupus erythematosus (SLE) 28 years back and was treated with various immunosuppressive agents including steroids, cyclophosphamide, and tacrolimus. She presented with a progressively worsening swelling of the right thigh for the last few months. Radiological examination revealed an intramuscular bulky tumor without any other lesions and the biopsy results led to a diagnosis of extranodal NK/T-cell lymphoma, nasal type (ENKL). Concurrent chemoradiotherapy resulted in a complete response, which has been sustained for more than 2 years without requiring additional therapy. After the initiation of chemotherapy, SLE did not worsen with the administration of low-dose corticosteroids. To the best of our knowledge, this is the first case report of a localized extranasal ENKL developing in a patient with SLE.
R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study. International-journal

Yoshitoyo Kagami, Kazuhito Yamamoto, Taro Shibata, Kensei Tobinai, Yoshitaka Imaizumi, Toshiki Uchida, Kazuyuki Shimada, Koichiro Minauchi, Noriko Fukuhara, Hirofumi Kobayashi, Nobuhiko Yamauchi, Hideki Tsujimura, Akira Hangaishi, Ryo Tominaga, Youko Suehiro, Shinichiro Yoshida, Yoshiko Inoue, Sachiko Suzuki, Michihide Tokuhira, Shigeru Kusumoto, Junya Kuroda, Yoshihiro Yakushijin, Yasushi Takamatsu, Yasushi Kubota, Kisato Nosaka, Satoko Morishima, Shigeo Nakamura, Michinori Ogura, Dai Maruyama, Tomomitsu Hotta, Yasuo Morishima, Kunihiro Tsukasaki, Hirokazu Nagai

Cancer science　111　(10)　3770-3779　2020/10

DOI： 10.1111/cas.14604 　

More details Close

The efficiency of upfront consolidation with high-dose chemotherapy/autologous stem-cell transplantation (HDCT/ASCT) for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in high-risk DLBCL patients having an age-adjusted International Prognostic Index (aaIPI) score of 2 or 3. As induction chemotherapy, 6 cycles of R-CHOP-14 (arm A) or 3 cycles of R-CHOP-14 followed by 3 cycles of CHASER (arm B) were planned, and patients who responded proceeded to HDCT with LEED and ASCT. The primary endpoint was 2-y progression-free survival (PFS), and the main secondary endpoints included overall survival, overall response rate, and adverse events (AEs). In total, 71 patients were enrolled. With a median follow-up of 40.3 mo, 2-y PFS in arms A and B were 68.6% (95% confidence interval [CI], 50.5%-81.2%) and 66.7% (95% CI: 48.8%-79.5%), respectively. Overall survival at 2 y in arms A and B was 74.3% (95% CI: 56.4%-85.7%) and 83.3% (95% CI: 66.6%-92.1%). Overall response rates were 82.9% in arm A and 69.4% in arm B. During induction chemotherapy, 45.7% and 75.0% of patients in arms A and B, respectively, had grade ≥ 3 non-hematologic toxicities. One patient in arm A and 6 in arm B discontinued induction chemotherapy due to AEs. In conclusion, R-CHOP-14 showed higher 2-y PFS and less toxicity compared with R-CHOP-14/CHASER in patients with high-risk DLBCL, suggesting the former to be a more promising induction regimen for further investigations (UMIN-CTR, UMIN000003823).
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. International-journal

Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi, Koji Izutsu

Cancer science　111　(9)　3327-3337　2020/09

DOI： 10.1111/cas.14561 　

More details Close

Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression-free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow-up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug-related atrial fibrillation or hypertension. Although the follow-up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI-173646).
A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis. International-journal

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Shunsuke Hatta, Koichi Onodera, Yasushi Onishi, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　100　(10)　2665-2668　2020/08/31

DOI： 10.1007/s00277-020-04241-w 　
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. International-journal

David G Maloney, Michinori Ogura, Noriko Fukuhara, Jaclyn Davis, Janet Lasher, Miguel Izquierdo, Hiya Banerjee, Kensei Tobinai

Blood advances　4　(16)　3886-3893　2020/08/25

DOI： 10.1182/bloodadvances.2020001942 　

More details Close

Because of high relapse rates with rituximab combinations, there is an unmet need for new therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular lymphoma (FL). In previous trials, ofatumumab in combination with chemotherapy showed good results in relapsed/refractory FL pretreated with rituximab. This phase 3 trial evaluated the efficacy and safety of single-agent ofatumumab vs single-agent rituximab in rituximab-sensitive relapsed FL that relapsed at least 6 months after completing the last prior treatment with single-agent rituximab or a rituximab-containing regimen. Patients were randomized 1:1 to receive either ofatumumab (1000 mg) or rituximab (375 mg/m2) every week for 4 weeks for the induction phase, followed by once every 2 months for 4 additional doses. The primary endpoint, progression-free survival (PFS) and secondary endpoints, overall response rate (ORR) and overall survival (OS), were evaluated. Overall, 438 patients were assigned to receive ofatumumab (n = 219) and rituximab (n = 219). Baseline characteristics were similar in both arms. The independent review committee assessed whether median PFS was shorter in the ofatumumab arm than in the rituximab arm (16.33 vs 21.29 months), with no significant difference (hazard ratio, 1.15; 95% confidence interval, 0.89-1.49; P = .29) and also showed a lower ORR (50%) compared with the rituximab arm (66%). At the time of analysis, data were not matured for OS results. The number of grade >3 adverse events was higher in the ofatumumab arm (37%) than the rituximab arm (28%). Ofatumumab showed no superiority over rituximab in patients with FL who had relapsed after a rituximab-containing therapy. This study was registered at www.clinicaltrials.gov as #NCT01200589.
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. International-journal

Ichiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, Tohru Kobayashi, Masahide Yamamoto, Akihisa Sawada, Yoshinori Ito, Noriko Fukuhara, Asao Hirose, Yusuke Takeda, Masanori Makita, Tomoyuki Endo, Shun-Ichi Kimura, Masataka Ishimura, Osamu Miura, Shouichi Ohga, Hiroshi Kimura, Shigeyoshi Fujiwara, Ayako Arai

Blood advances　4　(13)　2918-2926　2020/07/14

DOI： 10.1182/bloodadvances.2020001451 　

More details Close

Systemic chronic active Epstein-Barr virus infection (sCAEBV) was defined as a T- or NK-cell neoplasm in the 2017 World Health Organization (WHO) classification. To clarify the clinical features of sCAEBV under this classification and review the effects of chemotherapy, we performed a nationwide survey in Japan from 2016 through 2018 of patients with sCAEBV newly diagnosed from January 2003 through March 2016. One hundred cases were evaluated. The patients were aged 1 to 78 years (median, 21) and included 53 males and 47 females. Spontaneous regression was not observed in patients with active disease. In the childhood-onset group (age, <9 years), 78% of the patients were male. In contrast, 85% of the patients in the elderly-onset group (age, >45 years) were female. The prognosis of the childhood-onset group was better than those of the adolescent/adult- and elderly-onset groups. The main chemotherapies used were a combination of cyclosporine A, steroids, and etoposide (cooling therapy) in 52 cases and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) in 45 cases. The rate of complete response (CR), defined as complete resolution of disease activity, was 17% for cooling therapy and 13% for CHOP. Virological CR was not observed. The 3-year overall survival rates in patients treated with chemotherapy only (n = 20), chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 47), and allo-HSCT only (n = 12) were 0%, 65%, and 82%, respectively. Distinct characteristics were observed between childhood- and elderly-onset sCAEBV, and they appeared to be different disorders. Chemotherapy is currently insufficient to resolve disease activity and eradicate infected cells. The development of an effective treatment is urgently needed.
未治療又は再発/難治性の原発性マクログロブリン血症患者を対象としたチラブルチニブ(ONO/GS-4059)の国内第II相試験

棟方理, 関口直宏, 頼晋也, 鈴木憲史, 半田寛, 柴山浩彦, 遠藤知之, 照井康仁, 岩城憲子, 福原規子, 立津央, 飯田真介, 石川隆之, 椎橋竜太, 伊豆津宏二

日本リンパ網内系学会会誌　60　79-79　2020/07
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
未治療又は再発/難治性の原発性マクログロブリン血症患者を対象としたチラブルチニブ(ONO/GS-4059)の国内第II相試験

棟方理, 関口直宏, 頼晋也, 鈴木憲史, 半田寛, 柴山浩彦, 遠藤知之, 照井康仁, 岩城憲子, 福原規子, 立津央, 飯田真介, 石川隆之, 椎橋竜太, 伊豆津宏二

日本リンパ網内系学会会誌　60　79-79　2020/07
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. International-journal Peer-reviewed

Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa

Neuro-oncology　23　(1)　122-133　2020/06/25

DOI： 10.1093/neuonc/noaa145 　

More details Close

BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL). METHODS: Patients with relapsed/refractory PCNSL, Karnofsky performance status ≥70, and normal end-organ function received tirabrutinib 320 and 480 mg once daily (QD) in phase 1 to evaluate dose-limiting toxicity (DLT) within 28 days using a 3+3 dose escalation design and with 480 mg QD under fasted conditions in phase 2. RESULTS: Forty-four patients were enrolled; 20, seven and 17 received tirabrutinib at 320, 480 and 480 mg under fasted conditions, respectively. No DLTs were observed, and the maximum tolerated dose was not reached at 480 mg. Common grade ≥3 adverse events (AEs) were neutropenia (9.1%), lymphopenia, leukopenia, and erythema multiforme (6.8% each). One patient with 480 mg QD had grade 5 AEs (pneumocystis jirovecii pneumonia and interstitial lung disease). Independent review committee-assessed overall response rate (ORR) was 64%: 60% with five complete responses (CR)/unconfirmed complete responses (CRu) at 320 mg, 100% with four CR/CRu at 480 mg, and 53% with six CR/CRu at 480 mg under fasted conditions. Median progression-free survival was 2.9 months: 2.1, 11.1 and 5.8 months at 320, 480, and 480 mg under fasted conditions, respectively. Median overall survival was not reached. ORR was similar among patients harboring CARD11, MYD88, and CD79B mutations, and corresponding wild-types. CONCLUSION: These data indicate favorable efficacy of tirabrutinib in patients with relapsed/refractory PCNSL.
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). International-journal Peer-reviewed

Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, Noriko Fukuhara, Sachiko Seo, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura, Akira Hangaishi, Takahiro Yamauchi, Takahiko Utsumi, Ishikazu Mizuno, Yasushi Takamatsu, Yasuyuki Nagata, Koichiro Minauchi, Eiichi Ohtsuka, Ichiro Hanamura, Shinichiro Yoshida, Satoshi Yamasaki, Youko Suehiro, Yutaro Kamiyama, Kunihiro Tsukasaki, Hirokazu Nagai

British journal of haematology　192　(3)　531-541　2020/06/24

DOI： 10.1111/bjh.16878 　

More details Close

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45·8 and 35·1 mg/m2 , CR rate was 18·6% [95% confidence interval (CI) 8·4-33·4] and 6·7% (95% CI 1·4-18·3), and the median progression-free survival (PFS) was 2·5 and 1·4 years in Arms A and B [hazard ratio (HR) 1·93 (95% CI 1·09-3·42)], respectively. Frequent grade ≥3 haematologic toxicities in Arms A and B were neutropenia (64·4% vs. 28·3%) and thrombocytopenia (35·6% vs. 10·9%). Grade 2/3 peripheral neuropathy was observed in 24·4/2·2% in Arm A and 8·7/0% in Arm B. In conclusion, Arm A was the more promising regimen, suggesting that the twice weekly schedule of bortezomib in the first cycle and higher cumulative dose of both bortezomib and melphalan influences the efficacy of modified MPB.
Sustained remission of giant pancreatic plasmacytoma with daratumumab. International-journal

Satoshi Ichikawa, Eijiro Furukawa, Kei Saito, Noriko Fukuhara, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　100　(10)　2633-2634　2020/06/18

DOI： 10.1007/s00277-020-04145-9 　
【血液疾患と消化器系の異常】原発性十二指腸・小腸リンパ腫の病態と治療

市川聡, 福原規子, 一迫玲

血液内科　80　(6)　835-841　2020/06
Publisher: (有)科学評論社
ISSN： 2185-582X
Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Leukemia & lymphoma　61　(6)　1504-1507　2020/06

DOI： 10.1080/10428194.2020.1713322 　
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection. Peer-reviewed

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

Internal medicine (Tokyo, Japan)　59　(10)　1303-1308　2020/05/15

DOI： 10.2169/internalmedicine.4142-19 　

More details Close

Acquired factor X deficiency (AFXD) is a very rare coagulation disorder. A 40-year-old man with no comorbidities suffering from a fever, malaise, and severe hemorrhagic symptoms, including massive hematuria, was emergently admitted. His platelet count was normal, but his prothrombin time and activated partial thromboplastin time were markedly prolonged, which was thought to be due to autoantibody against a coagulation factor in the common pathway. Despite severe massive hematuria resulting in transient renal failure, he was successfully treated with urgent immunosuppressive therapy. Computed tomography revealed bronchopneumonia, which improved with antibiotic administration. AFXD without evidence of amyloidosis was subsequently diagnosed.
Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Tsuyoshi Shirai, Yasushi Onishi, Hisayuki Yokoyama, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　111　(5)　667-672　2020/05

DOI： 10.1007/s12185-020-02822-z 　

More details Close

Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX-CHL patients suffering from an autoimmune disease (AID), such as rheumatoid arthritis (RA), as they frequently have pulmonary complications. However, brentuximab vedotin (BV)-containing chemotherapy without bleomycin (A + AVD regimen) was recently reported to show favorable efficacy for CHL, and could therefore be beneficial in MTX-CHL. We treated three cases of MTX-CHL using the A + AVD regimen. All were female and had received MTX for more than 15 years. Underlying AIDs in these patients were RA in two patients, and overlap syndrome with systemic lupus erythematosus and dermatomyositis in one patient. The A + AVD regimen resulted in a complete response in all patients. Peripheral neuropathy developed in two patients, necessitating reduction of the BV dose. All three patients experienced hematological toxicity necessitating dose reduction; however, no severe adverse effects, including infection or pulmonary complication, were documented. RA was well-controlled without additional immunosuppressants. The A + AVD regimen is a promising chemotherapy for MTX-CHL with favorable efficacy and tolerable toxicity profiles.
節外性NK/T細胞リンパ腫の同種移植後早期再発に対して短期L-asparaginase投与が著効した1例

市川聡, 福原規子, 齋藤慧, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

臨床血液　61　(4)　418-418　2020/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. International-journal Peer-reviewed

Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

Bone marrow transplantation　55　(7)　1399-1409　2020/03/16

DOI： 10.1038/s41409-020-0859-8 　

More details Close

A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. International-journal Peer-reviewed

Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Masataka Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Tohru Izumi, Yoshihiro Kin, Kunihiro Tsukasaki, Daigo Hashimoto, Masaaki Yuge, Atsumi Yanagisawa, Yachiyo Kuwatsuka, Satoko Shimada, Yasufumi Masaki, Nozomi Niitsu, Hitoshi Kiyoi, Ritsuro Suzuki, Takashi Tokunaga, Shigeo Nakamura, Tomohiro Kinoshita

The Lancet. Oncology　21　(4)　593-602　2020/03/11

DOI： 10.1016/S1470-2045(20)30059-0 　

More details Close

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. METHODS: PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan. Eligible patients had untreated histologically confirmed IVLBCL, were aged 20-79 years, had an Eastern Cooperative Group performance status of 0-3, and had no apparent CNS involvement at diagnosis. Patients received three cycles of R-CHOP (rituximab 375 mg/m2 intravenously on day 1 [except cycle one, which was on day 8]; cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2·0 mg] intravenously on day 1 of cycle one and day 2 of cycles two and three; and prednisolone 100 mg/day orally on days 1-5 of cycle one and days 2-6 of cycles two and three) followed by two cycles of rituximab with high-dose methotrexate (3·5 g/m2 intravenously on day 2 of cycles four and five) every 2 weeks and three additional cycles of R-CHOP. Intrathecal chemotherapy (methotrexate 15 mg, cytarabine 40 mg, and prednisolone 10 mg) was administered four times during the R-CHOP phase. The primary endpoint was 2-year progression-free survival. Efficacy analyses were done in all enrolled patients; safety analyses were done in all enrolled and treated patients. The trial is registered in the UMIN Clinical Trials Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165); the trial is ongoing for long-term follow-up. FINDINGS: Between June 16, 2011, and July 21, 2016, 38 patients were enrolled, of whom 37 were eligible; one patient was excluded because of a history of testicular lymphoma. Median follow-up was 3·9 years (IQR 2·5-5·5). 2-year progression-free survival was 76% (95% CI 58-87). The most frequent adverse events of grade 3-4 were neutropenia and leucocytopenia, which were reported in all 38 (100%) patients. Serious adverse events were hypokalaemia, febrile neutropenia with hypotension, hypertension, and intracerebral haemorrhage (reported in one [3%] patient each). No treatment-related deaths occurred during protocol treatment. INTERPRETATION: R-CHOP combined with rituximab and high-dose methotrexate plus intrathecal chemotherapy is a safe and active treatment for patients with IVLBCL without apparent CNS involvement at diagnosis, and this regimen warrants future investigation. FUNDING: The Japan Agency for Medical Research and Development, the Center for Supporting Hematology-Oncology Trials, and the National Cancer Center.
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai, Tomoko Ohtsu, Stacey Kalambakas, Pierre Fustier, Shuichi Midorikawa, Kensei Tobinai

International journal of hematology　111　(3)　409-416　2020/03

DOI： 10.1007/s12185-019-02802-y 　

More details Close

Patients with indolent non-Hodgkin lymphoma (iNHL) typically respond to first-line immunochemotherapy, but relapse is common. Treatment options for relapsed iNHL include chemotherapy ± rituximab and rituximab monotherapy. Lenalidomide plus rituximab (R2) is an immunomodulatory regimen that enhances rituximab-mediated cytotoxicity and improves clinical activity in iNHL. AUGMENT was a double-blind phase III randomized trial of R2 vs. rituximab + placebo (R-placebo) in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma who were not refractory to rituximab. The primary endpoint was progression-free survival (PFS). Data reported here focus on Japanese patients from AUGMENT and reflect 36 patients (n = 18, each group). PFS was superior in the R2 group, HR = 0.32 (95% CI 0.11-0.96). Median PFS was not reached (95% CI 19.7-NE) in the R2 group vs. 16.5 months (95% CI 11.3-30.6) in the R-placebo group. Grade 3/4 adverse events were more frequent in patients treated with R2 (67%) than with R-placebo (22%), primarily attributable to increased neutropenia (50% vs 17%). R2 resulted in significantly longer median PFS than R-placebo in Japanese patients with R/R iNHL, and the efficacy and the safety profile of R2 were similar to those reported in the global population.
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide plus rituximab (R-2) vs. rituximab plus placebo in relapsed/refractory indolent non-Hodgkin lymphoma

Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai, Tomoko Ohtsu, Stacey Kalambakas, Pierre Fustier, Shuichi Midorikawa, Kensei Tobinai

INTERNATIONAL JOURNAL OF HEMATOLOGY　111　(3)　409-416　2020/03

DOI： 10.1007/s12185-019-02802-y 　

ISSN： 0925-5710

eISSN： 1865-3774
Primary ovarian diffuse large B-cell lymphoma preceded by autoimmune hemolytic anemia Peer-reviewed

Satoshi Ichikawa, Asami Sasaoka, Noriko Fukuhara, Yoko Okitsu, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Journal of Hematopathology　13　(1)　63-67　2020/03
Publisher: Springer Science and Business Media LLC
DOI： 10.1007/s12308-019-00377-5 　

ISSN： 1868-9256

eISSN： 1865-5785
Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Shotaro Watanabe, Yoko Okitsu, Koichi Onodera, Yasushi Onishi, Hideo Harigae

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　26　(2)　292-295　2020/02

DOI： 10.1016/j.jiac.2019.08.022 　

ISSN： 1341-321X

More details Close

Fusariosis is a critical infectious complication that can develop in immunocompromised hosts, mainly under conditions of prolonged neutropenia, and is often disseminated and associated with a high mortality rate. Disseminated fusariosis developing during the course of hematopoietic stem cell transplantation (HSCT) is a critical condition, and there have been few reports of successful treatment of cases complicated with fusariosis before HSCT. Here, we present a case of acute myeloid leukemia (AML) with the development of fungal endophthalmitis during chemotherapy. Vitrectomy was performed and Fusarium solani infection was confirmed by vitreal culture. The infection was also disseminated to the lung, triceps, and spleen. The splenic lesions disappeared with the administration of antifungal agents, and residual lesions in the lung and triceps were surgically resected. After two courses of consolidation chemotherapy, the patient received cord blood transplantation (CBT) twice because of graft failure in the first transplantation. Antifungal agents were administered continuously during chemotherapy and transplantation. Although Fusarium sinusitis developed after neutrophil engraftment, it was well controlled by surgical resection. Thereafter, the patient has been well without recurrence of fusariosis for more than 2 years since transplantation. A combination of continuous administration of antifungal agents and vigorous surgical intervention may be important for management of disseminated fusariosis in the setting of HSCT.
Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study International-journal

Noriko Fukuhara, Go Yamamoto, Hideki Tsujimura, Takaaki Chou, Hirohiko Shibayama, Tomoko Yanai, Kazunori Shibuya, Koji Izutsu

Leukemia & Lymphoma　61　(1)　176-180　2020/01/02
Publisher: Informa UK Limited
DOI： 10.1080/10428194.2019.1654100 　

ISSN： 1042-8194

eISSN： 1029-2403
[Updates in treatment strategies for follicular lymphoma].

Noriko Fukuhara

[Rinsho ketsueki] The Japanese journal of clinical hematology　61　(9)　1252-1258　2020

DOI： 10.11406/rinketsu.61.1252 　

More details Close

Follicular lymphoma (FL) is incurable with the current standard therapeutic strategy despite improvements of the natural history of FL in the last few decades. For advanced-stage patients with low-tumor burden, watchful waiting remains the standard treatment. The optimal timing of rituximab monotherapy has not been elucidated. For advanced-stage patients with high-tumor burden, anti-CD20 monoclonal antibody and chemotherapy are the standard care. A subset of FL patients who had early progression of relapse within 24 months has a significantly poor prognosis. Among the early progression of the disease group, more early progression and transformation are important factors. Recently, genomic analysis suggests that high-risk biology may depend on the type of chemotherapy. Therefore, the genomic profile could help develop appropriate treatment selection in the future. This review includes the current FL treatment strategy and prognostic factors.
Primary adrenal extranodal NK/T-cell lymphoma: A case report and literature review. International-journal

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Leukemia research reports　14　100223-100223　2020

DOI： 10.1016/j.lrr.2020.100223 　

More details Close

A 37-year-old man was admitted to our department following the detection of bulky tumors in his bilateral adrenal glands. A biopsy resulted in the diagnosis of extranodal NK/T cell lymphoma, nasal type (ENKL). After debulking by chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHCT) was performed. Relapses in the liver and adrenal glands were identified 2 months post alloHCT, for which temporary administration of l-asparaginase resulted in complete metabolic response. However, multiple relapses in the central nervous system and lethal lymphomatous meningitis successively developed. Primary adrenal ENKL could tend to present as bulky lesion and follow an aggressive clinical course.
輸血依存の再生不良性貧血に対してeltrombopagが奏効しferritin値の改善とともに血球回復が得られた1例

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　60　(11)　1595-1596　2019/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. Peer-reviewed

Keita Iwaki, Tohru Fujiwara, Takako Ito, Chie Suzuki, Katsuyuki Sasaki, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Tohru Tanaka, Hideto Tamura, Minami Fujiwara, Hideo Harigae

The Tohoku journal of experimental medicine　249　(1)　19-28　2019/09

DOI： 10.1620/tjem.249.19 　

ISSN： 0040-8727

More details Close

Multiple myeloma is the cancer of plasma cells. Along with the development of new and effective therapies, improved outcomes in patients with multiple myeloma have increased the interest in minimal residual disease (MRD) monitoring. However, the considerable heterogeneity of immunophenotypic and molecular markers of myeloma cells has limited its clinical application. 5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway. Following ALA treatment, tumor cells preferentially accumulate porphyrins because of the differential activities of aerobic glycolysis, known as Warburg effect. Among various porphyrins, protoporphyrine IX is a strong photosensitizer; thus, ALA-based photodynamic diagnosis has been widely used in various solid cancers. Here, the feasibility of flow cytometry-based photodynamic detection of MRD was tested in multiple myeloma. Among various human cell lines of hematological malignancies, including K562 erythroleukemia, Jurkat T-cell leukemia, Nalm6 pre-B cell leukemia, KG1a myeloid leukemia, and U937 monocytic leukemia, human myeloma cell line, KMS18, and OPM2 abundantly expressed ALA transporters, such as SLC36A1 and SLC15A2, and 1 mM ALA treatment for 24 h resulted in nearly 100% porphyrin fluorescence expression, which could be competitively inhibited by ALA transport with gamma-aminobutyric acid. Titration studies revealed that the lowest ALA concentration required to achieve nearly 100% porphyrin fluorescence in KMS18 cells was 0.25 mM, with an incubation period of 2 h. Under these conditions, incubation of primary peripheral blood mononuclear cells resulted in only 1.8 % of the cells exhibiting porphyrin fluorescence. Therefore, flow cytometry-based photodynamic diagnosis is a promising approach for detecting MRD in multiple myeloma.
Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome. International-journal Peer-reviewed

Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Kohno A, Onishi Y, Fukuhara N, Kasai M, Fujii N, Yokoyama H, Iida H, Kanemura N, Fujieda A, Ago H, Tsutsumi Y, Nakamura F, Yago K, Moriuchi Y, Ota S, Ohashi H, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, Murata M, Nagoya Blood, Marrow Transplantation Group

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation　26　(1)　139-144　2019/09

DOI： 10.1016/j.bbmt.2019.09.021 　

ISSN： 1083-8791

More details Close

Almost comparable transplantation outcomes have been reported with HLA-matched unrelated donor transplantation (UDT) and cord blood transplantation (CBT). We conducted a prospective phase 2 study to assess the efficacy and safety of single-unit myeloablative CBT in adult leukemia and myelodysplastic syndrome. Because the day 180 survival of UDT was approximately 80%, we determined the alternative hypothesis of expected day 180 survival with a successful engraftment rate of 80% and set the null hypothesis of threshold rate at 65%. Sixty-two patients (median age, 37 years) were registered, including 28 with acute myelogenous leukemia, 25 with acute lymphoblastic leukemia, and 9 with myelodysplastic syndrome. Of 61 eligible patients, 52 were successfully engrafted and survived at day 180 (85%; 95% confidence interval, 74% to 93%). Single-unit CBT was judged to be effective because the null hypothesis was rejected (P < .001). Furthermore, neutrophil engraftment was observed in 57 patients (92%); the incidences of grade II-IV acute and chronic graft-versus-host disease were 30% and 32%, respectively; and the cumulative incidences of nonrelapse mortality and relapse at 2 years were 18% and 13%, respectively. The present study showed favorable survival outcomes with single-unit CBT. Therefore, this method may be considered if a well-HLA-matched UDT cannot be obtained.
Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. International-journal Peer-reviewed

Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri, Koichi Onodera, Eijiro Furukawa, Sayaka Sano, Kei Saito, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Hideo Harigae

Annals of hematology　98　(8)　1999-2001　2019/08

DOI： 10.1007/s00277-019-03645-7 　

ISSN： 0939-5555
再発又は難治性のCD30陽性古典的ホジキンリンパ腫/全身性未分化大細胞リンパ腫に対するBrentuximab Vedotin再治療の安全性及び有効性に関する後方視的検討

山本豪, 福原規子, 辻村秀樹, 張高明, 柴山浩彦, 矢内友子, 渋谷和憲, 伊豆津宏二

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

日本リンパ網内系学会会誌　59　147-147　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. International-journal Peer-reviewed

Wataru Munakata, Kiyoshi Ando, Kiyohiko Hatake, Noriko Fukuhara, Tomohiro Kinoshita, Suguru Fukuhara, Yukari Shirasugi, Masahiro Yokoyama, Satoshi Ichikawa, Ken Ohmachi, Naokazu Gion, Arata Aoi, Kensei Tobinai

Cancer science　110　(5)　1686-1694　2019/05

DOI： 10.1111/cas.13983 　

ISSN： 1347-9032

More details Close

We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). This was an open-label, multicenter, phase I study. Seventeen patients (male N = 8) with a median age of 70 years were enrolled in 4 dose cohorts (160 mg once daily [N = 3], 320 mg once daily [N = 3], 480 mg once daily [N = 4] and 300 mg twice daily [N = 7]); 4 patients had continued tirabrutinib administration as of 4 January 2018. The maximum tolerated dose was not reached. Pneumonitis (N = 1) was the dose-limiting toxicity for 300 mg twice daily. Common adverse events (AEs) were rash (35.3%) and vomiting (29.4%). Eight patients (47.1%) developed grade ≥3 AEs: neutropenia (23.5%), anemia (11.8%) and leukopenia (11.8%) were frequent. The overall response rate (≥PR) was 76.5% (13/17 patients), including 4 DLBCL patients with no CD79A/B or MYD88 mutations, and 1 CLL patient with a TP53 mutation, providing promising data for future developments. Of 16 patients with measurable lesions during the screening period, 12 showed ≥50% reductions in tumor diameter. In many patients, the tumor size decreased soon after beginning treatment. The maximum serum concentration for tirabrutinib was 611, 1220, 1280 and 886 ng/mL on Day 1 and 484, 971 1940, and 961 ng/mL on Day 28 for Cohorts 1-4, respectively. Tirabrutinib pharmacokinetics were linear, with little accumulation following multiple doses. Tirabrutinib was well tolerated and showed promising efficacy for B-cell NHL/CLL.
Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. International-journal Peer-reviewed

Saito K, Fujiwara T, Hatta S, Morita M, Ono K, Suzuki C, Fukuhara N, Onishi Y, Nakamura Y, Kawamata S, Shimizu R, Yamamoto M, Harigae H

Molecular and cellular biology　39　(7)　2019/04

DOI： 10.1128/MCB.00387-18 　

ISSN： 0270-7306

More details Close

Ring sideroblasts are a hallmark of sideroblastic anemia, although little is known about their characteristics. Here, we first generated mutant mice by disrupting the GATA-1 binding motif at the intron 1 enhancer of the ALAS2 gene, a gene responsible for X-linked sideroblastic anemia (XLSA). Although heterozygous female mice showed an anemic phenotype, ring sideroblasts were not observed in their bone marrow. We next established human induced pluripotent stem cell-derived proerythroblast clones harboring the same ALAS2 gene mutation. Through coculture with sodium ferrous citrate, mutant clones differentiated into mature erythroblasts and became ring sideroblasts with upregulation of metal transporters (MFRN1, ZIP8, and DMT1), suggesting a key role for ferrous iron in erythroid differentiation. Interestingly, holo-transferrin (holo-Tf) did not induce erythroid differentiation as well as ring sideroblast formation, and mutant cells underwent apoptosis. Despite massive iron granule content, ring sideroblasts were less apoptotic than holo-Tf-treated undifferentiated cells. Microarray analysis revealed upregulation of antiapoptotic genes in ring sideroblasts, a profile partly shared with erythroblasts from a patient with XLSA. These results suggest that ring sideroblasts exert a reaction to avoid cell death by activating antiapoptotic programs. Our model may become an important tool to clarify the pathophysiology of sideroblastic anemia.
Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. International-journal Peer-reviewed

Fukuhara N, Ishizawa K

Japanese journal of clinical oncology　49　(4)　306-310　2019/04

DOI： 10.1093/jjco/hyz008 　

ISSN： 0368-2811

More details Close

The introduction of a chimeric anti-CD20 monoclonal antibody, rituximab, for the treatment of follicular lymphoma (FL) has dramatically improved the prognosis of this disease. Despite advances in therapy, the disease remains incurable with current standard therapeutic strategies. For advanced-stage and high-tumor-burden FL patients, a combination of rituximab with chemotherapy has improved the overall survival rates, and subsequent rituximab maintenance following successful rituximab-based chemotherapy induction also prolongs progression-free survival. Conversely, for advanced-stage low-tumor-burden FL patients, watchful waiting remains the appropriate approach, whereas rituximab monotherapy has also been suggested as a good alternative. However, the optimal timing of rituximab monotherapy in low-tumor-burden FL patients has not been clarified. It is important to address this issue for chemo-free treatment strategies. Furthermore, a predictive model for advanced low-tumor-burden patients is required to appropriately identify those patients who may benefit from immediate treatment. In this review, we address the current treatment approaches and present potential future management strategies for advanced-stage, low-tumor-burden patients.
免疫不全に合併したNTM症 MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

結核　94　(3)　168-168　2019/03
Publisher: (一社)日本結核・非結核性抗酸菌症学会
ISSN： 0022-9776

eISSN： 1884-2410
Immunohistochemical pattern of c-MYC protein judged as "+/(weak)+/-" by a new notation correlates with MYC gene nontranslocation in large B-cell lymphoma. International-journal Peer-reviewed

Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Usubuchi H, Sato S, Ota Y, Yashima-Abo A, Nakamura T, Nakaya N, Harigae H, Sasano H, Ichinohasama R

Human pathology　85　112-118　2019/03

DOI： 10.1016/j.humpath.2018.10.025 　

ISSN： 0046-8177

More details Close

Immunohistochemistry is not only the most important tool for pathologists to establish a final diagnosis, but it can also inform decisions regarding optimal treatment methods. However, there is no universal standard notation for expressing immunohistochemical findings. For a diagnosis of malignant lymphoma, it is important to confirm the presence or absence of MYC translocation and communicate these results to a clinical audience. However, the criteria for selecting cases for fluorescence in situ hybridization (FISH) analysis to confirm MYC translocation are ill defined. We therefore devised a notation that we termed proportion of immunoreactivity/expression for immunohistochemistry (PRIME notation) based on the cellular proportion showing different antigen-antibody reactivity in immunohistochemistry (CPAR) and used it to examine the relationship between MYC translocation and the proportion of c-MYC+ lymphoma cells. We reviewed 82 cases diagnosed as diffuse large B-cell lymphoma or diffuse large B-cell lymphoma coexisting with grade 3A to 3B follicular lymphoma. The most common notation was "+/(weak)+/-" (49/82 cases [59.8%]); cases that were CPAR positive, weakly positive, and negative for tumor cells each accounted for about one-third of the total. Unexpectedly, no MYC translocation was observed by FISH in this group. Thus, FISH is not needed even if more than half of cells are c-MYC positive by PRIME notation. This is the first report describing a correspondence between immunohistochemical findings and chromosomal abnormality, reflecting findings at the protein and gene levels, respectively.
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study. Peer-reviewed

Tobinai K, Uchida T, Fukuhara N, Nishikawa T

International journal of hematology　109　(3)　366-368　2019/03

DOI： 10.1007/s12185-018-02577-8 　

ISSN： 0925-5710
Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. International-journal Peer-reviewed

Tetsuro Ochi, Yasushi Onishi, Kentaro Nasu, Koichi Onodera, Masahiro Kobayashi, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Minami Yamada-Fujiwara, Hideo Harigae

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation　25　(2)　e55-e59-e59　2019/02

DOI： 10.1016/j.bbmt.2018.09.039 　

ISSN： 1083-8791

More details Close

Umbilical cord blood transplantation (UCBT) is a possible option for patients with aplastic anemia (AA) without a related or unrelated HLA-matched donor, particularly if immunosuppressive therapy (IST) has failed or transplantation is urgently needed. However, a higher rate of graft failure after UCBT remains a major problem, and the optimal conditioning regimen for stable engraftment after UCBT has not been established. Here we investigated 6 adult patients with AA who underwent UCBT using a reduced-intensity conditioning (RIC) regimen comprising fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, and 4 Gy of total body irradiation (Flu/CY/TBI4Gy) without antithymocyte globulin (ATG). Five patients underwent UCBT after IST failure, and 1 patient underwent UCBT as a first-line treatment due to a fulminant clinical finding of a neutrophil count of 0, despite granulocyte colony-stimulating factor administration. Regarding graft-versus-host disease (GVHD) prophylaxis, 2 patients received tacrolimus plus short-term methotrexate and 4 patients received tacrolimus plus mycophenolate mofetil, and all patients achieved sustained engraftment of both neutrophils and platelets, at a median of 17.5 days (range, 14 to 37 days) and 38.5 days (range, 31 to 86 days), respectively, with complete donor chimerism confirmed in all patients at a median of 14 days (range, 14 to 32 days). Three patients developed grade II acute GVHD (aGVHD), but grade III/IV aGVHD was not observed, whereas 4 patients developed chronic GVHD involving only skin. At the time of this report, all 6 patients were alive without the need for blood transfusion, at a median follow-up of 16 months (range, 12 to 131 months). Although further study is needed, our findings suggest that conditioning with Flu/CY/TBI4Gy without ATG might allow stable engraftment in UCBT for adults with AA.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven Horwitz, Owen A. O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Arpad Illes, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Huttmann, Kerry J. Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trumper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie De Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven Legouill, Paul Larosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, Pierluigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain, Pier Luigi Zinzan

LANCET　393　(10168)　229-240　2019/01

DOI： 10.1016/S0140-6736(18)32984-2 　

ISSN： 0140-6736

eISSN： 1474-547X
γδ T cell clonal proliferation early after PD-1 blockade. International-journal Peer-reviewed

Koya Ono, Yasushi Onishi, Masahiro Kobayashi, Shunsuke Hatta, Kentaro Nasu, Shotaro Watanabe, Satoshi Ichikawa, Yoko Okitsu, Noriko Fukuhara, Hideo Harigae

Annals of hematology　98　(1)　219-220　2019/01

DOI： 10.1007/s00277-018-3406-6 　

ISSN： 0939-5555
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Peer-reviewed

Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T

Journal of clinical and experimental hematopathology : JCEH　59　(2)　98-100　2019

DOI： 10.3960/jslrt.19006 　

ISSN： 1346-4280

eISSN： 1880-9952
Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601 Peer-reviewed

Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Youko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Dai Maruyama, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai

BLOOD　132　2018/11

DOI： 10.1182/blood-2018-99-110201 　

ISSN： 0006-4971

eISSN： 1528-0020
Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma. Peer-reviewed

Satoshi Shimada, Takashi Nakamichi, Gen Yamada, Kaori Narumi, Hajime Usubuchi, Tae Yamamoto, Satoshi Ichikawa, Noriko Fukuhara, Mariko Miyazaki, Hideo Harigae, Hiroshi Sato, Sadayoshi Ito

CEN case reports　7　(2)　248-252　2018/11

DOI： 10.1007/s13730-018-0336-z 　

More details Close

A recent systematic review showed that hematological malignancy is often complicated by membranous nephropathy (MN). Histologically, the deposition of IgG subclasses other than IgG4 may imply secondary MN, such as malignancy-associated MN (M-MN). We describe a very rare case of concurrent isolated IgG2-positive MN and B-cell lymphoma. An 83-year-old woman was hospitalized at our institute for facial and lower extremity edema persisting for 2 months. Laboratory tests showed urinary protein level of 10.8 g/day, serum albumin level of 1.6 g/dl, and serum creatinine level of 2.34 mg/dl. Soon after diagnosis of nephrotic syndrome, treatment with corticosteroid was initiated, but it proved to be ineffective. Renal biopsy showed isolated IgG2-positive MN with highly infiltrated CD20-positive lymphoid cells in the kidney. Computed tomography revealed systemic lymphadenopathy, and aberrant B-cells with immunoglobulin light chain restriction were detected in peripheral blood and bone marrow, which led to the diagnosis of mature B-cell lymphoma. Although rituximab (375 mg/m2/week) was administered, the patient suddenly died from gastrointestinal bleeding on day 40 of hospitalization. It is, thus, necessary to consider hematological malignancy when a diagnosis of MN is made. Further studies are expected to elucidate the pathogenesis and to help establish the adequate treatment for this rare situation.
日本人再発難治性MCL患者に対するIbrutinibの第II相試験：最終解析結果 Peer-reviewed

福原規子, 永井宏和, 丸山大, 北野俊行, 石川隆之, 柴山浩彦, 崔日承, 畠清彦, 内田俊樹, 錦織桃子, 木下朝博, 松野吉宏, 西川智章, 飛内賢正

第80回日本血液学会学術集会　2018/10
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, Martine Bagot, Lauren Pinter-Brown, Alain H. Rook, Pierluigi Porcu, Steven M. Horwitz, Sean Whittaker, Yoshiki Tokura, Maarten Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz-Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig Elmets, Stephane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei Shustov, Barbara Pro, Larisa J. Geskin, Karen Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg Akilov, Onder Alpdogan, Marie Beylot-Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dreno, Reinhard Dummer, Timothy Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil Korman, Bryone Jean Kuss, Zanetta Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence Mark, Tomomitsu Miyagaki, Javier Munoz, Jan Peter Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem William, Kentaro Yonekura

The Lancet Oncology　19　(9)　1192-1204　2018/09

DOI： 10.1016/S1470-2045(18)30379-6 　

ISSN： 1470-2045

eISSN： 1474-5488
Successful Treatment of Aggressive Mature B-cell Lymphoma Mimicking Immune Thrombocytopenic Purpura. Peer-reviewed

Koya Ono, Yasushi Onishi, Masahiro Kobayashi, Satoshi Ichikawa, Shunsuke Hatta, Shotaro Watanabe, Yoko Okitsu, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

Internal medicine (Tokyo, Japan)　57　(17)　2573-2579　2018/09/01

DOI： 10.2169/internalmedicine.0560-17 　

ISSN： 0918-2918

More details Close

A 55-year-old woman suffered from hemorrhagic tendency. She had severe thrombocytopenia without any hematological or coagulatory abnormalities, and a bone marrow examination revealed an increased number of megakaryocytes without any abnormal cells or blasts. No lymphadenopathy or hepatosplenomegaly was observed on computed tomography. She was initially diagnosed with immune thrombocytopenic purpura (ITP). None of the treatments administered for ITP produced a response. However, abnormal cells were eventually found during the third bone marrow examination. The pathological diagnosis was mature B-cell lymphoma. Rituximab-containing chemotherapy produced a marked increase in the patient's platelet count, and her lymphoma went into complete remission.
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. International-journal Peer-reviewed

Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki, Kisato Nosaka, Norifumi Tsukamoto, Tatsu Shimoyama, Noriko Fukuhara, Yoshihiro Yakushijin, Kazunori Ohnishi, Kana Miyazaki, Kenichi Sawada, Nobuyuki Takayama, Ichiro Hanamura, Hirokazu Nagai, Hirofumi Kobayashi, Kensuke Usuki, Naoki Kobayashi, Kazuma Ohyashiki, Takahiko Utsumi, Kyoya Kumagai, Dai Maruyama, Ken Ohmachi, Yoshihiro Matsuno, Shigeo Nakamura, Tomomitsu Hotta, Kunihiro Tsukasaki

Cancer science　109　(9)　2830-2840　2018/09

DOI： 10.1111/cas.13719 　

ISSN： 1347-9032

More details Close

Although induction immunochemotherapy including high-dose cytarabine and rituximab followed by high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) is recommended for younger patients (≤65 years old) with untreated mantle cell lymphoma (MCL), no standard induction and HDC regimen has been established. We conducted a phase II study of induction immunochemotherapy of R-High-CHOP/CHASER followed by HDC of LEED with ASCT in younger patients with untreated advanced MCL. Eligibility criteria included untreated MCL, stage II bulky to IV, and age 20-65 years. Patients received 1 cycle of R-High-CHOP followed by 3 cycles of CHASER every 3 weeks. Peripheral blood stem cells (PBSC) were harvested during CHASER. LEED with ASCT was delivered to patients who responded to R-High-CHOP/CHASER. Primary endpoint was 2-year progression-free survival (PFS). From June 2008 to June 2012, 45 patients (median age 59 years; range 38-65 years) were enrolled. PBSC were successfully harvested from 36 of 43 patients. Thirty-five patients completed ASCT. Two-year PFS was 77% (80% CI 68-84), which met the primary endpoint. Five-year PFS and overall survival were 52% (95% CI 34-68%) and 71% (95% CI 51-84%), respectively. Overall response and complete response rates after induction immunochemotherapy were 96% and 82%, respectively. The most common grade 4 toxicities were hematological. In younger patients with untreated MCL, R-High-CHOP/CHASER/LEED with ASCT showed high efficacy and acceptable toxicity, and it can now be considered a standard treatment option.
Sustained Remission of γδ T-Cell Lymphoma by Graft-Versus-Lymphoma Effect That Relapsed Early After Cord Blood Transplantation. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Clinical lymphoma, myeloma & leukemia　18　(9)　e369-e372-e372　2018/09

DOI： 10.1016/j.clml.2018.06.019 　

ISSN： 2152-2650
Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study). International-journal Peer-reviewed

Miyamoto K, Fukuhara N, Maruyama D, Shibata T, Nakamura K, Ishizawa K, Tsukasaki K, Nagai H, Lymphoma Study, Group of, the, Japan Clinical, Oncology Group

Japanese journal of clinical oncology　48　(8)　777-780　2018/08

DOI： 10.1093/jjco/hyy085 　

ISSN： 0368-2811

More details Close

A randomized phase III trial comparing watchful waiting with first-line rituximab for advanced stage follicular lymphoma commenced in Japan in December 2016. Watchful waiting is the current standard treatment for stages III and IV (Ann Arbor classification) follicular lymphoma with low tumour burden. This study aimed to confirm the superiority of early administration of first-line rituximab in terms of event-free survival to watchful waiting for stages III and IV follicular lymphoma with low tumour burden. A total of 290 patients will be accrued from 50 Japanese institutions within 5 years. The primary endpoint is event-free survival defined as the period from registration to diagnosis of high tumour burden, therapy using cytotoxic chemotherapy and/or radiotherapy, or death. The secondary endpoints are overall survival, progression-free survival, cytotoxic chemotherapy/radiotherapy-free survival, histological transformation-free survival, response rate, adverse events and serious adverse events. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000025187 (http://www.umin.ac.jp/ctr/index.htm).
Successful Cord Blood Stem Cell Transplantation for Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated with Cerebral Infiltration. Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Shunsuke Hatta, Masahito Himuro, Hiroki Katsushima, Kentaro Nasu, Koya Ono, Kyoko Inokura, Masahiro Kobayashi, Yasushi Onishi, Hiroshi Fujii, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

Internal medicine (Tokyo, Japan)　57　(14)　2051-2055　2018/07/15

DOI： 10.2169/internalmedicine.0568-17 　

ISSN： 0918-2918

More details Close

A 16-year-old boy, who had been initially examined for bilateral blepharedema and slight eruption, presented with rapidly deteriorating symptoms in associating with headache and consciousness disturbance. He was diagnosed to have primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCAE-CTL) by a biopsy of the skin and brain. After whole-brain radiation and some courses of chemotherapy, cord blood transplantation was performed with myeloablative conditioning. After transplantation, the cerebral dysfunction gradually improved. Disease remission was confirmed by the disappearance of any abnormal findings on electroencephalogram and magnetic resonance imaging. PCAE-CTL is reported to be an extremely aggressive disease with a poor prognosis, but the timely performance of cord blood transplantation is considered to be a promising treatment strategy.
Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report. International-journal Peer-reviewed

Kumata H, Nakanishi C, Murakami K, Miyagi S, Fukuhara N, Carreras J, Nakamura N, Ichinohasama R, Unno M, Kamei T, Sasano H

Surgical case reports　4　(1)　72-72　2018/07

DOI： 10.1186/s40792-018-0480-x 　

More details Close

BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can be difficult to treat; moreover, determination of the pathophysiological type is difficult. We report a rare case of a patient who developed two types of Epstein-Barr virus (EBV)-negative PTLD following living donor liver transplantation (LDLT). CASE PRESENTATION: A 64-year-old man underwent LDLT for acute fulminant hepatitis B. Sixty-five months later, he developed EBV-negative monomorphic B cell PTLD. Reduction of immunosuppressive therapy and chemotherapy with rituximab resulted in a partial response. He received radioimmunotherapy with yttrium-90-ibritumomab tiuxetan, which was effective for all lesions, except for the splenic hilar lesion, which enlarged and seemed to penetrate the stomach. Therefore, he underwent resection of the pancreatic tail with splenectomy and partial gastrectomy. The pathological diagnosis was EBV-negative classical Hodgkin lymphoma (cHL)-type PTLD. CONCLUSIONS: This patient showed an unexpected course of PTLD, from both a clinical and pathological perspective. There are no prior reports of an adult case of EBV-negative cHL-type PTLD coexisting with EBV-negative monomorphic B cell PTLD. When a strange and refractory lesion persists despite effective therapy for PTLD, we must consider the possibility of another type of PTLD within the residual lesion.
Incidence Rate, Subtype Frequency, and Occurrence Site of Malignant Lymphoma in the Gastrointestinal Tract: Population-Based Analysis in Miyagi, Japan. Peer-reviewed

Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Sasano H, Ichinohasama R

The Tohoku journal of experimental medicine　245　(3)　159-165　2018/07

DOI： 10.1620/tjem.245.159 　

ISSN： 0040-8727

More details Close

Primary gastrointestinal lymphoma (PGIL) has been reported in many studies of lymphomas of the gastrointestinal tract worldwide. However, there have been few accurate population-based reports on lymphomas, and it is difficult to apply the strict definition of PGIL to all lymphomas occurring in the gastrointestinal tract. Accordingly, instead of using PGIL, this study included newly diagnosed lymphomas with biopsy or excision specimens obtained from the gastrointestinal tract (GI-related lymphomas) and aimed at presenting the incidence rate, subtype frequency, and occurrence site of GI-related lymphomas. Additionally, we examined GI-related lymphomas diagnosed using flow cytometry (FCM) analysis, cytogenetics analysis, and molecular analysis (multimetric and/or integrated analysis). We extracted data on GI-related lymphomas from 2,098 lymphoma cases registered from the entire Miyagi Prefecture in Japan. The number of GI-related lymphomas was 350, and the incidence rate was 2.97 per 100,000 persons. Diffuse large B-cell lymphoma was the most common subtype (47.4%), followed by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (32.6%) and follicular lymphoma (8.3%). The stomach was the most common site (62.6%), followed by the large intestine (15.4%), small intestine (14.3%), and duodenum (6.0%). Of the 350 included cases, 111 were diagnosed using multimetric and/or integrated analysis, in which the proportions of positive results for FCM analysis, cytogenetics analysis, and molecular analysis were 81%, 33%, and 51%, respectively. These results may provide a representation of lymphomas occurring in the gastrointestinal tract in Japan. Multimetric and/or integrated analysis of GI-related lymphomas could enable us to acquire useful information for the diagnosis.
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy Peer-reviewed

Motoko Yamaguchi, Ritsuro Suzuki, Seok Jin Kim, Young Hyeh Ko, Masahiko Oguchi, Naoko Asano, Kana Miyazaki, Yasuhiko Terui, Nobuko Kubota, Takeshi Maeda, Yukio Kobayashi, Jun Amaki, Toshinori Soejima, Bungo Saito, Emiko Shimoda, Noriko Fukuhara, Norifumi Tsukamoto, Kazuyuki Shimada, Ilseung Choi, Takahiko Utsumi, Yasuo Ejima, Won Seog Kim, Naoyuki Katayama

Cancer Science　109　(6)　2056-2062　2018/06/01
Publisher: Blackwell Publishing Ltd
DOI： 10.1111/cas.13597 　

ISSN： 1349-7006 1347-9032
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review. International-journal Peer-reviewed

Eikan Mishima, Takehiro Suzuki, Yoichi Takeuchi, Kazumasa Seiji, Noriko Fukuhara, Kei Takase, Hideo Harigae, Takaaki Abe, Sadayoshi Ito

Journal of clinical hypertension (Greenwich, Conn.)　20　(4)　798-804　2018/04

DOI： 10.1111/jch.13257 　

ISSN： 1524-6175

More details Close

Myeloproliferative neoplasms (MPNs) with Janus kinase 2 (JAK2) mutation are associated with a high risk for occlusive vascular diseases. We report 2 cases of renovascular hypertension associated with JAK2 V617F mutation-positive MPNs and provide a literature review. In Case 1, a 63-year-old woman had resistant hypertension, massive proteinuria, and erythrocytosis. Evaluations revealed right renal artery stenosis causing renovascular hypertension and polycythemia vera with JAK2 V617F mutation. Renin-angiotensin system inhibitors and subsequent angioplasty controlled the blood pressure and the proteinuria resolved. In Case 2, a 74-year-old woman had resistant hypertension and thrombocytosis. Evaluations confirmed left renal artery stenosis and essential thrombocythemia with JAK2 V617F. Angioplasty cured the hypertension. A literature review of 18 cases revealed the following as the most common characteristics of MPN-associated renovascular hypertension: manifests primarily in women; is associated with untreated polycythemia vera and essential thrombocythemia, concomitant leukocytosis, and JAK2 mutation positivity; and is responsive to angioplasty. This report demonstrates that JAK2 mutation-positive MPNs are a less common but important underlying cause of adult renovascular hypertension.
Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation? International-journal Peer-reviewed

Hiroki Katsushima, Noriko Fukuhara, Sachiko Konosu-Fukaya, Masahito Himuro, Yuko Kitawaki, Satoshi Ichikawa, Kenichi Ishizawa, Hironobu Sasano, Hideo Harigae, Ryo Ichinohasama

Leukemia & lymphoma　59　(3)　758-762　2018/03

DOI： 10.1080/10428194.2017.1357172 　

ISSN： 1042-8194
Establishment of a Screening System to Identify Novel GATA-2 Transcriptional Regulators. Peer-reviewed

Keiichi Ohashi, Tohru Fujiwara, Koichi Onodera, Yo Saito, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae

The Tohoku journal of experimental medicine　244　(1)　41-52　2018/01

DOI： 10.1620/tjem.244.41 　

ISSN： 0040-8727

More details Close

Hematopoietic stem cells can self-renew and differentiate into all blood cell types. The transcription factor GATA-2 is expressed in hematopoietic stem and progenitor cells and is essential for cell proliferation and differentiation. Heterozygous germline GATA2 mutations induce GATA-2 deficiency syndrome, characterized by monocytopenia, a predisposition to myelodysplasia and acute myeloid leukemia, and a profoundly reduced dendritic cell (DC) population, which is associated with increased susceptibility to viral infections. Because patients with GATA-2 deficiency syndrome could retain a wild-type copy of GATA-2, boosting residual wild-type GATA-2 activity may represent a novel therapeutic strategy for the disease. Here, we sought to establish a screening system to identify GATA-2 activators using human U937 monocytic cells as a potential model of the DC progenitor. Enforced GATA-2 expression in U937 cells induces CD205 expression, a marker of DC differentiation, indicating U937 cells as a surrogate of human primary DC progenitors. Transient luciferase reporter assays in U937 cells reveals a high promoter activity of the -0.5 kb GATA-2 hematopoietic-specific promoter (1S promoter) fused with two tandemly connected GATA-2 +9.9 kb intronic enhancers. We thus established U937-derived cell lines stably expressing tandem +9.9 kb/-0.5 kb 1S-luciferase. Importantly, forced GATA-1 expression, a repressor for GATA-2 expression, in the stable clones caused significant decreases in the luciferase activities. In conclusion, our system represents a potential tool for identifying novel regulators of GATA-2, thereby contributing to the development of novel therapeutic approaches.
Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Shunsuke Hatta, Masahito Himuro, Kentaro Nasu, Koya Ono, Yoko Okitsu, Masahiro Kobayashi, Yasushi Onishi, Masaki Ri, Ryo Ichinohasama, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　58　(1)　39-42　2018

DOI： 10.3960/jslrt.17035 　

ISSN： 1346-4280
Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Onco Peer-reviewed

Kagami Yoshitoyo, Yamamoto Kazuhito, Shibata Taro, Tobinai Kensei, Imaizumi Yoshitaka, Uchida Toshiki, Shimada Kazuyuki, Minauchi Koichiro, Fukuhara Noriko, Kobayashi Hirofumi, Yamauchi Nobuhiko, Tsujimura Hideki, Hangaishi Akira, Tominaga Ryo, Suehiro Youko, Yoshida Shinichiro, Inoue Yoshiko, Suzuki Sachiko, Tokuhira Michihide, Nagai Hirokazu, Kusumoto Shigeru, Kuroda Junya, Yakushijin Yoshihiro, Takamatsu Yasushi, Kubota Yasushi, Nosaka Kisato, Morishima Satoko, Nakamura Shigeo, Maruyama Dai, Hotta Tomomitsu, Morishima Yasuo, Tsukasaki Kunihiro

BLOOD　130　2017/12

ISSN： 0006-4971
Effects of in vivo deletion of GATA2 in bone marrow stromal cells International-journal Peer-reviewed

Shin Hasegawa, Tohru Fujiwara, Yoko Okitsu, Hiroki Kato, Yuki Sato, Noriko Fukuhara, Yasushi Onishi, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　56　31-45　2017/12

DOI： 10.1016/j.exphem.2017.08.004 　

ISSN： 0301-472X

eISSN： 1873-2399
A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review International-journal Peer-reviewed

Tohru Fujiwara, Noriko Fukuhara, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Yasushi Onishi, Kazumichi Furuyama, Hideo Harigae

ANNALS OF HEMATOLOGY　96　(11)　1955-1957　2017/11

DOI： 10.1007/s00277-017-3106-7 　

ISSN： 0939-5555

eISSN： 1432-0584
Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells International-journal Peer-reviewed

Kei Saito, Tohru Fujiwara, Urara Ota, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Masahiro Ishizuka, Tohru Tanaka, Hideo Harigae

Biochemistry and Biophysics Reports　11　105-111　2017/09/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.bbrep.2017.07.006 　

ISSN： 2405-5808
Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. International-journal Peer-reviewed

Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida

Cancer science　108　(8)　1634-1639　2017/08

DOI： 10.1111/cas.13291 　

ISSN： 1347-9032

More details Close

The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR ≥4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 × 107 /kg (range, 2.0-4.9 × 107 /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils ≥0.5 × 109 /L, reticulocytes ≥1%, and platelets ≥20 × 109 /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.
Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients International-journal Peer-reviewed

Keiko Ishi, Yasushi Onishi, Namiko Miyamura, Noriko Fukuhara, Kenichi Ishizawa, Mutsumi Nakanishi, Satoru Ohnaka, Tomomitsu Miyasaka, Emi Kanno, Kazuyoshi Kawakami, Hideo Harigae, Mitsuo Kaku

JOURNAL OF MEDICAL VIROLOGY　89　(7)　1265-1273　2017/07

DOI： 10.1002/jmv.24775 　

ISSN： 0146-6615

eISSN： 1096-9071
Case of late-onset erythropoietic protoporphyria with myelodysplastic syndrome who has homozygous IVS3-48C polymorphism in the ferrochelatase gene International-journal Peer-reviewed

Hiromi Suzuki, Katsuko Kikuchi, Noriko Fukuhara, Hajime Nakano, Setsuya Aiba

JOURNAL OF DERMATOLOGY　44　(6)　651-655　2017/06

DOI： 10.1111/1346-8138.13709 　

ISSN： 0385-2407

eISSN： 1346-8138
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma International-journal Peer-reviewed

Dai Maruyama, Kiyohiko Hatake, Tomohiro Kinoshita, Noriko Fukuhara, Ilseung Choi, Masafumi Taniwaki, Kiyoshi Ando, Yasuhito Terui, Yusuke Higuchi, Yasushi Onishi, Yasunobu Abe, Tsutomu Kobayashi, Yukari Shirasugi, Kensei Tobinai

CANCER SCIENCE　108　(5)　1007-1012　2017/05

DOI： 10.1111/cas.13230 　

ISSN： 1349-7006
Impact of TET2 deficiency on iron metabolism in erythroblasts International-journal Peer-reviewed

Kyoko Inokura, Tohru Fujiwara, Kei Saito, Tatsuya Iino, Shunsuke Hatta, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Kazuya Shimoda, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　49　56-67　2017/05

DOI： 10.1016/j.exphem.2017.01.002 　

ISSN： 0301-472X

eISSN： 1873-2399
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma Peer-reviewed

Dai Maruyama, Kiyohiko Hatake, Tomohiro Kinoshita, Noriko Fukuhara, Ilseung Choi, Masafumi Taniwaki, Kiyoshi Ando, Yasuhito Terui, Yusuke Higuchi, Yasushi Onishi, Yasunobu Abe, Tsutomu Kobayashi, Yukari Shirasugi, Kensei Tobinai

Cancer Science　108　(5)　1007-1012　2017/05/01
Publisher: Blackwell Publishing Ltd
DOI： 10.1111/cas.13230 　

ISSN： 1349-7006 1347-9032
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan Peer-reviewed

Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai

INTERNATIONAL JOURNAL OF HEMATOLOGY　105　(4)　470-477　2017/04

DOI： 10.1007/s12185-016-2146-4 　

ISSN： 0925-5710

eISSN： 1865-3774
Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1 International-journal Peer-reviewed

Tohru Fujiwara, Katsuyuki Sasaki, Kei Saito, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS　485　(2)　380-387　2017/04

DOI： 10.1016/j.bbrc.2017.02.068 　

ISSN： 0006-291X

eISSN： 1090-2104
An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma International-journal Peer-reviewed

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Onishi, Noriko Fukuhara, Ryo Ichinohasama, Yoshinori Okada, Hideo Harigae

STEM CELLS　35　(3)　739-753　2017/03

DOI： 10.1002/stem.2499 　

ISSN： 1066-5099

eISSN： 1549-4918
Relapsing Polychondritis Complicated by Myelodysplastic Syndrome Is Resistant to Immunosuppression: Comment on the Article by Dion et al International-journal Peer-reviewed

Tsuyoshi Shirai, Hiroshi Fujii, Ryoko Saito, Kentaro Nasu, Yukiko Kamogawa, Noriko Fukuhara, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　69　(3)　682-683　2017/03

DOI： 10.1002/art.39969 　

ISSN： 2326-5191

eISSN： 2326-5205
早期にrituximabを使用した難治性血栓性血小板減少性紫斑病の1例（原著論文/症例報告)（日本内科学会雑誌） Peer-reviewed

市川聡, 氷室真仁, 沖津庸子, 福原規子, 渡邉真威, 八田俊介, 小林匡洋, 大西康, 松本雅則, 張替秀郎

日本内科学会雑誌　106　(1)　99-104　2017/01

DOI： 10.2169/naika.106.99 　
[Successful Treatment of Severe and Refractory Thrombotic Thrombocytopenic Purpura with Early Rituximab Administration]. Peer-reviewed

Satoshi Ichikawa, Masahito Himuro, Yoko Okitsu, Noriko Fukuhara, Mai Watanabe, Shunsuke Hatta, Masahiro Kobayashi, Yasushi Onishi, Masanori Matsumoto, Hideo Harigae

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine　106　(1)　99-106　2017/01

ISSN： 0021-5384
Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia International-journal Peer-reviewed

Kenichi Ishizawa, Noriko Fukuhara, Chiaki Nakaseko, Shigeru Chiba, Michinori Ogura, Akihiko Okamoto, Yoshinori Sunaga, Kensei Tobinai

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　47　(1)　54-60　2017/01

DOI： 10.1093/jjco/hyw146 　

ISSN： 0368-2811

eISSN： 1465-3621
Management strategy for follicular lymphoma. Peer-reviewed

Fukuhara N

[Rinsho ketsueki] The Japanese journal of clinical hematology　58　(10)　2020-2025　2017
Publisher: The Japanese Society of Hematology
DOI： 10.11406/rinketsu.58.2020 　

ISSN： 0485-1439

More details Close

<p>Follicular lymphoma (FL) is incurable with the current standard therapeutic strategy, although the natural history of FL has improved in the last few decades. Treatment strategy for FL is considered by stage and tumor burden. For advanced-stage FL patients with low tumor burden, monitoring remains an appropriate approach. Single agent rituximab is also suggested as a good alternative. The addition of rituximab to chemotherapy has improved overall survival in advanced-stage FL patients with high tumor burden. The optimal chemotherapy to partner with rituximab might be CHOP or bendamustine. Rituximab maintenance after successful induction rituximab-based chemotherapy prolongs PFS. Recently, progression within 24 months of first-line chemotherapy has been established as a predictor of inferior outcome, with a 50% risk of death in 5 years. Addressing this high-risk group is important for optimal future treatment strategies.</p>
Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture International-journal Peer-reviewed

Hiroki Katsushima, Noriko Fukuhara, Satoshi Ichikawa, Yasunori Ota, Kengo Takeuchi, Kenichi Ishizawa, Hironobu Sasano, Hideo Harigae, Ryo Ichinohasama

LEUKEMIA & LYMPHOMA　58　(1)　80-88　2017

DOI： 10.1080/10428194.2016.1183254 　

ISSN： 1042-8194

eISSN： 1029-2403
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma International-journal Peer-reviewed

Dai Maruyama, Hirokazu Nagai, Noriko Fukuhara, Toshiyuki Kitano, Takayuki Ishikawa, Hirohiko Shibayama, Ilseung Choi, Kiyohiko Hatake, Toshiki Uchida, Momoko Nishikori, Tomohiro Kinoshita, Yoshihiro Matsuno, Tomoaki Nishikawa, Satoko Takahara, Kensei Tobinai

CANCER SCIENCE　107　(12)　1785-1790　2016/12

DOI： 10.1111/cas.13076 　

ISSN： 1347-9032

eISSN： 1349-7006
Primary AL amyloidosis presenting with systemic lymphadenopathy with calcification Peer-reviewed

Tsuyoshi Fujita, Satoshi Ichikawa, Yoko Okitsu, Noriko Fukuhara, Tsuneaki Yoshinaga, Masahide Yazaki, Hideo Harigae

INTERNATIONAL JOURNAL OF HEMATOLOGY　104　(6)　641-643　2016/12

DOI： 10.1007/s12185-016-2090-3 　

ISSN： 0925-5710

eISSN： 1865-3774
Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis Peer-reviewed

Kazuki Sakurai, Tohru Fujiwara, Shin Hasegawa, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Minami Yamada-Fujiwara, Ryo Ichinohasama, Hideo Harigae

International Journal of Hematology　104　(2)　190-199　2016/08/01
Publisher: Springer Tokyo
DOI： 10.1007/s12185-016-2006-2 　

ISSN： 1865-3774 0925-5710
GATA2 regulates dendritic cell differentiation International-journal Peer-reviewed

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

BLOOD　128　(4)　508-518　2016/07

DOI： 10.1182/blood-2016-02-698118 　

ISSN： 0006-4971

eISSN： 1528-0020
濾胞性リンパ腫に対する無治療経過観察と合理的な治療介入基準 Invited

福原規子

血液内科科学評論社　73　(1)　13-16　2016/06
がん性髄膜炎併発未分化大細胞リンパ腫に対してbrentuximab Vedotin(BV)療法を施行した1例 Peer-reviewed

八田俊介, 氷室真仁, 渡邉真威, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 大西康, 張替秀郎

臨床血液　57　(4)　497-497　2016/04
Identification of a novel putative mitochondrial protein FAM210B associated with erythroid differentiation Peer-reviewed

Aiko Kondo, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Kenichi Sawada, Hideo Harigae

INTERNATIONAL JOURNAL OF HEMATOLOGY　103　(4)　387-395　2016/04

DOI： 10.1007/s12185-016-1968-4 　

ISSN： 0925-5710

eISSN： 1865-3774
再発・難治低悪性度B細胞リンパ腫に対するPl3‐Kinase阻害薬の有効性 Invited

福原規子

血液内科科学評論社　72　(4)　439-444　2016/04
Publisher:
ISSN： 2185-582X
Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing. International-journal Peer-reviewed

Pan X, Nariai N, Fukuhara N, Saito S, Sato Y, Katsuoka F, Kojima K, Kuroki Y, Danjoh I, Saito R, Hasegawa S, Okitsu Y, Kondo A, Onishi Y, Nagami F, Kiyomoto H, Hozawa A, Fuse N, Nagasaki M, Shimizu R, Yasuda J, Harigae H, Yamamoto M

Br J Haematol.　176　(2)　318-321　2016/01/29

DOI： 10.1111/bjh.13948. 　

More details Close

[Epub ahead of print]
未治療濾胞性リンパ腫に対する合理的な治療選択 Invited

福原規子

血液内科科学評論社　72　(1)　51-55　2016/01
Publisher:
ISSN： 2185-582X
Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome Peer-reviewed

Satoshi Ichikawa, Taro Takahashi, Hiroki Katsushima, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

INTERNAL MEDICINE　55　(2)　191-196　2016

DOI： 10.2169/internalmedicine.55.5942 　

ISSN： 0918-2918

eISSN： 1349-7235
Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL) Peer-reviewed

Tomohiro Kinoshita, Noriko Fukuhara, Hirokazu Nagai, Koji Izutsu, Yukio Kobayashi, Yusuke Higuchi, Hideo Harigae, Takashi Tokunaga, Henry Adewoye, Michelle Robeson, Shringi Sharma, Masato Fukui, Jie Gao, Christine Christenson, Kensei Tobinai

BLOOD　126　(23)　2015/12

DOI： 10.1182/blood.V126.23.5089.5089 　

ISSN： 0006-4971

eISSN： 1528-0020
【副腎腫瘍の新しいマネジメント】副腎原発悪性リンパ腫の臨床病理学的特徴(解説/特集) Invited

市川聡, 福原規子, 一迫玲, 張替秀郎

腎臓内科・泌尿器科科学評論社　2　(4)　372-377　2015/10
High-Throughput siRNA Screening to Reveal GATA-2 Upstream Transcriptional Mechanisms in Hematopoietic Cells International-journal Peer-reviewed

Yo Saito, Tohru Fujiwara, Keiichi Ohashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

PLOS ONE　10　(9)　e0137079　2015/09

DOI： 10.1371/journal.pone.0137079 　

ISSN： 1932-6203
初発の非胚中心B細胞様びまん性大細胞型B細胞性リンパ腫患者を対象としたブルトン型チロシンキナーゼ(BTK)阻害薬PCI-32765(ibrutinib)の国際共同第III相試験

頼晋也, 豊嶋崇徳, 福原規子, 飛内賢正, 畠清彦, 下山達, 安藤潔, 内田俊樹, 永井宏和, 谷脇雅史, 柴山浩彦, 中前博久, 松村到, 石川隆之, 一戸辰夫, 加藤光次, 日高道弘

日本リンパ網内系学会会誌　55　108-108　2015/06
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Heparin-responsive angiopathy in the central nervous system caused by intravascular large B-cell lymphoma International-journal Peer-reviewed

Shun Yoshida, Hiroshi Kuroda, Noriko Fukuhara, Hidehiko Konno, Mika Watanabe, Tetsuya Akaishi, Maki Tateyama, Masashi Aoki

JOURNAL OF THE NEUROLOGICAL SCIENCES　352　(1-2)　117-119　2015/05

DOI： 10.1016/j.jns.2015.03.026 　

ISSN： 0022-510X

eISSN： 1878-5883
[Antimyeloma drugs].

Noriko Fukuhara

Nihon rinsho. Japanese journal of clinical medicine　73 Suppl 2　195-7　2015/02

ISSN： 0047-1852
びまん性大細胞型B細胞リンパ腫におけるBACH2発現の臨床病理学的意義 Invited

市川聡, 福原規子

血液内科科学評論社　70　(1)　82-86　2015/01
Publisher:
ISSN： 2185-582X
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan International-journal Peer-reviewed

Tomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, Chiaki Nakaseko, Hiroshi Arima, Kazuyuki Shimada, Akihiro Tomita, Makoto Sasaki, Jun Takizawa, Kinuko Mitani, Tadahiko Igarashi, Yoshinobu Maeda, Noriko Fukuhara, Fumihiro Ishida, Nozomi Niitsu, Ken Ohmachi, Hirotaka Takasaki, Naoya Nakamura, Tomohiro Kinoshita, Shigeo Nakamura, Michinori Ogura

HAEMATOLOGICA　99　(12)　1817-1825　2014/12

DOI： 10.3324/haematol.2014.111203 　

ISSN： 0390-6078
臍帯血移植後の自己造血回復から3ヵ月後に完全ドナー型キメラを達成した原発性骨髄線維症の1例 Peer-reviewed

渡邊正太郎, 大西, 康突田, 真紀子, 齋藤慧, 鈴木, 琢磨, 大橋, 圭一, 小林, 匡洋, 沖津, 庸子, 福原, 規子, 藤原, 亨, 藤原, 実名美, 亀岡, 淳一, 石澤, 賢一, 張替秀郎

臨床血液　55　(11)　2356-2357　2014/11

DOI： 10.11406/rinketsu.55.2356 　
GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells International-journal Peer-reviewed

Mayumi Kamata, Yoko Okitsu, Tohru Fujiwara, Masahiko Kanehira, Shinji Nakajima, Taro Takahashi, Ai Inoue, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

HAEMATOLOGICA　99　(11)　1686-1696　2014/11

DOI： 10.3324/haematol.2014.105692 　

ISSN： 0390-6078
Induction of thymic stromal lymphopoietin in mesenchymal stem cells by interaction with myeloma cells International-journal Peer-reviewed

Shinji Nakajima, Tohru Fujiwara, Hiroto Ohguchi, Yasushi Onishi, Mayumi Kamata, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

LEUKEMIA & LYMPHOMA　55　(11)　2605-2613　2014/11

DOI： 10.3109/10428194.2014.881478 　

ISSN： 1042-8194

eISSN： 1029-2403
Effect of 5-aminolevulinic acid on erythropoiesis: A preclinical in vitro characterization for the treatment of congenital sideroblastic anemia International-journal Peer-reviewed

Tohru Fujiwara, Koji Okamoto, Ryoyu Niikuni, Kiwamu Takahashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Yukio Nakamura, Motowo Nakajima, Tohru Tanaka, Hideo Harigae

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS　454　(1)　102-108　2014/11

DOI： 10.1016/j.bbrc.2014.10.050 　

ISSN： 0006-291X

eISSN： 1090-2104
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. International-journal

Jun Ueda, Jolene Caifeng Ho, Kian Leong Lee, Shojiro Kitajima, Henry Yang, Wendi Sun, Noriko Fukuhara, Norazean Zaiden, Shing Leng Chan, Makoto Tachibana, Yoichi Shinkai, Hiroyuki Kato, Lorenz Poellinger

Molecular and cellular biology　34　(19)　3702-20　2014/10/01

DOI： 10.1128/MCB.00099-14 　

More details Close

Hypoxia promotes stem cell maintenance and tumor progression, but it remains unclear how it regulates long-term adaptation toward these processes. We reveal a striking downregulation of the hypoxia-inducible histone H3 lysine 9 (H3K9) demethylase JMJD1A as a hallmark of clinical human germ cell-derived tumors, such as seminomas, yolk sac tumors, and embryonal carcinomas. Jmjd1a was not essential for stem cell self-renewal but played a crucial role as a tumor suppressor in opposition to the hypoxia-regulated oncogenic H3K9 methyltransferase G9a. Importantly, loss of Jmjd1a resulted in increased tumor growth, whereas loss of G9a produced smaller tumors. Pharmacological inhibition of G9a also resulted in attenuation of tumor growth, offering a novel therapeutic strategy for germ cell-derived tumors. Finally, Jmjd1a and G9a drive mutually opposing expression of the antiangiogenic factor genes Robo4, Igfbp4, Notch4, and Tfpi accompanied by changes in H3K9 methylation status. Thus, we demonstrate a novel mechanistic link whereby hypoxia-regulated epigenetic changes are instrumental for the control of tumor growth through coordinated dysregulation of antiangiogenic gene expression.
再発性緩慢性B細胞リンパ腫に対するFR療法に続く90Y-ibritumomab tiuxetan投与の第I相試験(FR therapy followed by 90Y-ibritumomab tiuxetan for relapsed indolent B cell lymphoma, phase 1 study)

Himuro Masahito, Kamata Mayumi, Kameoka Yoshihiro, Takahashi Naoto, Okitsu Youko, Fukuhara Noriko, Onishi Yasushi, Ishizawa Kenichi, Harigae Hideo, Ishida Youji, Sawada Kenichi

臨床血液　55　(9)　1278-1278　2014/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia International-journal Peer-reviewed

Tohru Fujiwara, Noriko Fukuhara, Ryo Funayama, Naoki Nariai, Mayumi Kamata, Takeshi Nagashima, Kaname Kojima, Yasushi Onishi, Yoji Sasahara, Kenichi Ishizawa, Masao Nagasaki, Keiko Nakayama, Hideo Harigae

ANNALS OF HEMATOLOGY　93　(9)　1515-1522　2014/09

DOI： 10.1007/s00277-014-2090-4 　

ISSN： 0939-5555

eISSN： 1432-0584
Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis International-journal Peer-reviewed

Miyuki Suguro, Noriaki Yoshida, Akira Umino, Harumi Kato, Hiroyuki Tagawa, Masao Nakagawa, Noriko Fukuhara, Sivasundaram Karnan, Ichiro Takeuchi, Toby D. Hocking, Kotaro Arita, Kennosuke Karube, Shinobu Tsuzuki, Shigeo Nakamura, Tomohiro Kinoshita, Masao Seto

CANCER SCIENCE　105　(7)　897-904　2014/07

DOI： 10.1111/cas.12442 　

ISSN： 1347-9032

eISSN： 1349-7006
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Hiroki Katsushima, Taro Takahashi, Joji Yamamoto, Hisayuki Yokoyama, Osamu Sasaki, Osamu Fukuhara, Jun Nomura, Kenichi Ishizawa, Ryo Ichinohasama, Akihiko Muto, Kazuhiko Igarashi, Hideo Harigae

CANCER SCIENCE　105　(4)　437-444　2014/04

DOI： 10.1111/cas.12361 　

ISSN： 1347-9032

eISSN： 1349-7006
Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome Peer-reviewed

H. Kato, Y. Onishi, S. Nakajima, Y. Okitsu, N. Fukuhara, T. Fujiwara, M. Yamada-Fujiwara, J. Kameoka, K. Ishizawa, H. Harigae

BONE MARROW TRANSPLANTATION　49　(3)　458-459　2014/03

DOI： 10.1038/bmt.2013.198 　

ISSN： 0268-3369

eISSN： 1476-5365
3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation International-journal Peer-reviewed

Tohru Fujiwara, Haruka Saitoh, Ai Inoue, Masahiro Kobayashi, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

JOURNAL OF BIOLOGICAL CHEMISTRY　289　(12)　8121-8134　2014/03

DOI： 10.1074/jbc.M114.548651 　

ISSN： 0021-9258

eISSN： 1083-351X
悪性リンパ腫患者に合併する腫瘍崩壊症候群の特徴とマネジメントのポイント Peer-reviewed

那須健太郎

血液内科　68　(4)　552-556　2014
Publisher:
ISSN： 2185-582X
Fatal visceral varicella-zoster developing early after autologous hematopoietic stem cell transplantation for refractory diffuse large B-cell lymphoma. Peer-reviewed

Satoshi Ichikawa, Mihyun Kim, Shin Hasegawa, Keiichi Ohashi, Aiko Kondo, Hiroki Kato, Mayumi Kamata, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　54　(3)　237-41　2014

DOI： 10.3960/jslrt.54.237 　

eISSN： 1880-9952

More details Close

A middle-aged woman who had undergone autologous hematopoietic stem cell transplantation (HSCT) 1 month previously suffered severe epigastralgia and relapse of lymphoma. The epigastralgia was not relieved by chemotherapy. Thereafter, her pancreatic and hepatic enzyme levels were markedly elevated and disseminated varicella emerged. Despite acyclovir administration, her general condition deteriorated rapidly and she died. Serum varicella zoster virus (VZV) DNA level was shown to be elevated and a diagnosis of disseminated VZV infection was established postmortem. In patients with severe abdominal pain following HSCT, early suspicion and therapeutic intervention for VZV are important, even in the absence of skin lesions.
5q-症候群に対する少量レナリドミド療法開始後に合併する肺サルコイドーシスが改善した1例 Peer-reviewed

加藤浩貴, 大西康, 大橋圭一, 近藤愛子, 長谷川慎, 勝岡優奈, 沖津庸子, 福原規子, 亀岡淳一, 石澤賢一, 玉田勉

臨床血液　54　(12)　2210　2013/12
レナリドミド+デキサメタゾンとクラリスロマイシンの併用が奏功した治療抵抗性多発性骨髄腫の一例 Peer-reviewed

加藤浩貴, 大西康, 那須健太郎, 鈴木真紀子, 中嶌真治, 勝岡優奈, 沖津庸子, 福原規子, 亀岡淳一, 石澤賢一, 高川真徳

臨床血液　54　(12)　2208　2013/12
Elucidation of the role of LMO2 in human erythroid cells International-journal Peer-reviewed

Ai Inoue, Tohru Fujiwara, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　41　(12)　1062-1076　2013/12

DOI： 10.1016/j.exphem.2013.09.003 　

ISSN： 0301-472X

eISSN： 1873-2399
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide International-journal Peer-reviewed

Hiroki Kato, Yasushi Onishi, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Masanori Takagawa, Hideo Harigae

ANNALS OF HEMATOLOGY　92　(12)　1711-1712　2013/12

DOI： 10.1007/s00277-013-1761-x 　

ISSN： 0939-5555

eISSN： 1432-0584
A Low-Molecular-Weight Compound K7174 Represses Hepcidin: Possible Therapeutic Strategy against Anemia of Chronic Disease International-journal Peer-reviewed

Tohru Fujiwara, Takashi Ikeda, Yuki Nagasaka, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Naohisa Tomosugi, Hideo Harigae

PLoS ONE　8　(9)　e75568-e75568　2013/09/27

DOI： 10.1371/journal.pone.0075568 　

ISSN： 1932-6203
再発性緩慢性B細胞リンパ腫患者における地固め放射免疫療法の有効性(The efficacy of consolidation radioimmunotherapy in patients with relapsed indolent B cell lymphoma)

Himuro Masahito, Kamata Mayumi, Kimura Jun, Ichikawa Satoshi, Takagawa Masanori, Yamamoto Jouji, Kohata Katsura, Sasaki Osamu, Tohmiya Yasuo, Harazaki Yoriko, Ine Syouji, Fujii Masami, Kimura Tomofumi, Kameoka Yoshihiro, Nomura Jun, Meguro Kuniaki, Ishikawa Izumi, Suzuki Makiko, Nakajima Shinji, Katsuoka Yuna, Fujiwara Tohru, Okitsu Youko, Fukuhara Noriko, Onishi Yasushi, Kameoka Junichi, Ishizawa Kenichi, Harigae Hideo

臨床血液　54　(9)　1062-1062　2013/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Ai Inoue, Hiroki Katsushima, Rie Ohba, Yuna Katsuoka, Yasushi Onishi, Joji Yamamoto, Osamu Sasaki, Jun Nomura, Osamu Fukuhara, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

Experimental hematology & oncology　2　(1)　19-19　2013/08/02

DOI： 10.1186/2162-3619-2-19 　

More details Close

BACKGROUND: Primary adrenal lymphoma (PAL) is an extremely rare subtype of extranodal non-Hodgkin's lymphoma. Some researchers have reported some of the characteristics of PAL and its association with poor prognosis; however, the clinicopathological features of PAL remain to be elucidated. METHODS: From 2008 to 2011 we experienced seven cases of PAL in our institutions. We retrospectively analyzed the clinical and pathological features of these patients. RESULTS: The patients ranged in age from 50 to 85 years, with a median of 71 years. The overall male:female ratio was 6:1. All seven patients were diagnosed with diffuse large B-cell lymphoma (DLBCL) pathologically. Bilateral adrenal involvement was confirmed in five patients. The median largest tumor diameter at diagnosis was 58 mm. The Ki-67 index was generally high (>70%). All patients were treated with rituximab-containing chemotherapy, and central nervous system (CNS) prophylaxis was conducted for three patients. One patient with CNS involvement at the time of the diagnosis also received whole-brain radiation. The overall survival rate at two years was 57% (median follow-up; 24.8 months). It is noteworthy that the three patients who received a full course of the rituximab-containing regimen and CNS prophylaxis are currently alive without disease relapse, and that none of the seven patients died due to progression of lymphoma. CONCLUSIONS: Primary adrenal DLBCL can be a clinically aggressive disease entity. Rituximab-containing chemotherapy combined with CNS prophylaxis could be a reasonable option for the treatment of PAL; however, analyses of more PAL cases are needed for the establishment of this strategy.
遺伝子組み換え第IX因子製剤の持続輸注により冠動脈バイパス術を施行した血友病Bの1例

沖津庸子, 石川, 正明, 鈴木, 宗三, 鈴木, 智之, 勝岡, 優奈, 福原, 規子, 大西, 康, 川本, 俊輔, 石澤, 賢一, 齋木, 佳克, 張替秀郎

日本血栓止血学会誌　24　(2)　206-206　2013/04
Publisher:
ISSN： 0915-7441

eISSN： 1880-8808
Role of transcriptional corepressor ETO2 in erythroid cells International-journal Peer-reviewed

Tohru Fujiwara, Yarob Wael Alqadi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　41　(3)　303-315　2013/03

DOI： 10.1016/j.exphem.2012.10.015 　

ISSN： 0301-472X
Expression profiling of ETO2-regulated miRNAs in erythroid cells: Possible influence on miRNA abundance International-journal Peer-reviewed

Tohru Fujiwara, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

FEBS OPEN BIO　3　428-432　2013

DOI： 10.1016/j.fob.2013.10.004 　

ISSN： 2211-5463
Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS) International-journal Peer-reviewed

Rie Ohba, Kazumichi Furuyama, Kenichi Yoshida, Tohru Fujiwara, Noriko Fukuhara, Yasushi Onishi, Atsushi Manabe, Etsuro Ito, Keiya Ozawa, Seiji Kojima, Seishi Ogawa, Hideo Harigae

ANNALS OF HEMATOLOGY　92　(1)　1-9　2013/01

DOI： 10.1007/s00277-012-1564-5 　

ISSN： 0939-5555
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor International-journal Peer-reviewed

Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

ANNALS OF HEMATOLOGY　91　(11)　1825-1826　2012/11

DOI： 10.1007/s00277-012-1477-3 　

ISSN： 0939-5555

eISSN： 1432-0584
Gene Expression Profiling Identifies HOXB4 as a Direct Downstream Target of GATA-2 in Human CD34+Hematopoietic Cells International-journal Peer-reviewed

Tohru Fujiwara, Hisayuki Yokoyama, Yoko Okitsu, Mayumi Kamata, Noriko Fukuhara, Yasushi Onishi, Shinichi Fujimaki, Shinichiro Takahashi, Kenichi Ishizawa, Emery H. Bresnick, Hideo Harigae

PLOS ONE　7　(9)　e40959-e40959　2012/09

DOI： 10.1371/journal.pone.0040959 　

ISSN： 1932-6203
急性リンパ球性白血病を発症した5番染色体長腕部欠失を伴う骨髄異形成症候群(5q-MDS)の一症例 Peer-reviewed

関修, 熊谷由紀, 鈴木千恵, 渡邊治樹, 佐藤光子, 長沢光章, 賀来満夫, 福原規子, 石澤賢一, 張替秀郎

日本検査血液学会雑誌　13　(学術集会)　S105-S105　2012/06
低悪性度B細胞性リンパ腫に対する90Y-ibritumomab tiuxetanの有効性長期奏効者の解析(Efficacy of 90Y-ibritumomab tiuxetan for low grade B cell lymphoma:analysis of long term responders)

Kamata Mayumi, Kimura Jun, Niitu Hidetaka, Kimura Tomohumi, Sasaki Toru, Takagawa Masanori, Sasaki Osamu, Harasaki Yoriko, Tohmiya Yasuo, Ine Syoji, Yokoyama Hisayuki, Nomura Jun, Kameoka Yoshihiro, Inokura Kyoko, Fukuhara Noriko, Katsuoka Yuna, Ohba Rie, Kohata Katsura, Oonishi Yasushi, Yamamoto Joji, Ishizawa Kenichi, Harigae Hideo

臨床血液　52　(9)　1127-1127　2011/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Successful treatment with bortezomib and thalidomide for POEMS syndrome International-journal Peer-reviewed

Hiroto Ohguchi, Rie Ohba, Yasushi Onishi, Noriko Fukuhara, Yoko Okitsu, Joji Yamamoto, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

ANNALS OF HEMATOLOGY　90　(9)　1113-1114　2011/09

DOI： 10.1007/s00277-010-1133-8 　

ISSN： 0939-5555
Favorable Outcome of Unrelated Cord Blood Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia International-journal Peer-reviewed

Yasushi Onishi, Osamu Sasaki, Satoshi Ichikawa, Kyoko Inokura, Yuna Katsuoka, Rie Ohtsuka Ohba, Yoko Okitsu, Katsura Kohata, Hiroto Ohguchi, Noriko Fukuhara, Hisayuki Yokoyama, Minami Fujiwara Yamada, Joji Yamamoto, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION　17　(7)　1093-1097　2011/07

DOI： 10.1016/j.bbmt.2011.01.010 　

ISSN： 1083-8791
Clinicopathological Features of Malignant Lymphoma in Japan: The Miyagi Study Peer-reviewed

Yukiko Miura, Noriko Fukuhara, Joji Yamamoto, Katsura Kohata, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　224　(2)　151-160　2011/06

DOI： 10.1620/tjem.224.151 　

ISSN： 0040-8727

eISSN： 1349-3329
Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type International-journal Peer-reviewed

Hisayuki Yokoyama, Joji Yamamoto, Yasuo Tohmiya, Minami F. Yamada, Hiroto Ohguchi, Yasushi Ohnishi, Yoko Okitsu, Noriko Fukuhara, Rie Ohba-Ohtsuka, Katsura Kohata, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

Leukemia and Lymphoma　51　(8)　1509-1512　2010/08

DOI： 10.3109/10428194.2010.487958 　

ISSN： 1042-8194 1029-2403

eISSN： 1029-2403
妊娠合併ITP症例の後方視的検討 Peer-reviewed

沖津庸子, 亀岡淳一, 鎌田真弓, 小林匡洋, 大場理恵, 福原規子, 大口裕人, 木幡桂, 山本譲司, 横山寿行, 千坂泰, 石澤賢一, 鈴木宗三, 八重樫伸生, 張替秀郎

日本血栓止血学会誌　21　(2)　209-209　2010/04
Publisher:
ISSN： 0915-7441

eISSN： 1880-8808
後天性第X因子低下症の一例 Peer-reviewed

沖津庸子, 鈴木宗三, 鎌田真弓, 小林匡洋, 福原規子, 大口裕人, 木幡桂, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

東北止血・血栓研究会会誌　XXIII　(1)　12-16　2010/03
Publisher:
ISSN： 0914-6598
Successful Allogeneic Hematopoietic Stem Cell Transplantation for Aggressive NK Cell Leukemia Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Joji Yamamoto, Makiko Suzuki, Shinji Nakajima, Yoko Okitsu, Katsura Kohata, Yasushi Onishi, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

INTERNAL MEDICINE　49　(17)　1907-1910　2010

DOI： 10.2169/internalmedicine.49.3814 　

ISSN： 0918-2918

eISSN： 1349-7235
Chromosomal imbalances are associated with outcome of Helicobacter pylori eradication in t(11;18)(q21;q21) negative gastric mucosa-associated lymphoid tissue lymphomas International-journal Peer-reviewed

Noriko Fukuhara, Tsuneya Nakamura, Masao Nakagawa, Hiroyuki Tagawa, Ichiro Takeuchi, Yasushi Yatabe, Yasuo Morishima, Shigeo Nakamura, Masao Seto

GENES CHROMOSOMES & CANCER　46　(8)　784-790　2007/08

DOI： 10.1002/gcc.20464 　

ISSN： 1045-2257
Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma International-journal Peer-reviewed

Noriko Fukuhara, Hiroyuki Tagawa, Yoshihiro Kameoka, Yumiko Kasugai, Sivasundaram Karnan, Junichi Kameoka, Takeshi Sasaki, Yasuo Morishima, Shigeo Nakamura, Masao Seto

Cancer Science　97　(6)　499-504　2006/06

DOI： 10.1111/j.1349-7006.2006.00209.x 　

ISSN： 1347-9032 1349-7006
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (Y-90-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma Peer-reviewed

T Watanabe, S Terui, K Itoh, T Terauchi, T Igarashi, N Usubuchi, M Nakata, S Nawano, N Sekiguchi, S Kusumoto, K Tanimoto, Y Kobayashi, K Endo, T Seriu, M Hayashi, K Tobinai

CANCER SCIENCE　96　(12)　903-910　2005/12

DOI： 10.1111/j.1349-7006.2005.00120.x 　

ISSN： 1347-9032
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5 '-deoxy-5-fluorouridine (5 '-DFUR) Peer-reviewed

H Ebi, Y Sigeoka, T Saeki, K Kawada, T Igarashi, N Usubuchi, R Ueda, Y Sasaki, H Minami

CANCER CHEMOTHERAPY AND PHARMACOLOGY　56　(2)　205-211　2005/08

DOI： 10.1007/s00280-004-0934-7 　

ISSN： 0344-5704
2回の臍帯血移植施行後にγδ型LGL白血病を発症した急性骨髄性白血病の1例 Peer-reviewed

楠本茂, 森慎一郎, 野坂生郷, 片山雄太, 大西康, 臼渕規子, 岸友紀子, 村重直子, 田野崎隆二, 上昌広, 平家勇司, 渡辺隆, 飛内賢正, 高上洋一

日本血液学会・日本臨床血液学会総会プログラム・抄録集　66回・46回　777-777　2004/09
Publisher: 日本臨床血液学会
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation Peer-reviewed

A Hori, M Kami, SW Kim, A Chizuka, R Kojima, O Imataki, M Sakiyama, T Hamaki, Y Onishi, N Usubuchi, Y Kisbi, N Murashige, K Tajima, S Miyakoshi, Y Heike, S Masuo, S Taniguchi, Y Takaue

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION　10　(1)　65-72　2004/01

DOI： 10.1016/j.bbmt.2003.09.006 　

ISSN： 1083-8791
Masking of the contribution of V protein to Sendai virus pathogenesis in an infection model with a highly virulent field isolate. International-journal

Takemasa Sakaguchi, Katsuhiro Kiyotani, Hitoshi Watanabe, Cheng Huang, Noriko Fukuhara, Yutaka Fujii, Yukie Shimazu, Fumihiro Sugahara, Yoshiyuki Nagai, Tetsuya Yoshida

Virology　313　(2)　581-7　2003/09/01

ISSN： 0042-6822

More details Close

Sendai virus V protein is not essential for virus replication in cultured cells but is essential for efficient virus replication and pathogenesis in mice, indicating that the V protein has a luxury function to facilitate virus propagation in mice. This was discovered in the Z strain, an egg-adapted avirulent laboratory strain. In the present study, we reexamined the function of Sendai virus V protein by generating a V-knockout Sendai virus derived from the Hamamatsu strain, a virulent field isolate, which is an appropriate model for studying the natural course of Sendai virus infection in mice. We unexpectedly found that the V-knockout virus propagated efficiently in mice and was as virulent as the wild-type virus. Switching of the functionally important V unique region demonstrated that this region of the Hamamatsu strain was also functional in a Z strain background. It thus appears that the V protein is nonsense in a field isolate of Sendai virus. However, the V protein was required for virus growth and pathogenesis of the Hamamatsu strain in mice when the virulence of the virus was attenuated by introducing mutations that had been found in an egg-adapted, avirulent virus. The V protein therefore seems to be potentially functional in the highly virulent Hamamatsu strain and to be prominent if virus replication is restricted.
進行固形癌に対するドセタキセル(DOC)と塩酸イリノテカン(IRN)併用毎週投与の第1相試験と薬物動態

河田健司, 佐々木康綱, 田原信, 松澤かおり, 衣斐寛倫, 臼渕規子, 向井博文, 中田匡信, 五十嵐忠彦, 伊藤國明, 南博信

日本癌治療学会誌　38　(2)　636-636　2003/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
Identification of mutations associated with attenuation of virulence of a field Sendai virus isolate by egg passage. International-journal

Yutaka Fujii, Takemasa Sakaguchi, Katsuhiro Kiyotani, Chen Huang, Noriko Fukuhara, Tetsuya Yoshida

Virus genes　25　(2)　189-93　2002/10

ISSN： 0920-8569

More details Close

Abstract. We have reported that attenuation of the virulence of a field Sendai virus (SeV) isolated by egg passage is associated with an impediment of viral genome replication in mouse respiratory cells (Kiyotani et al., Arch Virol 146, 893-908, 2001). To determine the molecular basis for the attenuation, we sequenced entire genomes of representative SeV clones isolated during egg passages and compared those with that of the parental SeV clone E0. E15c2, a 165-fold attenuated clone in 50% mouse lethal dose (MLD50) isolated at the 15th egg passage, possessed only four mutations in the entire genome: U to A at position 20 (U20A) and U24A in the leader promoter region and A9362G and A12174U in the L gene from the 5'-end of antigenome. The former mutation in the L gene was silent and the latter changed deduced amino acid Ser at position 1207 to Cys (Serl207Cys) in the L protein, a catalytic subunit of viral polymerase. E30c12, a further 6-fold attenuated clone isolated at the 30th egg passage, had an additional four mutations: A8074G (Glu461Gly) and A8077G (Asp462Gly) in the hemagglutinin-neuraminidase (HN) gene and A13598C (silent) and G13927A (Ser1791Asn) in the L gene. On the other hand, a virulent revertant clone, E30M15c15, which was obtained by 15 mouse passages of E30c12 and had 250-fold mouse virulence compared to E30c12, possessed eight mutaions: A24U in the leader, C1325U (silent) in the nucleocapsid gene, G8074A (Gly461Glu) in the HN gene, G10433U (Lys626Asn), C13598A (silent), A13927G (Asn1791Ser), C14626U (Thr2024Ile) and A15272C in the L gene. Among these, the mutations in the leader and the HN gene and two of the mutations in the L gene (C13598A and A13927G) were true reversions to E0. The significance of the mutations detected in the leader as well as in the L and HN genes was discussed in the context of attenuation of SeV pathogenicity by egg passage.
Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA. International-journal

Yutaka Fujii, Takemasa Sakaguchi, Katsuhiro Kiyotani, Cheng Huang, Noriko Fukuhara, Yoshiko Egi, Tetsuya Yoshida

Journal of virology　76　(17)　8540-7　2002/09

ISSN： 0022-538X

More details Close

We previously demonstrated that a systematic passage of a pathogenic field isolate of Sendai virus (SeV), the Hamamatsu strain, in embryonated eggs caused attenuation of virulence to mice, and we isolated viral clones of distinct virulence (K. Kiyotani et al. Arch. Virol. 146:893-908, 2001). One of the clones, E15cl2, which was obtained from the virus at the 15th egg passage of E0, the parental Hamamatsu clone for egg passage, had 165-fold-attenuated virulence to mice and possessed only four mutations in the entire 15,384-base genome: in an antigenomic sense, U to A at position 20 (U20A) and U to A at position 24 (U24A) in the leader sequence, the promoter for transcription and replication, and A to G at position 9346 (silent) and A to U at position 12174 (Ser to Cys) in the L gene. To examine the possibility that leader mutations affect virus pathogenesis, we recovered live viruses from cDNA derived from the Hamamatsu strain. A mutant virus possessing either a mutation of U20A or U24A in the leader sequence showed a slightly lower pathogenicity than that of the parental virus, whereas a double mutant virus possessing both of the mutations showed 25-fold-attenuated virulence, accompanying a significantly lower virus replication in the mouse lung. Replications of the leader mutant viruses were also impaired in a primary culture of mouse pulmonary epithelial cells but not in chicken embryo fibroblasts. These findings suggest that leader mutations of SeV affect virus pathogenesis by altering virus replication in a host-dependent manner.
Mutational analysis of the Sendai virus V protein: importance of the conserved residues for Zn binding, virus pathogenesis, and efficient RNA editing. International-journal

Noriko Fukuhara, Cheng Huang, Katsuhiro Kiyotani, Tetsuya Yoshida, Takemasa Sakaguchi

Virology　299　(2)　172-81　2002/08/01

ISSN： 0042-6822

More details Close

The V protein of Sendai virus (SeV) is nonessential for virus replication in cell culture but indispensable for viral pathogenicity in mice. At the C terminus of the V protein, there are amino acid residues conserved among the members of the Paramyxovinae subfamily that are clustered in three regions: region I, just downstream of the RNA editing site; and regions II and III, cysteine-rich zinc-finger-like regions. In the present study, we introduced mutations into the conserved amino acids and generated nine mutant viruses. All of the viruses had impaired virus replication in mouse lungs and attenuated virulence in mice. Furthermore, the C-terminal polypeptides fused with glutathione-S-transferase with a mutation in region I, II, or III all had impaired Zn binding in a (65)Zn-binding assay in solution. These results demonstrate that the conserved amino acids are important for V protein function, probably via protein conformation dependent on Zn binding. One mutant, SeV V-H(318)N, had inefficient RNA editing, indicating that the nucleotide that is a part of the codon encoding histidine at position 318 is conserved for the RNA editing machinery. In addition, to determine the function of the C-terminal extension of the V protein, which is not translated in recent virulent field isolates, a translational stop codon was introduced to generate the corresponding short V protein. The mutant virus showed similar virus propagation and pathogenicity, indicating that C-terminal extension of the V protein is not relevant to virus pathogenesis.
Alteration of Sendai virus morphogenesis and nucleocapsid incorporation due to mutation of cysteine residues of the matrix protein. International-journal

Takemasa Sakaguchi, Tsuneo Uchiyama, Cheng Huang, Noriko Fukuhara, Katsuhiro Kiyotani, Yoshiyuki Nagai, Tetsuya Yoshida

Journal of virology　76　(4)　1682-90　2002/02

ISSN： 0022-538X

More details Close

The matrix (M) protein of Sendai virus (SeV) has five cysteine residues, at positions 83, 106, 158, 251, and 295. To determine the roles of the cysteine residues in viral assembly, we generated mutant M cDNA possessing a substitution to serine at one of the cysteine residues or at all of the cysteine residues. Some mutant M proteins were unstable when expressed in cultured cells, suggesting that cysteine residues affect protein stability, probably by disrupting the proper conformation. In an attempt to generate virus from cDNA, SeV M-C(83)S, SeV M-C(106)S, and SeV M-C(295)S were successfully recovered from cDNA, while recombinant SeVs possessing other mutations were not. SeV M-C(83)S and SeV M-C(106)S had smaller virus particles than did the wild-type SeV, whereas SeV M-C(295)S had larger and heterogeneously sized particles. Furthermore, SeV M-C(106)S had a significant amount of empty particles lacking nucleocapsids. These results indicate that a single-point mutation at a cysteine residue of the M protein affects virus morphology and nucleocapsid incorporation, showing direct involvement of the M protein in SeV assembly. Cysteine-dependent conformation of the M protein was not due to disulfide bond formation, since the cysteines were shown to be free throughout the viral life cycle.
癌化学療法に伴う血液毒性の検討

臼渕規子, 石澤賢一, 五十嵐忠彦, 伊藤國明, 田原信, 南博信, 佐々木康綱

日本輸血学会雑誌　47　(6)　860-861　2002/01
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 0546-1448

eISSN： 1883-8383
B細胞性リンパ腫の表面マーカーの解析

石澤賢一, 一迫玲, 田丸淳一, 臼渕規子, 衣斐寛倫, 河田健司, 田原信, 南博信, 五十嵐忠彦, 伊藤国明

臨床血液　42　(10)　1007-1007　2001/10
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Clinical experiences of stenting in patients with esophago-bronchial fistula: Report of four cases Peer-reviewed

Noriko Fukuhara, Teruomi Miyazawa, Yoshinori Yamashita, Masao Doi, Masao Kuwabara, Tadashi Kamei, Mari Ochiai, Shinichi Ishioka, Michio Yamakido

Internal Medicine　39　(12)　1088-1093　2000
Publisher: Japanese Society of Internal Medicine
DOI： 10.2169/internalmedicine.39.1088 　

ISSN： 0918-2918
Three-dimensional bronchial imaging by spiral computed tomography as applied to tracheobronchial stent placement

Masao Doi, Teruomi Miyazawa, Masamichi Mineshita, Sunao Suei, Takayasu Kurata, Noriko Fukuhara, Mari Ochiai

Journal of Bronchology　6　(3)　155-158　1999
Publisher: Lippincott Williams and Wilkins
DOI： 10.1097/00128594-199907000-00003 　

ISSN： 1070-8030
Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections Peer-reviewed

Rinzo Soejima, Masashi Kimura, Yoshifumi Kubota, Toshio Kishimoto, Yoshihito Niki, Yoshihiko Tano, Toshiharu Matsushima, Tatsuo Nakatani, Kohichiro Nakata, Yoshiaki Kohri, Takekuni Iwata, Hiroko Nakajima, Masao Kuwabara, Ryoko Asaoku, Noriko Fukuhara, Masao Doi, Teruomi Miyazawa, Mitsuo Kaku, Hironori Tanaka, Hironobu Koga, Shigeru Kohno, Kohei Hara, Kohichi Watanabe, Takeshi Ishizaki, Naohumi Suyama, Seisin Nakano, Hidenori Sugiyama, Mutsushi Oka, Hozumi Yamada, Kaimei Nakahara, Masaya Yamaguchi, Yoichiro Goto, Toru Yamazaki, Hiroyuki Nagai, Hiroshi Kono, Masaru Nasu, Jun Goto, Kazuo Kitagawa, Eiichi Ohtsuka, Mitsunobu Akashi, Yoshinobu Kuroda, Eiji Yamagata, Hiroshi Nagaoka, Kaoru Nakama, Saburo Urakami, Hisashi Fukuhara, Yuei Irabu, Atsushi Saito, Hiroshi Nakamura, Masahiro Taira, Atsushi Ohhama, Yasuko Kanamoto

CHEMOTHERAPY　42　(7)　877-889　1994

DOI： 10.11250/chemotherapy1953.42.877 　

ISSN： 0009-3165

Show all ︎Show first 5

Misc. 211

白血病・リンパ腫さまざまな白血病・リンパ腫病型における診療のポイント濾胞性リンパ腫の診断と治療

福原規子

Medical Practice　42　(2)　2025

ISSN： 0910-1551
炎症性腸疾患に併発した造血器腫瘍に対し,同種造血幹細胞移植を行った4例

櫻井一貴, 福原規子, 中川諒, 猪倉恭子, 八田俊介, 小野寺晃一, 大西康, 藤原実名美, 張替秀郎

日本内科学会雑誌　114　2025

ISSN： 0021-5384
Rituximab maintenance therapy for low tumor burden follicular lymphoma.

福原規子

月刊血液内科　89　(4)　428-431　2024/10
Publisher: (有)科学評論社
ISSN： 2185-582X
非ホジキンリンパ腫を有する日本人患者におけるタファシタマブの第1b相試験(J-MIND試験)

福島健太郎, 福原規子, 湯田淳一朗, 末廣陽子, 楠本茂, 柴崎裕子, Chen Xuejun, Casadebaig Marie-Laure, 鈴川和己, 伊豆津宏二

日本血液学会学術集会　86回　O1-4　2024/10
Publisher: (一社)日本血液学会
難治性T濾胞ヘルパー細胞リンパ腫に対する予後予測因子とバイオマーカーの探索

須摩桜子, 坂田麻実子[柳元], 末原泰人, 荒隆英, 臼杵憲祐, 伊豆津宏二, 山口素子, 福原規子, 堺田惠美子, 安藤潔, 末永孝生, 木村哲, 永井宏和, 丸山大, 西本光孝, 竹内賢吾, 中村直哉, 寺内隆司, 藤澤学, 安部佳亮, 槇島健一, 坂本竜弘, 錦井秀和, 金田朋洋, 小川誠司, 慶野直人, 五所正彦, 細川博行, 橋本幸一, 千葉滋

日本血液学会学術集会　86回　O1-1　2024/10
Publisher: (一社)日本血液学会
高齢者DLBCLに対するPola-R-CHP療法の感染関連事象 MDVデータ研究

斎藤陽, 織田哲朗, 中西晋平, 太田稔, 大入直仁, 小塚大輔, 福原規子

日本血液学会学術集会　86回　O1-5　2024/10
Publisher: (一社)日本血液学会
T細胞とミエロイド細胞の運命決定におけるGata2の役割

佐野沙矢香, 加藤浩貴, 古川瑛次郎, 燕艶, 道又大吾, 田中悠也, 櫻井一貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原亨, 張替秀郎

日本血液学会学術集会　86回　O1-1　2024/10
Publisher: (一社)日本血液学会
造血幹前駆細胞におけるSAM合成によるDNAの安定化とp53経路抑制を介した恒常性の維持

古川瑛次郎, 加藤浩貴, 佐野沙矢香, 燕艶, 道又大吾, 田中裕也, 櫻井一貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 三枝大輔, 藤原亨, 五十嵐和彦, 張替秀郎

日本血液学会学術集会　86回　O1-4　2024/10
Publisher: (一社)日本血液学会
Targeting patient-specific vulnerabilities in anti-apoptotic pathway combined with CXCR4 expressing CAR-T cells eliminates high-risk leukemia(タイトル和訳中)

中川諒, 福原規子, 鈴木紅音, 小松弘香, 諸田直哉, 八田俊介, 神波圭太, 渡邊樹也, 木葉大地, 橋本和貴, 猪倉恭子, 小野寺晃一, 大西康, 張替秀郎

日本血液学会学術集会　86回　O1-6　2024/10
Publisher: (一社)日本血液学会
再発濾胞性リンパ腫に対するオビヌツズマブ+ベンダムスチン療法第II相試験の安全性評価造血器腫瘍研究会

入山智沙子, 酒井リカ, 齋藤統子, 中村信彦, 松田安史, 笠原千嗣, 梶口智弘, 福原規子, 加藤丈晴, 小林宣彦, 鏡味良豊, 古川勝也, 岡田耕平, 澤正史, 齋藤明子, 山本松雄, 木下朝博, 小椋美知則, 永井宏和, 山本一仁

日本血液学会学術集会　86回　O1-1　2024/10
Publisher: (一社)日本血液学会
初発マントル細胞リンパ腫に対するイブルチニブ併用BR療法 SHINE試験8年追跡結果

福原規子, 三嶋裕子, 一井倫子, 内田俊樹, 加藤光次, 丸山大, 尾見歩惟, 興梠陽介, 志賀要, 豊嶋崇徳

日本血液学会学術集会　86回　O1-2　2024/10
Publisher: (一社)日本血液学会
初発マントル細胞リンパ腫に対するイブルチニブ併用BR療法完全奏効と無増悪生存期間延長の関連

三嶋裕子, 橋本大吾, 一井倫子, 福原規子, 内田俊樹, 加藤光次, 尾見歩惟, 興梠陽介, 志賀要, 丸山大

日本血液学会学術集会　86回　O1-3　2024/10
Publisher: (一社)日本血液学会
骨破壊を伴う巨大頭蓋腫瘍として発症した成人T細胞白血病/リンパ腫

諸田直哉, 市川聡, 安部宇明, 久保龍大, 中村嘉詞, 橋本和貴, 中川諒, 猪倉恭子, 小野寺晃一, 大西康, 福原規子, 張替秀郎

日本血液学会学術集会　86回　P1-9　2024/10
Publisher: (一社)日本血液学会
Targeting patient-specific vulnerabilities in anti-apoptotic pathway combined with CXCR4 expressing CAR-T cells eliminates high-risk leukemia(タイトル和訳中)

中川諒, 福原規子, 鈴木紅音, 小松弘香, 諸田直哉, 八田俊介, 神波圭太, 渡邊樹也, 木葉大地, 橋本和貴, 猪倉恭子, 小野寺晃一, 大西康, 張替秀郎

日本血液学会学術集会　86回　TGP-7　2024/10
Publisher: (一社)日本血液学会
t(8;14)(q24;q11.2)/TCR::MYCを伴った血管免疫芽球性T細胞リンパ腫

市川聡, 加藤浩貴, 諸田直哉, 安部宇明, 川尻昭寿, 猪倉恭子, 中川諒, 八田俊介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会　86回　P2-6　2024/10
Publisher: (一社)日本血液学会
Flow Cytometric Analysis of T-cell Lymphoma Secondary to Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue: A Case Report

大久保礼由, 菅原新吾, 鈴木千恵, 武田卓也, 安久美子, 石塚静江, 真山晃史, 牧優冶, 吉岡翔, 阿部裕子, 藤巻慎一, 加藤浩貴, 加藤浩貴, 市川聡, 福原規子, 亀井尚, 亀井尚

日本臨床検査医学会誌　72　(9)　761-767　2024/09
Publisher: (一社)日本臨床検査医学会
ISSN： 2436-2727
新規解析技術がもたらす悪性リンパ腫研究の新展開一細胞解析による難治性T細胞リンパ腫の腫瘍微小環境の解明とバイオマーカーの探索(New Developments in Lymphoma Research through Novel Technologies Single-cell analysis reveals tumor microenvironment and biomarkers of intractable T-cell lymphomas)

須摩桜子, 坂田麻実子, 末原泰人, 伊豆津宏二, 山口素子, 福原規子, 安藤潔, 末永孝生, 永井宏和, 丸山大, 竹内賢吾, 中村直哉, 藤澤学, 小川誠司, 橋本幸一, 千葉滋

日本癌学会総会記事　83回　S03-4　2024/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
高強度化学療法の適応を有する再発・難治急性骨髄性白血病患者に対するアザシチジン+ベネトクラクス併用療法による救援療法

中村嘉詞, 小野寺晃一, 安部宇明, 久保龍大, 諸田直哉, 橋本和貴, 中川諒, 猪倉恭子, 市川聡, 福原規子, 大西康, 張替秀郎

臨床血液　65　(4)　284-285　2024/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
多発髄外腫瘤を伴ったIgH::MYC陽性多発性骨髄腫

佐々木勇杜, 市川聡, 櫻井一貴, 中村嘉詞, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　65　(3)　147-152　2024/03
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Current status and future prospects of CAR-T cell therapy for follicular lymphoma.

福原規子

月刊血液内科　88　(2)　137-142　2024/02
Publisher: (有)科学評論社
ISSN： 2185-582X
Sustained remission after cord blood transplantation for myeloid/NK precursor leukemia

市川聡, 小松弘香, 安部宇明, 竹中健太, 中村嘉詞, 諸田直哉, 櫻井一貴, 川尻昭寿, 猪倉恭子, 小野寺晃一, 大西康, 福原規子, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　46th　2024
Comparison of Acute GVHD Prophylaxis in CBT: single institute analysis

橋本和貴, 張替秀郎, 横山寿行, 福原規子, 大西康, 市川聡, 小野寺晃一, 猪倉恭子, 川尻昭寿, 中村嘉詞, 諸田直哉, 久保龍大, 安倍宇明

日本造血・免疫細胞療法学会総会プログラム・抄録集　46th　2024
Long-term remission with CAR-T therapy for a case of relapsed DLBCL after allogeneic transplantation

久保龍大, 小野寺晃一, 安部宇明, 諸田直哉, 中村嘉詞, 橋本和貴, 川尻昭寿, 猪倉恭子, 市川聡, 大西康, 福原規子, 藤原実名美, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　46th　2024
Analysis of rituximab blood concentration in patients with B-cell non-Hodgkin lymphoma.

佐藤祥子, 福原規子, 猪倉恭子, 氷室真仁, 相澤桂子, 伊藤巧, 我妻恭行, 石澤賢一

日本薬学会年会要旨集(Web)　144th　2024

ISSN： 0918-9823
Single-cell analysis reveals tumor microenvironment and biomarkers of intractable T-cell lymphomas

須摩桜子, 坂田麻実子, 坂田麻実子, 坂田麻実子, 末原泰人, 末原泰人, 伊豆津宏二, 山口素子, 福原規子, 安藤潔, 末永孝生, 永井宏和, 丸山大, 竹内賢吾, 中村直哉, 藤澤学, 小川誠司, 小川誠司, 橋本幸一, 千葉滋

日本癌学会学術総会抄録集(Web)　83rd　2024
早期の同種造血幹細胞移植施行により救命し得たEBV陽性節性T/NK細胞リンパ腫の1例

市川聡, 市川聡, 安部宇明, 諸田直哉, 川尻昭寿, 中川諒, 猪倉恭子, 八田俊介, 勝岡優奈, 小野寺晃一, 福原規子, 大西康, 横山寿行, 横山寿行, 一迫玲, 張替秀郎

臨床血液　65　(12)　2024

ISSN： 0485-1439
脳死膵腎移植後GVHDによる汎血球減少に対して臍帯血移植を施行した1例

上武佳生, 小野寺晃一, 鈴木紅音, 神波圭太, 小松弘香, 渡邉樹也, 木葉大地, 中川諒, 猪倉恭子, 八田俊介, 大西康, 福原規子, 張替秀郎

臨床血液　65　(12)　2024

ISSN： 0485-1439
フローサイトメトリー検査実践講座2023 MALTリンパ腫の経過中にT細胞リンパ腫を発症し診断に苦慮した1症例

大久保礼由, 菅原新吾, 鈴木千恵, 武田卓也, 安久美子, 石塚静江, 真山晃史, 牧優治, 吉岡翔, 阿部裕子, 藤巻慎一, 加藤浩貴, 市川聡, 福原規子, 亀井尚

日本臨床検査医学会誌　71　(補冊)　054-054　2023/10
Publisher: (一社)日本臨床検査医学会
ISSN： 2436-2727
Aggressive NK-cell leukemiaにおけるEpstein-Barr virusの臨床的意義

藤本亜弓, 藤本亜弓, 前田猛, 福原規子, 宮崎香奈, 山口素子, 石田文宏, 鈴木律朗

日本リンパ網内系学会会誌　63　2023

ISSN： 1342-9248
ヒト赤芽球細胞株を用いた造血性プロトポルフィリン症の病態解明

二階堂舞香, 藤原亨, 鈴木千恵, 鈴木千恵, 小野浩弥, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本鉄バイオサイエンス学会学術集会プログラム・抄録集　47th　2023
CAR-T療法後に長期病勢制御を得られた治療抵抗性濾胞性リンパ腫grade3Bの1例

金輝, 市川聡, 福原規子, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　64　(10)　2023

ISSN： 0485-1439
A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors Hematologic Malignancies Dose Escalation Cohort

Hisayuki Yokoyama, Koji Ando, Noriko Fukuhara, Hiroatsu Iida, Suguru Fukuhara, Hiroshi Miyake, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Akio Mizutani, Daisuke Morishita, Kunihiko Takeyama, Toshio Shimizu, Noboru Yamamoto

BLOOD　140　6211-6212　2022/11

DOI： 10.1182/blood-2022-157241 　

ISSN： 0006-4971

eISSN： 1528-0020
再発又は難治性の中枢神経系原発リンパ腫を対象とした国内第1/2相試験におけるチラブルチニブ投与期間中のQualty of Life及びKarnofsky Performance Statusの経時的変化の報告

照井康仁, 成田善孝, 永根基雄, 三島一彦, 荒川芳輝, 米澤大, 浅井克則, 福原規子, 杉山一彦, 篠島直樹, 葵新, 西川亮

日本リンパ網内系学会会誌　62　95-95　2022/06
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Blinatumomab for ALL relapse after allogeneic hematopoietic stem cell transplantation

小野寺晃一, 小松弘香, 竹中健太, 渡邉樹也, 鳴海善洋, 中村嘉詞, 橋本和貴, 櫻井一貴, 内堀雄介, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　45th　2022
Retrospective comparison of CBT with RIC using FLU-BU-MEL and FLU-MEL-TBI: single institute analysis

橋本和貴, 小野寺晃一, 大西康, 内堀雄介, 小松弘香, 竹中健太, 横山寿行, 福原規子, 市川聡, 猪倉恭子, 櫻井一貴, 中村嘉詞, 鳴海善洋, 渡邊樹也, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　45th　2022
The impact of leucovorin rescue on outcomes after cord blood transplantation

小野寺晃一, 木葉大地, 諸田直哉, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
Significance of pre-transplant chemotherapy for myelodysplastic syndromes with excess blasts

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
Two cases of conjunctival lesions due to acute GVHD after allogeneic HSCT

諸田直哉, 小野寺晃一, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
Outcome of allogeneic hematopoietic stem cell transplantation for CML-BC at our hospital

道又大吾, 大西康, 諸田直哉, 木葉大地, 田中悠也, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 張替秀雄

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
ベンダムスチン、オビヌツズマブ療法後に潰瘍性大腸炎様の薬剤性大腸炎を発症した濾胞性リンパ腫の一例(Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab)

猪倉恭子, 福原規子, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　83回　PS-4　2021/09
Publisher: (一社)日本血液学会
【CAR-T細胞療法の現在と将来展望】治療成績濾胞性リンパ腫

福原規子

医学のあゆみ　277　(10)　897-900　2021/06
Publisher: 医歯薬出版(株)
ISSN： 0039-2359
【支持療法・副作用対策/非ホジキンリンパ腫】非ホジキンリンパ腫濾胞性リンパ腫

福原規子

腫瘍内科　27　(4)　403-406　2021/04
Publisher: (有)科学評論社
ISSN： 1881-6568
髄外造血に関連した半月体形成性糸球体腎炎

渡邊裕文, 藤島史喜, 三浦豪, 國吉真平, 佐藤聡子, 福原規子, 笹野公伸

日本病理学会会誌　110　(1)　353-353　2021/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

横山寿行, 櫻井一貴, 橋本和貴, 古川瑛次郎, 齋藤慧, 八田俊介, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 勝岡優奈, 大西康, 和泉透, 張替秀朗

日本造血細胞移植学会総会プログラム・抄録集　43rd　2021
Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

古川瑛次郎, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 藤原亨, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　43rd　2021
Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab

猪倉恭子, 福原規子, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Clinicopathological features of B-cell lymphoma with three-way chromosomal translocation

渡邊正太郎, 市川聡, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 大西康, 横山寿行, 斎藤陽, 八田俊介, 鎌田真弓, 大橋圭一, 中嶌真治, 菅原知広, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Eight cases of allogeneic hematopoietic stem cell transplantation for follicular lymphoma

市川聡, 齋藤慧, 齋藤慧, 阿部未玲, 阿部未玲, 福原規子, 渡邊正太郎, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 大西康, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
The impact of HLA-DRB1 matching status on outcomes of UCBT: A single-institute retrospective study

小野寺晃一, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Four cases of carcinoma that primarily presented with cytopenia due to bone marrow dissemination

市川聡, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Outcome of allogeneic stem cell transplantation in adult patients with EBV-positive T/NK LPDs

大西康, 小野寺晃一, 櫻井一貴, 橋本和貴, 道又大吾, 古川瑛次郎, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Cellular models of X-linked sideroblastic anemia based on immortalized human erythroid progenitors

小野浩弥, 藤原亨, 藤原亨, 齋藤慧, 鈴木千恵, 高橋昇之, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Four cases with discordant development of follicular and classic Hodgkin lymphoma

阿部未玲, 阿部未玲, 福原規子, 市川聡, 櫻井一貴, 橋本和貴, 道又大吾, 古川瑛次郎, 渡邊正太郎, 猪倉恭子, 小野寺晃一, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Sustained remission of atypical CML in accelerated phase after development of severe acute GVHD

櫻井一貴, 横山寿行, 橋本和貴, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
KIR-ligand mismatch effect on GVHD and NK-cell gene expression after cord blood transplantation

横山寿行, 渡邊正太郎, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 市川聡, 齋藤慧, 八田俊介, 勝岡優奈, 和泉透, 鎌田真弓, 遠宮靖雄, 原崎頼子, 佐々木治, 福原規子, 大西康, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
FOG1-dependent transcriptional network involves glucose metabolic regulation of erythroid cells

藤原亨, 藤原亨, 鈴木千恵, 鈴木千恵, 小野浩弥, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Elucidation of the role of FAM210B in mitochondrial metabolism in erythroblasts

鈴木千恵, 鈴木千恵, 藤原亨, 藤原亨, 島弘季, 小野浩弥, 齋藤慧, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 五十嵐和彦, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Significance of elevated serum vitamin B12 levels in myeloid malignancies

亀岡淳一, 沖津庸子, 小林匡洋, 野村順, 阿部正理, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原実名美, 高橋伸一郎, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
同種造血幹細胞移植後の菌血症に対しバック法で採取した顆粒球輸血を行った2症例

横山寿行, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 島貫美和子, 関修, 成田香魚子, 藤原実名美, 張替秀郎, 張替秀郎

日本輸血細胞治療学会誌　67　(6)　2021

ISSN： 1881-3011
再発または難治性の末梢性および皮膚T細胞性リンパ腫の日本人患者を対象とした、E7777の第2相試験

清原英司, 安藤潔, 丸山大, 山本一仁, 照井康仁, 福原規子, 宮垣朝光, 戸倉新樹, 坂田麻実子[柳元], 五十嵐忠彦, 黒田純也, 飛内賢正

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　36回　121-121　2020/12
Publisher: (一社)日本皮膚悪性腫瘍学会
ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Kazuhiko Mishima, Yoshitaka Narita, Motoo Nagane, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa

NEURO-ONCOLOGY　22　57-58　2020/11

ISSN： 1522-8517

eISSN： 1523-5866
【悪性リンパ腫に対する新たな治療展開】濾胞性リンパ腫

福原規子

ヘマトロジー　(3)　36-43　2020/11
Publisher: (同)クリニコ出版
ISSN： 2435-2012
悪性リンパ腫に対するオビヌツズマブ併用療法により肺サルコイドーシスが増悪した1例

村上康司, 玉田勉, 奈良正之, 福原規子, 榊原智博, 杉浦久敏

日本サルコイドーシス/肉芽腫性疾患学会雑誌　40　(サプリメント号)　52-52　2020/10
Publisher: 日本サルコイドーシス
ISSN： 1883-1273
ボルテゾミブの有害事象に関わるバイオマーカー候補HLAアリルの探索

亀位涼, 中嶋琢人, 坂部彩, 頭金正博, 李政樹, 飯田真介, 丸山大, 大佐賀智, 福原規子, 宮崎香奈, 宮本憲一, 永井宏和, 日本臨床腫瘍研究グループ(JCOG)リンパ腫グループ

臨床薬理　51　(Suppl.)　S301-S301　2020/10
Publisher: (一社)日本臨床薬理学会
ISSN： 0388-1601

eISSN： 1882-8272
【白血病・リンパ腫かかりつけ医として知っておきたい最新の知識】知っておきたい最新の情報インドレントリンパ腫の診断・治療戦略・予後

福原規子

Medical Practice　37　(9)　1399-1402　2020/09
Publisher: (株)文光堂
ISSN： 0910-1551
FL治療の最前線

福原規子

臨床血液　61　(9)　1252-1258　2020/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
【造血器腫瘍学(第2版)-基礎と臨床の最新研究動向-】リンパ系腫瘍の臨床 B細胞リンパ腫濾胞性リンパ腫の病因・病態と治療

福原規子

日本臨床　78　(増刊3 造血器腫瘍学)　505-508　2020/08
Publisher: (株)日本臨床社
ISSN： 0047-1852
末梢性T細胞リンパ腫/非特異型の分子病態による分類免疫組織化学での応用も見据えて

齋藤慧, 藤島史喜, 福原規子, 張替秀郎, 一迫玲

血液内科　81　(1)　107-113　2020/07
Publisher: (有)科学評論社
ISSN： 2185-582X
濾胞性リンパ腫の治療戦略

福原規子

日本リンパ網内系学会会誌　60　65-65　2020/07
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
【血液疾患と消化器系の異常】原発性十二指腸・小腸リンパ腫の病態と治療

市川聡, 福原規子, 一迫玲

血液内科　80　(6)　835-841　2020/06
Publisher: (有)科学評論社
ISSN： 2185-582X
HLA-DR Expression in Acute Myeloid Leukemia has an Impact upon the Outcome of Allogenic Stem Cell Transplantation

李尹河, 田中悠也, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
Impact of peripheral blood absolute monocyte counts on the outcomes of cord blood transplantation

小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
Reactivation of HCV after direct acting antivirals therapy in a patient with AML who received UCBT

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
Successful treatment with R-EPOCH for hepatic PTLD after unrelated BMT in a patient with SAA

中川諒, 大西康, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 藤原亨, 福原規子, 横山寿行, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
ABCB7異常に伴う鉄芽球性貧血モデルの樹立

藤原亨, 藤原亨, 大地哲朗, 鈴木千恵, 小野浩弥, 齋藤慧, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
X連鎖性鉄芽球性貧血へのフェロトーシスの関与

小野浩弥, 藤原亨, 藤原亨, 齋藤慧, 鈴木千恵, 鈴木千恵, 高橋昇之, 高橋昇之, 燕艶, 佐野沙矢香, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
High resolution melting解析による簡易SF3B1遺伝子変異スクリーニング法の確立

鈴木千恵, 鈴木千恵, 藤原亨, 藤原亨, 大地哲朗, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤巻慎一, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
成人難治性血液悪性腫瘍に対する非血縁者間移植と臍帯血移植の前方視的評価研究(C-SHOT0601付随試験)

後藤辰徳, 後藤辰徳, 寺倉精太郎, 寺倉精太郎, 西田徹也, 西田徹也, 澤正史, 澤正史, 加藤智則, 加藤智則, 宮尾康太郎, 宮尾康太郎, 小澤幸泰, 小澤幸泰, 河野彰夫, 河野彰夫, 尾関和貴, 尾関和貴, 大西康, 福原規子, 藤井伸治, 横山寿行, 笠井雅信, 笠井雅信, 飯田浩充, 飯田浩充, 飯田浩充, 兼村信宏, 兼村信宏, 遠藤知之, 吾郷浩厚, 鬼塚真仁, 井山諭, 永田泰之, 倉橋信悟, 倉橋信悟, 柳澤昌実, 鈴木律朗, 鈴木律朗, 鍬塚八千代, 鍬塚八千代, 鍬塚八千代, 熱田由子, 熱田由子, 宮村耕一, 宮村耕一, 村田誠, 村田誠

日本血液学会学術集会抄録(Web)　82nd　2020
完全分子学的寛解期におけるPh陽性ALLに対するフルダラビンを用いた前処置による同種移植の成績

大西康, 小野寺晃一, 橋本和貴, 櫻井一貴, 古川瑛次郎, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
抗PD-1抗体療法後早期に生じたγδTリンパ球のクローン性増殖

小野浩弥, 大西康, 渡邊正太郎, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 藤原亨, 横山寿行, 鈴木千恵, 渡辺裕文, 及川麻理子, 山崎有人, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
宮城県におけるびまん性大細胞型B細胞リンパ腫を合併した濾胞性リンパ腫の予後

渡邊正太郎, 福原規子, 横山寿行, 小野寺晃一, 市川聡, 大西康, 勝岡優奈, 八田俊介, 齋藤慧, 佐々木治, 原崎頼子, 鎌田真弓, 遠宮靖雄, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
同種臍帯血移植におけるサイトメガロウイルス再活性化の影響

横山寿行, 田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 渡邉真威, 八田俊介, 勝岡優奈, 福原規子, 大西康, 目黒邦昭, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
びまん性大細胞型B細胞リンパ腫に対する市販後チサゲンレクルユーセルの単施設後方視的検討

齋藤慧, 市川聡, 小野寺晃一, 福原規子, 大西康, 横山寿行, 藤原実名美, 佐合健, 田地規朗, 大橋圭一, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
ATGを前処置に用いたHLA半合致移植後に中枢神経系移植後リンパ増殖性疾患を合併した2例

古川瑛次郎, 大西康, 中嶌真治, 小野寺晃一, 橋本和貴, 櫻井一貴, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
無顆粒球症を呈した成熟γδT細胞白血病の一例

市川聡, 齋藤慧, 福原規子, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 藤原亨, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
深部静脈血栓症を契機に診断されたフィラデルフィア染色体陽性急性白血病の3例

橋本和貴, 大西康, 小野寺晃一, 古川瑛次郎, 櫻井一貴, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, Yoshitaka Narita, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa

BLOOD　134　2019/11

DOI： 10.1182/blood-2019-123362 　

ISSN： 0006-4971

eISSN： 1528-0020
輸血依存の再生不良性貧血に対してeltrombopagが奏効しferritin値の改善とともに血球回復が得られた1例

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　60　(11)　1595-1596　2019/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
B細胞性リンパ腫

福原規子

日本リンパ網内系学会会誌　59　96-96　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
再発又は難治性のCD30陽性古典的ホジキンリンパ腫/全身性未分化大細胞リンパ腫に対するBrentuximab Vedotin再治療の安全性及び有効性に関する後方視的検討

山本豪, 福原規子, 辻村秀樹, 張高明, 柴山浩彦, 矢内友子, 渋谷和憲, 伊豆津宏二

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

日本リンパ網内系学会会誌　59　147-147　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
巨大な膵形質細胞腫を伴った再発難治性多発性骨髄腫の1例

古川瑛次郎, 市川聡, 福原規子, 齋藤慧, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 大西康, 張替秀郎

臨床血液　60　(4)　331-331　2019/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Daratumumab併用療法後にCD38陰性化を伴って病勢増悪を来した再発難治性多発性骨髄腫の1例

齋藤慧, 古川瑛次郎, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 市川聡, 大西康, 福原規子, 張替秀郎

臨床血液　60　(4)　337-337　2019/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
【血液疾患に合併する感染症とその対策】悪性リンパ腫治療における感染症の動向とその対策

市川聡, 福原規子

血液内科　78　(3)　321-326　2019/03
Publisher: (有)科学評論社
ISSN： 2185-582X
【リンパ腫update I:WHO 2017、臨床的事項、低悪性度Bリンパ腫】慢性リンパ球性白血病/小細胞リンパ腫とマントル細胞リンパ腫

齋藤慧, 福原規子, 一迫怜

病理と臨床　37　(3)　242-249　2019/03
Publisher: (株)文光堂
ISSN： 0287-3745
【日本血液学会造血器腫瘍診療ガイドライン2018年版-リンパ腫-】濾胞性リンパ腫

伊豆津宏二, 福原規子

臨床血液　60　(3)　236-237　2019/03
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
免疫不全に合併したNTM症 MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

結核　94　(3)　168-168　2019/03
Publisher: (一社)日本結核病学会
ISSN： 0022-9776
家族支援が奏効した血液腫瘍患者の2例

長谷川涼子, 今野朱美, 大西康, 福原規子, 福土審, 張替秀郎

心身医学　59　(1)　79-79　2019/01
Publisher: (一社)日本心身医学会
ISSN： 0385-0307
【悪性リンパ腫の最新分類と新規治療】注目の新薬 Polatuzumab Vedotin(抗CD79b抗体薬物複合体)

市川聡, 福原規子

最新医学　73　(11)　1492-1497　2018/11
Publisher: (株)最新医学社
ISSN： 0370-8241
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
X連鎖性鉄芽球性貧血の細胞モデルの解析(Characterization of in vitro model of X-linked sideroblastic anemia)

齋藤慧, 藤原亨, 八田俊介, 小野寺晃一, 市川聡, 福原規子, 大西康, 中村幸夫, 張替秀郎

臨床血液　59　(9)　1498-1498　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
再発/難治性の成熟B細胞腫瘍日本人患者に対するibrutinibの第I相試験最終解析結果(Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: phase 1 final analysis)

内田俊樹, 飛内賢正, 福原規子, 棟方理, 蒔田真一, 小林美希, 齊藤繁紀, 山口洋平, 西川智章

臨床血液　59　(9)　1502-1502　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
日本人再発難治性MCL患者に対するIbrutinibの第II相試験最終解析結果(Phase 2 study of ibrutinib in Japanese patients with relapsed/refractory MCL: final analysis)

福原規子, 永井宏和, 丸山大, 北野俊行, 石川隆之, 柴山浩彦, 崔日承, 畠清彦, 内田俊樹, 錦織桃子, 木下朝博, 松野吉宏, 西川智章, 飛内賢正

臨床血液　59　(9)　1502-1502　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
再発または難治性の日本人低悪性度B細胞リンパ腫患者に対するコパンリシブの第Ib相試験(Phase Ib study of copanlisib in Japanese patients with relapsed/refractory indolent B-cell lymphoma)

福原規子, 丸山大, 畠清彦, 永井宏和, 亀崎健次郎, 小坂さおり, 飛内賢正

臨床血液　59　(9)　1502-1502　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
初発進行期、末梢性T細胞リンパ腫に対するTHP-COP療法の第II相試験(THP-3試験)(A phase II study of THP-COP in newly diagnosed advanced peripheral T-cell lymphoma: THP-3 study)

小椋美知則, 大間知謙, 鈴木律朗, 熱田由子, 伊藤達也, 大屋敷一馬, 矢野真吾, 日高道弘, 安藤潔, 福原規子, 森下剛久, 鈴木孝世, 塚崎邦弘, 小林直樹, 塚本憲史, 小澤幸泰, 山本一仁, 堀田知光, 木下朝博

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
既治療CTCL患者に対するモガムリズマブの国際共同第III相比較試験(Phase III trial of mogamulizumab vs. vorinostat in previously treated cutaneous T-cell lymphoma)

飛内賢正, 菅谷誠, 福原規子, 戸倉新樹

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Aggressive lymphomaに対するDA-EPOCH -/+ Rituximab療法の忍容性と安全性に関する後方視的解析(A retrospective analysis of tolerability and safety of DA-EPOCH ± Rituximab for aggressive lymphoma)

松田真一朗, 末廣陽子, 富田直人, 伊豆津宏二, 福原規子, 今泉芳孝, 島田和之, 仲里朝周, 吉田功, 高橋勉, 鈴木律朗, 山口素子, 鈴宮淳司

臨床血液　59　(9)　1556-1556　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
大量化療前導入治療R-CHOP-14とR-CHOP-14/CHASERの比較試験 JCOG0908(R-CHOP-14 vs. R-CHOP-14/CHASER induction prior to HDT in poor-risk untreated DLBCL: JCOG0908)

丸山大, 鏡味良豊, 柴田大朗, 飛内賢正, 山本一仁, 今泉芳孝, 内田俊樹, 島田和之, 皆内康一郎, 福原規子, 小林泰文, 山内寛彦, 辻村秀樹, 半下石明, 富永亮, 末廣陽子, 吉田真一郎, 井上佳子, 鈴木左知子, 得平道英, 楠本茂, 黒田純也, 薬師神芳洋, 高松泰, 久保田寧, 野坂生郷, 森島聡子, 中村栄男, 堀田知光, 森島泰雄, 塚崎邦弘, 永井宏和

臨床血液　59　(9)　1556-1556　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
T-LGL白血病に対するシクロスポリンA治療単施設の経験(Cyclosporine A treatment for T-cell large granular lymphocytic leukemia: a single-center experience)

大西康, 藤原実名美, 佐野沙矢香, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 張替秀郎

臨床血液　59　(9)　1569-1569　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
未治療移植非適応多発性骨髄腫に対するMPB療法変法のランダム化第II相試験(JCOG 1105)(Randomized phase II study to optimize MPB in untreated transplant-ineligible myeloma: JCOG1105)

飯田真介, 丸山大, 小川岳人, 楠本茂, 福原傑, 福原規子, 瀬尾幸子, 宮崎香奈, 吉満誠, 黒田純也, 塚本憲史, 辻村秀樹, 半下石明, 山内高弘, 内海貴彦, 水野石一, 高松泰, 永田泰之, 皆内康一郎, 大塚英一, 花村一朗, 徳永隆之, 吉田真一郎, 山崎聡, 末廣陽子, 神山祐太郎, 宮本憲一, 渡部裕子, 塚崎邦弘, 永井宏和

臨床血液　59　(9)　1610-1610　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
成熟T細胞性リンパ腫に対する臍帯血移植 10例の報告(Umbilical cord blood transplantation for mature T-cell lymphoma: report of 10 cases)

佐野沙矢香, 大西康, 古川瑛次郎, 中川諒, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

臨床血液　59　(9)　1680-1680　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
転写因子GATA-2の制御因子同定のためのスクリーニング法の確立(Establishment of a screening system to identify novel GATA-2 transcriptional regulators)

大橋圭一, 藤原亨, 小野寺晃一, 齋藤陽, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 大西康, 張替秀郎

臨床血液　59　(9)　1696-1696　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
びまん性大細胞型B細胞リンパ腫におけるsIL-2R値の層別化予後因子としての意義(Serum sIL-2R level is a prognostic stratification marker of diffuse large B-cell lymphoma)

市川聡, 福原規子, 小林匡洋, 沖津庸子, 大西康, 一迫玲, 石澤賢一, 張替秀郎

臨床血液　59　(9)　1785-1785　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
ダラツムマブ投与中にサイトメガロウイルス抗原血症陽性化を示した多発性骨髄腫の2例(Two cases of multiple myeloma with cytomegalovirus antigenemia during daratumumab therapy)

小林匡洋, 佐野沙矢香, 大地哲朗, 那須健太郎, 市川聡, 福原規子, 大西康, 亀岡淳一, 張替秀郎

臨床血液　59　(9)　1805-1805　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
【血液疾患に対する新規治療薬の現状と今後の課題】 B細胞性腫瘍に対するイブルチニブおよびidelalisib

福原規子

血液内科　77　(2)　230-235　2018/08
Publisher: (有)科学評論社
ISSN： 2185-582X
【血液疾患を見逃さないために-プライマリ・ケアと専門医コンサルトのタイミング】血液疾患患者に対する一般診療上の注意点治療終了後のフォローアップを依頼されたら

小林匡洋, 福原規子

Medicina　55　(8)　1152-1154　2018/07
Publisher: (株)医学書院
ISSN： 0025-7699
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy International-journal Peer-reviewed

Motoko Yamaguchi, Ritsuro Suzuki, Seok Jin Kim, Young Hyeh Ko, Masahiko Oguchi, Naoko Asano, Kana Miyazaki, Yasuhiko Terui, Nobuko Kubota, Takeshi Maeda, Yukio Kobayashi, Jun Amaki, Toshinori Soejima, Bungo Saito, Emiko Shimoda, Noriko Fukuhara, Norifumi Tsukamoto, Kazuyuki Shimada, Ilseung Choi, Takahiko Utsumi, Yasuo Ejima, Won Seog Kim, Naoyuki Katayama

Cancer Science　109　(6)　2056-2062　2018/06/01
Publisher: Blackwell Publishing Ltd
DOI： 10.1111/cas.13597 　

ISSN： 1349-7006 1347-9032
short tandem repeat(STR)-PCR法を用いた造血幹細胞移植後のキメリズム解析の評価

関修, 成田香魚子, 大西康, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

日本検査血液学会雑誌　19　(学術集会)　S163-S163　2018/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
全身治療歴を有するCTCL患者を対象とした、モガムリズマブ第III相国際共同治験の成績

戸倉新樹, 宮垣朝光, 加藤雪彦, 佐野栄紀, 福原規子, 米倉健太郎, 上原治朗, 波部幸司, 岡本祐之, 清原英司, 宇原久, 濱田利久, 和田秀文, 菅谷誠, 飛内賢正

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　129-129　2018/06
Publisher: (一社)日本皮膚悪性腫瘍学会
リツキシマブ単剤療法の役割

福原規子

日本リンパ網内系学会会誌　58　88-88　2018/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
【臨床で遭遇する難治な血液疾患の病態解析研究と治療の進歩】再発・再燃濾胞性リンパ腫の治療

福原規子

血液内科　76　(4)　480-486　2018/04
Publisher: (有)科学評論社
ISSN： 2185-582X
Dasatinibによる治療を行ったphiladelphia染色体陽性骨髄異形成症候群

大地哲朗, 大西康, 佐野沙矢香, 大橋圭一, 那須健太郎, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

臨床血液　59　(4)　448-448　2018/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Intrabone single unit cord blood transplantation for hematological malignancies Peer-reviewed

Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Fukuhara Noriko, Nishida Tetsuya, Terakura Seitaro, Ishikawa Yuichi, Tanimoto Mitsune, Shibasaki Yasuhiko, Suzuki Ritsuro, Kodera Yoshihisa, Kiyoi Hitoshi, Naoe Tomoki

CANCER SCIENCE　109　757-757　2018/01

ISSN： 1349-7006
【T細胞リンパ腫の診断と新たな治療開発】再発・治療抵抗性T細胞リンパ腫に対する救援化学療法

福原規子

血液内科　75　(6)　715-718　2017/12
Publisher: (有)科学評論社
ISSN： 2185-582X
【悪性リンパ腫の新規標的治療薬】 PI3K(phosphatidylinositol-3-kinase)阻害薬

福原規子

血液フロンティア　28　(1)　31-36　2017/12
Publisher: (株)医薬ジャーナル社
ISSN： 1344-6940
移植後リンパ増殖性疾患の再発に対して大量化学療法、自家末梢血幹細胞移植を施行し完全寛解を達成した1例

櫻井一貴, 福原規子, 市川聡, 氷室真仁, 沖津庸子, 渡邊正太郎, 大地哲朗, 那須健太郎, 八田俊介, 小林匡洋, 大西康, 張替秀郎

臨床血液　58　(12)　2473-2473　2017/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
臨床研究におけるリツキシマブ血中濃度測定のバリデーション

佐藤祥子, 福原規子, 伏見千佳子, 中田郁美, 相澤千恵, 猪倉恭子, 石澤賢一, 鈴木常義

臨床薬理　48　(Suppl.)　S294-S294　2017/11
Publisher: (一社)日本臨床薬理学会
ISSN： 0388-1601
【がん免疫療法の躍進】がん免疫療法の臨床がん種別治療 Hodgkinリンパ腫に対する抗PD-1抗体療法

福原規子

医学のあゆみ　263　(1)　92-96　2017/10
Publisher: 医歯薬出版(株)
ISSN： 0039-2359
濾胞性リンパ腫に対する治療戦略

福原規子

臨床血液　58　(10)　2020-2025　2017/10
Publisher: (一社)日本血液学会-東京事務局
DOI： 10.11406/rinketsu.58.2020 　

ISSN： 0485-1439
【免疫チェックポイント阻害薬がん薬物療法の新時代】各腫瘍における免疫チェックポイント阻害薬の現状ホジキンリンパ腫

大地哲朗, 福原規子

薬事　59　(12)　2420-2423　2017/09
Publisher: (株)じほう
ISSN： 0016-5980
サルコイド反応を伴う末梢性T細胞リンパ腫の1例

中嶋夏磯, 水芦政人, 佐々木留伊, 大竹映香, 遠野久幸, 日高高徳, 神林由美, 岡田修子, 相場節也, 市川聡, 福原規子, 一迫玲, 村井孝弥

日本皮膚科学会雑誌　127　(10)　2341-2341　2017/09
Publisher: (公社)日本皮膚科学会
ISSN： 0021-499X
血液悪性疾患に対する骨髄内臍帯血移植

村田誠, 前田嘉信, 増子正義, 福原規子, 西田徹也, 寺倉精太郎, 石川裕一, 谷本光音, 柴崎康彦, 鈴木律朗, 小寺良尚, 清井仁, 直江知樹

日本癌学会総会記事　76回　P-2373　2017/09
Publisher: 日本癌学会
ISSN： 0546-0476
【造血器・リンパ系腫瘍のWHO分類 2016 version】リンパ系腫瘍成熟B細胞腫瘍慢性リンパ性白血病/小リンパ球性リンパ腫,濾胞性リンパ腫,マントル細胞リンパ腫(解説/特集)

市川聡, 福原規子, 一迫玲, 張替秀郎

医学書院　61　(7)　836-840　2017/07
Publisher: 医学書院
DOI： 10.11477/mf.1542201320 　

ISSN： 0485-1420
ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA

K. Saito, T. Fujiwara, M. Morita, Y. Okitsu, N. Fukuhara, Y. Onishi, Y. Nakamura, R. Shimizu, H. Harigae

HAEMATOLOGICA　102　241-241　2017/06

ISSN： 0390-6078
EXPLORING THE MECHANISM OF FOG1-DEPENDENT TRANSCRIPTIONAL REGULATION IN ERYTHROID CELLS

T. Fujiwara, K. Sasaki, K. Saito, S. Hatta, S. Ichikawa, M. Kobayashi, Y. Okitsu, N. Fukuhara, Y. Onishi, H. Harigae

HAEMATOLOGICA　102　454-454　2017/06

ISSN： 0390-6078
A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)

K. Yamamoto, K. Hatake, N. Fukuhara, S. Kusumoto, H. Nagai, Y. Kobayashi, T. Kakihara, M. Shintani, A. Roberts, P. Maciag, S. K. Agarwal, A. H. Salem, K. J. Freise, T. Kiriyama, K. Tobinai

HAEMATOLOGICA　102　468-468　2017/06

ISSN： 0390-6078
造血器腫瘍患者の終末期に関連した意思決定に関する意識調査

李美玲, 今野朱美, 福原規子, 宮下光令, 張替秀郎

Palliative Care Research　12　(Suppl.)　S543-S543　2017/06
Publisher: (NPO)日本緩和医療学会
【免疫表現型に基づいたリンパ系腫瘍の理解】末梢T細胞性リンパ腫の免疫表現型とnormal counterpart

八田俊介, 福原規子, 一迫玲

血液内科　74　(6)　791-797　2017/06
Publisher: (有)科学評論社
ISSN： 2185-582X
皮膚筋炎との鑑別を要したPrimary Cutanous Aggressive Epidermotropic CD8+T-cell lymphomaの1例

吉田紗彩, 照井仁, 山崎研志, 相場節也, 福原規子, 張替秀郎

日本皮膚科学会雑誌　127　(5)　1151-1151　2017/05
Publisher: (公社)日本皮膚科学会
ISSN： 0021-499X
濾胞性リンパ腫診療の現在の到達点と今後の課題

福原規子

血液内科　74　(4)　481-486　2017/04/28
Publisher: 科学評論社
ISSN： 2185-582X
脳病変を伴った皮膚原発CD8陽性劇症型表皮向性細胞障害性T細胞リンパ腫に対して臍帯血移植を施行した1例

市川聡, 福原規子, 八田俊介, 氷室真仁, 那須健太郎, 小野浩弥, 渡邉真威, 猪倉恭子, 小林匡洋, 大西康, 石澤賢一, 一迫玲, 張替秀郎

臨床血液　58　(4)　403-403　2017/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
心アミロイドーシスの鑑別に心臓MRI T1マッピングが有用であった多発性骨髄腫の一例

佐藤遥, 杉村宏一郎, 建部俊介, 青木竜男, 山本沙織, 矢尾板信裕, 神津克也, 紺野亮, 佐藤公雄, 福原規子, 下川宏明

日本循環器学会東北地方会(Web)　164th　TOHOKU164,49 (WEB ONLY)　2017
Intrabone Transplantation of a Single Cord Blood Unit Using Non-Irradiated Reduced-Intensity Conditioning

Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Tadashi Matsushita, Yoshihisa Kodera, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida

BLOOD　128　(22)　2016/12

ISSN： 0006-4971

eISSN： 1528-0020
当科で経験したEBV陽性びまん性大細胞型B細胞リンパ腫の2例

渡邉真威, 小林匡洋, 小野浩弥, 氷室真仁, 那須健太郎, 八田俊介, 市川聡, 福原規子, 大西康, 張替秀郎

臨床血液　57　(12)　2604-2604　2016/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
脳死肺移植後に発症した移植後リンパ増殖性疾患の1例

石際康平, 市川聡, 福原規子, 小野浩弥, 渡邉真威, 那須健太郎, 八田俊介, 大西康, 松田安史, 岡田克典, 張替秀郎

臨床血液　57　(12)　2604-2605　2016/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
【白血病学(上)-最新の基礎、臨床研究-】白血病・骨髄異形成症候群・骨髄増殖性腫瘍のWHO分類前駆型リンパ球系腫瘍

福原規子

日本臨床増刊白血病学(上)　74　(増刊8)　412-417　2016/10
日本における⁹⁰Y-イブリツモマブ・チウキセタンの適正使用

丸山大, 福原規子, 福田哲也, 岡諭, 大中貴史, 崔日承, 飛内賢正

血液内科 = Hematology　73　(3)　423-434　2016/09
Publisher: 科学評論社
ISSN： 2185-582X
B細胞性リンパ腫合併膜性腎症に対してリツキシマブを投与した1例

島田佐登志, 中道崇, 山田元, 鳴海かほり, 市川聡, 福原規子, 山本多恵, 宮崎真理子, 張替秀郎, 佐藤博, 伊藤貞嘉

日本腎臓学会誌　58　(6)　776-776　2016/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.

Kenichi Ishizawa, Michinori Ogura, Dai Maruyama, Yasunobu Abe, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Imaizumi Yoshitaka, Noriko Fukuhara, Toshiki Uchida, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai

JOURNAL OF CLINICAL ONCOLOGY　34　(15)　2016/05

DOI： 10.1200/JCO.2016.34.15_suppl.e19050 　

ISSN： 0732-183X

eISSN： 1527-7755
Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

Kiyohiko Hatake, Tomohiro Kinoshita, Noriko Fukuhara, Ilseung Choi, Masafumi Taniwaki, Kiyoshi Ando, Dai Maruyama, Yasuhito Terui, Yusuke Higuchi, Yasushi Onishi, Yasunobu Abe, Tsutomu Kobayashi, Yukari Shirasugi, Kensei Tobinai

JOURNAL OF CLINICAL ONCOLOGY　34　(15)　2016/05

DOI： 10.1200/JCO.2016.34.15_suppl.e19018 　

ISSN： 0732-183X

eISSN： 1527-7755
ADAMTS13 inhibitor高値を示した難治性血栓性血小板減少性紫斑病の一例

宮内健一郎, 秋保真穂, 山本多恵, 藤倉恵美, 宮崎真理子, 氷室真仁, 市川聡, 沖津庸子, 福原規子

日本透析医学会雑誌　49　(Suppl.1)　611-611　2016/05
Publisher: (一社)日本透析医学会
ISSN： 1340-3451
第4章研修で学ぶべき検査と治療法 A-7.リンパ節生検

福原規子

血液科研修ノート　124-126　2016/05
Publisher: 診断と治療社
Philadelphia染色体陽性ALLに対する同種造血幹細胞移植36例の後方視的解析

小林匡洋, 大西康, 横山寿行, 佐々木治, 突田真紀子, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　38th　2016
Impaired Lysophosphatidic Acid Receptor 3 Signaling in Mesenchymal Stromal Cells Promotes Multiple Myeloma Progression through Cellular Senescence and Transdifferentiation into Tumor-Associated Fibroblasts

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Ohnishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
GATA-2 Regulates Dendritic Cell Differentiation

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
【外来で診るリンパ腫・骨髄腫-治癒または長期共存を目指して】リンパ腫診療の進歩診療指針濾胞性リンパ腫(解説/特集)

福原規子

Medicina　52　(12)　2095-2099　2015/11
Publisher: 医学書院
骨髄間質細胞におけるリゾホスファチジン酸受容体シグナルは多発性骨髄腫の進展を制御する

兼平雅彦, 福原規子, 一迫玲, 張替秀郎

日本癌学会総会記事　74回　P-2264　2015/10
Publisher: 日本癌学会
ISSN： 0546-0476
THE SIGNALING BALANCE BETWEEN LYSOPHOSPHATIDIC ACID RECEPTOR 1 AND 3 IN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS DETERMINES PROGRESSION OF MULTIPLE MYELOMA

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Onishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　43　(9)　S71-S71　2015/09

ISSN： 0301-472X

eISSN： 1873-2399
HIGH-THROUGHPUT SIRNA SCREENING REVEALS GATA-2 UPSTREAM TRANSCRIPTIONAL MECHANISMS IN HEMATOPOIETIC CELLS

Y. Saito, T. Fujiwara, M. Kobayashi, M. Suzuki, Y. Okitsu, N. Fukuhara, Y. Onishi, K. Ishizawa, H. Harigae

HAEMATOLOGICA　100　123-123　2015/06

ISSN： 0390-6078
Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406)

Michinori Ogura, Kensei Tobinai, Taro Shibata, Kiyoshi Ando, Mitsutoshi Kurosawa, Hiroshi Gomyo, Naokuni Uike, Norifumi Tsukamoto, Noriko Fukuhara, Tatsu Shimoyama, Masafumi Taniwaki, Kisato Nosaka, Yoshihiro Matsuno, Tomomitsu Hotta, Kunihiro Tsukasaki, Yasuo Morishima, Kazuhito Yamamoto

JOURNAL OF CLINICAL ONCOLOGY　33　(15)　2015/05

ISSN： 0732-183X

eISSN： 1527-7755
Mantle cell lymphomaとperipheral T-cell lymphomaが同一リンパ節内に認められたcomposite lymphomaの一例

勝嶌浩紀, 中嶌真治, 高川真徳, 福原規子, 板倉裕子, 高橋徹, 笹野公伸, 一迫玲

日本病理学会会誌　104　(1)　366-366　2015/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
抗多発性骨髄腫薬抗がん剤の副作用と支持療法―より適切な抗がん剤の安全使用をめざして

福原規子

日本臨牀増刊号　195-197　2015/02/20
Publisher: 日本臨牀社
オファツムマブ

福原規子

最新醫學別冊診断と治療のABC 102 血液領域の分子標的治療薬　108-114　2015/02/15
Publisher: 最新医学社
【抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-】系統別抗がん剤の副作用化学療法薬その他抗多発性骨髄腫薬(解説/特集)

福原規子

日本臨床 (0047-1852)　73巻　(増刊)　195-197　2015/02
Publisher: 日本臨床社
Impact of TET2 Deficiency on Iron Metabolism in Eryhroblasts: A Potential Link to Ring Sideroblast Formation

Kyoko Inokura, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Kazuya Shimoda, Hideo Harigae

BLOOD　124　(21)　2014/12

ISSN： 0006-4971

eISSN： 1528-0020
Exploring the Potential Usefulness of 5-Aminolevulinic Acid for X-Linked Sideroblastic Anemia

Tohru Fujiwara, Ryoyu Niikuni, Koji Okamoto, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Yukio Nakamura, Tohru Tanaka, Hideo Harigae

BLOOD　124　(21)　2014/12

ISSN： 0006-4971

eISSN： 1528-0020
ブレンツキシマブベドチン

福原規子

がんの薬物療法マニュアル[第2版]　283-285　2014/12
Publisher: 中外医学社
前駆型リンパ球系腫瘍

福原規子, 一迫玲

リンパ腫アトラス改訂・改題第４版　58-66　2014/10/20
Publisher: 文光堂
リゾホスファチジン酸シグナルを標的とした新たな多発性骨髄腫治療法開発の試み(A novel therapeutic approach of multiple myeloma targeting lysophosphatidic acid signaling in tumor and stroma)

兼平雅彦, 福原規子, 石澤賢一, 張替秀郎

日本癌学会総会記事　73回　P-2285　2014/09
Publisher: 日本癌学会
ISSN： 0546-0476
IDENTIFICATION OF ACQUIRED MUTATIONS BY WHOLE-GENOME SEQUENCING IN MONOMAC SYNDROME EVOLVING INTO MYELODYSPLASIA AND ACUTE LEUKEMIA

T. Fujiwara, N. Fukuhara, R. Funayama, N. Nariai, M. Kamata, T. Nagashima, K. Kojima, Y. Onishi, Y. Sasahara, K. Ishizawa, M. Nagasaki, K. Nakayama, H. Harigae

HAEMATOLOGICA　99　81-82　2014/06

ISSN： 0390-6078
GATA2 REGULATES DIFFERENTIATION OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS

M. Kamata, Y. Okitsu, T. Fujiwara, S. Nakajima, T. Takahashi, A. Inoue, N. Fukuhara, Y. Onishi, K. Ishizawa, R. Shimizu, M. Yamamoto, H. Harigae

HAEMATOLOGICA　99　173-173　2014/06

ISSN： 0390-6078
Methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis

68　(4)　500-504　2014/04
Publisher: 科学評論社
ISSN： 2185-582X
骨髄生検でB-リンパ芽球性白血病/リンパ腫と濾胞性リンパ腫が同時に認められた一例

勝嶌浩紀, 大田泰徳, 沖津庸子, 福原規子, 張替秀郎, 笹野公伸, 一迫玲

日本病理学会会誌　103　(1)　371-371　2014/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
本邦における遺伝性鉄芽球性貧血の臨床病理学的特徴

藤原亨, 大場理恵, 古山和道, 福原規子, 大西康, 伊藤悦朗, 小澤敬也, 小島勢二, 小川誠司, 張替秀郎

日本内科学会雑誌　103　(Suppl.)　262-262　2014/02
Publisher: (一社)日本内科学会
ISSN： 0021-5384

eISSN： 1883-2083
A Low-Molecular-Weight Compound K7174 Represses Hepcidin: Possible Therapeutic Strategy Against Anemia Of Chronic Disease

Tohru Fujiwara, Takashi Ikeda, Yuki Nagasaka, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Naohisa Tomosugi, Hideo Harigae

BLOOD　122　(21)　2013/11

ISSN： 0006-4971

eISSN： 1528-0020
A CLINICOPATHOLOGICAL ANALYSIS OF LYMPHOPROLIFERATIVE DISORDERS IN RHEUMATOID ARTHRITIS

Y. Kamogawa, N. Fukuhara, M. Suzuki, S. Nakajima, Y. Okitsu, Y. Katsuoka, Y. Onishi, T. Ishii, K. Ishizawa, H. Harigae

ANNALS OF ONCOLOGY　24　2013/11

DOI： 10.1093/annonc/mdt459.98 　

ISSN： 0923-7534

eISSN： 1569-8041
Exploring The Mechanisms To Reveal The Contribution Of LMO2 To The Transcriptional Regulation In Human Erythroblasts

Al Inoue, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

BLOOD　122　(21)　2013/11

ISSN： 0006-4971

eISSN： 1528-0020
未治療低悪性度B細胞リンパ腫に対するrituximab+bendamustine vs.R-CHOPの第Ⅲ相試験 (特集血液腫瘍に対する重要な臨床試験と国内外の診療に及ぼすインパクト)

福原規子

血液内科　66　(4)　441-447　2013/04
Publisher: 科学評論社
ISSN： 2185-582X
Regulation of Erythropoiesis by Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin A (DZNep)

Tohru Fujiwara, Haruka Saitoh, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

BLOOD　120　(21)　2012/11

ISSN： 0006-4971
Elucidation of the Role of LMO2 (LIM-only protein 2) in Erythroid Cells

A. I. Inoue, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

BLOOD　120　(21)　2012/11

ISSN： 0006-4971
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

ANNALS OF HEMATOLOGY　91　(11)　1825-1826　2012/11

DOI： 10.1007/s00277-012-1477-3 　

ISSN： 0939-5555

eISSN： 1432-0584
若年成人における節外性NK/T細胞性リンパ腫の臨床病理学的解析 MIYAGI試験(A clinicopathological analysis of extranodal NK/T-cell lymphoma in younger adults: MIYAGI study)

Fukuhara Noriko, Ichikawa Satoshi, Suzuki Makiko, Nakajima Shinji, Okitsu Yoko, Katsuoka Yuna, Kohata Katsura, Fujiwara Tohru, Onishi Yasushi, Yamamoto Joji, Yokoyama Hisayuki, Fujiwara Minami, Meguro Kuniaki, Takahashi Taro, Ishikawa Izumi, Ishizawa Kenichi, Kameoka Junichi, Ichinohasama Ryo, Harigae Hideo

臨床血液　53　(9)　1163-1163　2012/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Gene Expression Profiling Identifies HOXB4 as a Direct Downstream Target of GATA-2 in Human CD34+Hematopoietic Cells

Tohru Fujiwara, Hisayuki Yokoyama, Yoko Okitsu, Mayumi Kamata, Noriko Fukuhara, Yasushi Onishi, Shinichi Fujimaki, Shinichiro Takahashi, Kenichi Ishizawa, Emery H. Bresnick, Hideo Harigae

PLOS ONE　7　(9)　e40959-e40959　2012/09

DOI： 10.1371/journal.pone.0040959 　

ISSN： 1932-6203
エンテカビル投与により寛解に至ったB型肝炎ウィルス感染、慢性リンパ性白血病合併ネフローゼ症候群の一例

吉田舞, 中道崇, 大場郁子, 柳澤紀子, 宮崎真理子, 佐藤博, 伊藤貞嘉, 福原規子, 張替秀郎

日本腎臓学会誌　54　(6)　728-728　2012/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
トシリズマブが寛解導入に有効であったAAアミロイドーシスによるネフローゼ症候群の一例

中道崇, 中山恵輔, 宮崎真理子, 佐藤博, 伊藤貞嘉, 福原規子, 石井智徳, 張替秀郎

日本腎臓学会誌　54　(6)　741-741　2012/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
Initial therapeutic strategy in low-tumor burden follicular lymphoma

65　(1)　65-71　2012/07
Publisher: 科学評論社
ISSN： 2185-582X
【血液疾患はどこまで外来で診られるか】どのような場合に低悪性度リンパ腫を無治療経過観察とするか (血液内科)

福原規子, 石澤賢一

血液内科　64　(6)　690-694　2012/06
Publisher: 科学評論社
ISSN： 2185-582X
心タンポナーデで発症し,外科的切除と術後化学療法により長期生存中の心臓原発悪性リンパ腫の1例

後岡広太郎, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 青木竜男, 建部俊介, 山本沙織, 下川宏明, 熊谷紀一郎, 齋木佳克, 山本譲司, 福原規子, 石澤賢一, 張替秀郎

日本循環器学会東北地方会(Web)　154th　2012
【リンパ系腫瘍診療のresearch questions】未治療濾胞性リンパ腫に対する無治療経過観察はrituximab eraにおいて許容しうる治療選択肢か? (血液内科)

福原規子, 石澤賢一

血液内科　63　(1)　8-13　2011/07
Publisher: 科学評論社
ISSN： 2185-582X
Flu/CY/ATGの前処置にてATGを先行投与し同種骨髄移植を施行した再生不良性貧血の1例

大場理恵, 猪倉恭一, 勝岡優奈, 沖津庸子, 福原規子, 大口裕人, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　33rd　2011
フルダラビン+大量エンドキサン+TBI 4Gyを前処置に用いた臍帯血移植の検討

大西康, 大場理恵, 猪倉恭子, 勝岡優奈, 沖津庸子, 木幡桂, 福原規子, 大口裕人, 山本譲司, 石澤賢一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　33rd　2011
マントル細胞リンパ腫長期生存例の後方視的解析

福原規子, 原崎頼子, 井根省二, 遠宮靖雄, 奥田光崇, 三浦由希子, 大口裕人, 大西康, 木幡桂, 横山寿行, 石澤賢一, 亀岡淳一, 一迫玲, 佐々木治, 張替秀郎

日本臨床腫瘍学会学術集会プログラム・抄録集　9th　2011
腸症型T細胞リンパ腫 MIYAGI研究会による臨床病理学的解析(Enteropathy-associated T-cell lymphoma: a clinicopathoiogical analysis from MIYAGI study group)

Fukuhara Noriko, Kamata Mayumi, Yamamoto Joji, Yokoyama Hisayuki, Takahashi Taro, Ishikawa Izumi, Sugawara Tomohiro, Takagawa Masanori, Sasaki Osamu, Katsuoka Yuna, Miura Yukiko, Ohba Rie, Okitsu Yoko, Kohata Katsura, Ohguchi Hiroto, Onishi Yasushi, Ishizawa Kenichi, Kameoka Junichi, Ichinohasama Ryo, Harigae Hideo

臨床血液　51　(9)　983-983　2010/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
血縁者間同種末梢血幹細胞移植を早期に施行し寛解を得ているAggressive NK-cell leukemiaの1例

市川聡, 福原規子, 山本譲司, 鎌田真弓, 小林匡洋, 大場理恵, 沖津庸子, 大口裕人, 木幡桂, 大西康, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
再発・難治低悪性度リンパ腫に対する90Y-イブリツモマブ・チウキセタン療法の有効性・安全性の検討

鎌田真弓, 木村淳, 新津秀孝, 木村朋文, 小林匡洋, 沖津庸子, 福原規子, 大場理恵, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

日本臨床腫瘍学会学術集会プログラム・抄録集　8th　2010
進行期Extranodal NK/T cell lymphoma,nasal typeに対する同種造血幹細胞移植の有用性

横山寿行, 山本譲司, 大口裕人, 遠宮靖雄, 大西康, 鎌田真弓, 渡辺龍, 小林匡洋, 沖津庸子, 木幡桂, 大場理恵, 福原規子, 山田実名美, 石澤賢一, 亀岡淳一, 目黒邦昭, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
当科における同種造血幹細胞移植の経験-20年間の歩み

山本譲司, 鎌田真弓, 渡辺龍, 小林匡洋, 市川聡, 中嶌真治, 鈴木真紀子, 井上あい, 三浦由希子, 沖津庸子, 木幡桂, 大場理恵, 福原規子, 大西康, 横山寿行, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
骨髄線維化と巨脾を伴う移行期CMLに非血縁者間骨髄移植を施行した一例

小林匡洋, 鈴木真紀子, 沖津庸子, 福原規子, 鎌田真弓, 大場理恵, 大口裕人, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
Ph染色体異常を有するB細胞性白血病の病態解析

鈴木真紀子, 市川聡, 中嶌真治, 大口裕人, 沖津庸子, 木幡桂, 福原規子, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 関正則, 遠宮靖雄, 張替秀郎

臨床血液　50　(9)　890-890　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
宮城県における悪性リンパ腫の臨床および病理学的特徴

三浦由希子, 鎌田真弓, 小林匡洋, 中嶌真治, 市川聡, 鈴木真紀子, 井上あい, 沖津庸子, 大口裕人, 福原規子, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

臨床血液　50　(9)　1026-1026　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
FISH法によるIgH転座解析を用いた濾胞性リンパ腫骨髄浸潤の検出

木幡桂, 三浦由希子, 大口裕人, 沖津庸子, 福原規子, 大西康, 山本譲司, 石澤賢一, 亀岡淳一, 張替秀郎, 横山寿行, 一迫玲, 安久美子, 賀来満夫

臨床血液　50　(9)　1043-1043　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Bortezomibが著効したIgM型多発性骨髄腫の1例

鎌田真弓, 山本譲司, 市川聡, 中嶌真治, 鈴木真紀子, 小林匡洋, 沖津庸子, 福原規子, 木幡桂, 大西康, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

臨床血液　50　(9)　1073-1073　2009
フルダラビン、メルファランを用いた造血器腫瘍に対する同種造血幹細胞移植当科における経験

山本譲司, 鎌田真弓, 渡辺龍, 小林匡洋, 市川聡, 中嶌真治, 鈴木真紀子, 井上あい, 三浦由希子, 沖津庸子, 木幡桂, 福原規子, 大西康, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

臨床血液　50　(9)　983-983　2009
胃MALTリンパ腫のH.pylori除菌反応性とゲノム異常

福原規子, 中村常哉, 田川博之, 中川雅夫, 谷田部恭, 森島泰雄, 中村栄男, 瀬戸加大

日本リンパ網内系学会会誌　47　99-99　2007/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
Genomic imbalances are associated with outcome of Helicobacter Pylori eradication in t(11;18)(q21;q21)-negative gastric MALT lymphomas.

Noriko Fukuhara, Hiroyuki Tagawa, Tsuneya Nakamura, Hiroshi Inagaki, Yasuo Morishima, Shigeo Nakamura, Masao Seto

BLOOD　108　(11)　686A-686A　2006/11

ISSN： 0006-4971
Indolent B細胞性リンパ腫(B-NHL)に対する免疫放射線療法90Y-ibritumomab tiuxetan(Y2B8)の第I相試験

伊藤国明, 渡辺隆, 五十嵐忠彦, 臼渕規子, 中田匡信, 関口直宏, 楠本茂, 谷本一樹, 小林幸夫, 芹生卓, 飛内賢正

日本癌学会総会記事　63回　357-357　2004/09
Publisher: 日本癌学会
ISSN： 0546-0476
Influence of complicated infection on grading of acute graft-versus-host disease (aGVHD) in reduced-intensity stem cell transplantation (RIST).

SW Kim, N Murashige, S Mori, M Kami, N Uchida, Y Kamitsuji, Y Onishi, Y Katayama, O Imataki, N Usubuchi, K Kobayashi, A Hori, T Hamaki, Y Heike, S Taniguchi, S Miyakoshi, K Tajima, Y Takaue

BLOOD　102　(11)　455B-455B　2003/11

ISSN： 0006-4971
Characterization of acute graft-versus-host disease (aGVHD) in reduced-intensity stem-cell transplantation (RIST): Possible existence of early- and late-onset aGVHD with different clinical features.

N Murashige, S Mori, M Kami, Y Kamitsuji, O Imataki, Y Katayama, SW Kim, A Hori, T Hamaki, Y Onishi, N Uchida, N Usubuchi, K Kobayashi, Y Heike, S Taniguchi, S Miyakoshi, K Tajima, Y Takaue

BLOOD　102　(11)　453B-453B　2003/11

ISSN： 0006-4971
Outcome after reduced-intensity stem cell transplantation (RIST) versus conventional stem cell transplantation (CST) for patients with refractory hematological disorders

Y Onishi, M Kami, N Murashige, N Usubuchi, Y Kishi, S Kimu, A Makimoto, R Tanosaki, S Mineishi, S Masuo, S Miyakoshi, Y Takaue

EXPERIMENTAL HEMATOLOGY　31　(7)　111-112　2003/07

ISSN： 0301-472X

Show all ︎Show first 5

Books and Other Publications 1

白血病リンパ腫骨髄腫今日の診断と治療

木崎昌弘, 福原規子, 亀岡淳一

中外医学社　2011/10/20

Presentations 311

自家移植後早期に中枢神経再発をきたしたマントル細胞リンパ腫の1例

田島隆斗, 市川聡, 櫻井一貴, 小松弘香, 竹中健太, 中村嘉詞, 猪倉恭子, 福原規子, 横山寿行, 張替秀郎

第229回日本内科学会東北地方会仙台国際センター
骨髄異形成症候群から進展した急性骨髄性白血病に対する化学療法中に急性心膜炎を発症した1例

竹中健太, 市川聡, 小松弘香, 中村嘉詞, 櫻井一貴, 猪倉恭子, 福原規子, 横山寿行, 大西康, 張替秀郎

第229回日本内科学会東北地方会仙台国際センター
骨髄異形成症候群に対する同種造血幹細胞移植後に発症したノカルジア症の一例

竹中健太, 市川聡, 横山寿行, 小松弘香, 鳴海善洋, 渡邊樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 福原規子, 大西康, 張替秀郎

第１３５回日本血液学会東北地方会 TKPガーデンシティPREMIUM仙台西口/ハイブリッド
骨髄検体のMYD88 L265P変異陽性から診断し得た血管内大細胞型B細胞リンパ腫の1例

小松弘香, 市川聡, 竹中健太, 中村嘉詞, 櫻井一貴, 猪倉恭子, 大西康, 福原規子, 横山寿行, 張替秀郎

第228回日本内科学会東北地方会 2023/2/18（土）仙台国際センター/WEB
Treatment strategy for relapsed/refractory follicular lymphoma
Retrospective comparison of CBT with RIC using FLU-BU-MEL and FLU-MEL-TBI: single institute analysis
Blinatumomab for ALL relapse after allogeneic hematopoietic stem cell transplantation
Japanese phase 1b study of an oral PI3K-delta/gamma inhibitor duvelisib in patients with r/r CLL/SLL
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with r/r PTCL
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory DLBCL
Long-term outcome of patients with immune thrombocytopenia
Chemorefractoriness in MUM1-positive high-grade follicular lymphoma with histological transformation
Two cases of de novo anaplastic multiple myeloma
特発性血小板減少性紫斑病に対するeltrombopag投与中に慢性骨髄性白血病を発症した1例

諸田直哉, 福原規子, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

第８４回日本血液学会学術集会福岡国際会議場
Management of CRS resistant to both tocilizumab and steroid: a case of B-ALL treated with CAR-T
Late-onset X-linked sideroblastic anemia due to heterozygous ALAS2 mutation
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in MDS
Ferritinophagy is impaired in X-linked sideroblastic anemia models during differentiation
Impact of FECH deficiency on ring sideroblast formation in erythroblasts
12．高感度デジタルPCR法を用いて中枢神経再発を診断し得たMYD88 L265P変異陽性B細胞性リンパ腫の一例

小松弘香, 小野寺晃一, 竹中健太, 橋本和貴, 内堀雄介, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

第１３４回日本血液学会東北地方会ホテルメトロポリタン山形 3階「出羽」/ Zoom
11．AITL治療経過中に発症した成人Systemic EBV-positive T-cell lymphoma

鎌田真弓, 斎藤陽, 遠宮靖雄, 原崎頼子, 福原規子, 佐々木治

第１３４回日本血液学会東北地方会ホテルメトロポリタン山形 3階「出羽」/ Zoom
10．著明な血小板減少を伴った血管免疫芽球性T細胞リンパ腫の一例

渡邉樹也, 市川聡, 鳴海善洋, 中村嘉詞, 櫻井一貴, 猪倉恭子, 小松弘香, 竹中健太, 橋本和貴, 内堀雄介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

第１３４回日本血液学会東北地方会ホテルメトロポリタン山形 3階「出羽」/ Zoom
難治性の出血性十二指腸潰瘍を合併した後天性血友病Aの１例

鳴海善洋, 市川聡, 渡邉樹也, 中村嘉詞, 櫻井一貴, 小野寺晃一, 大西康, 福原規子, 横山寿行, 張替秀郎

第２２７回日本内科学会東北地方会山形テルサおよびzoom
腹膜リンパ腫症を呈したびまん性大細胞型B細胞性リンパ腫の１例

中村嘉詞, 市川聡, 齋藤慧, 福原規子, 小野寺晃一, 大西康, 横山寿行, 張替秀郎, 一迫玲

第２２７回日本内科学会東北地方会山形テルサおよびzoom
O4-4 初発時に非ホジキンB細胞性リンパ腫を併発した慢性骨髄性白血病の一例

佐々木麻美, 鈴木千恵, 大久保礼由, 牧優治, 安久美子, 菅原新吾, 藤巻慎一, 福原規子, 藤原亨, 張替秀郎

第23回日本検査血液学会学術集会東京大学本郷キャンパス/ハイブリッド
寛解導入療法時にメトホルミンによる高乳酸血症を来したPh陽性急性リンパ性白血病の1例

中村捷, 道又大吾, 木葉大地, 田中悠也, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第226回日本内科学会東北地方会仙台（WEB)
Long-term survival after cord blood transplantation for AML complicated with disseminated fusariosis
Two cases of conjunctival lesions due to acute GVHD after allogeneic HSCT
Outcome of allogeneic hematopoietic stem cell transplantation for CML-BC at our hospital
O7-4臍帯血移植時のGVHD予防におけるロイコボリンレスキューが移植成績に与える影響

小野寺晃一, 木葉大地, 諸田直哉, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
O4-4芽球増加を伴う骨髄異形成症候群における同種移植前化学療法の意義：単施設の後方視的解析

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
Peritoneal lymphomatosisによって腹部コンパートメント症候群をきたしたB細胞性リンパ腫の一例

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

第133回日本血液学会東北地方会
[OS3-3B-3] Final results of phase 1 study of tirabrutinib (ONO-4059/GS-4059) in B-cell malignancies in Japan
[OS3-9D-3] Factors critical for the results of panel sequencing using DNA from FFPE samples in lymphoma
[PS-29-5] Blood concentration of rituximab in malignant B cell lymphoma patients
[OS2-9C-4] Four cases with discordant development of follicular and classic Hodgkin lymphoma
[OS2-9C-2] Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26
[BPA-2-2] Elucidation of the role of FAM210B in mitochondrial metabolism in erythroblasts
[OS2-13B-3] Cellular models of X-linked sideroblastic anemia based on immortalized human erythroid progenitors
[OS2-13B-2] FOG1-dependent transcriptional network involves glucose metabolic regulation of erythroid cells
[OS2-10A-2] Hepatic niche leads to aggressive NK-cell leukemia proliferation
[OS1-10D-3] Outcome of allogeneic stem cell transplantation in adult patients with EBV-positive T/NK LPDs
[OS1-6D-4] Significance of elevated serum vitamin B12 levels in myeloid malignancies
[OS1-10C-4] The impact of HLA-DRB1 matching status on outcomes of UCBT: A single-institute retrospective study
[BPA-1-3] Eight cases of allogeneic hematopoietic stem cell transplantation for follicular lymphoma
[OS1-4B-5] Clinicopathological features of B-cell lymphoma with three-way chromosomal translocation
[OS1-10A-4] KIR-ligand mismatch effect on GVHD and NK-cell gene expression after cord blood transplantation
[PS-28-4] Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab
[PS-14-6] Sustained remission of atypical CML in accelerated phase after development of severe acute GVHD
[PS-4-3]Four cases of carcinoma that primarily presented with cytopenia due to bone marrow dissemination
S-5 当科における臓器移植後リンパ増殖性疾患の経験（優秀演題口演）

渡邊正太郎, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

第61回日本リンパ網内系学会総会（WEB)
P-177 レテルモビル予防終了後の CMV 再活性化の検討 Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

古川瑛次郎, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 藤原亨, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
P-096 非血縁者間骨髄移植前に Mogamulizumab 単剤治療を行った化学療法抵抗性 ATLL の一例 A case of adult T-cell leukemia/lymphoma receiving mogamulizumab monotherapy preceding URBMT

久保龍大, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 古川瑛次郎, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
P-087 同種造血幹細胞移植後に神経リンパ腫症として再発した濾胞性リンパ腫の 2 例 Two cases of relapsed follicular lymphoma as presenting neurolymphomatosis after allogenic HSCT

阿部未玲, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
O5-2 同種臍帯血移植において KIR リガンド不適合が GVHD 予防法の効果に与える影響 The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

横山寿行, 櫻井一貴, 橋本和貴, 古川瑛次郎, 齋藤慧, 八田俊介, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 勝岡優奈, 大西康, 和泉透, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
持続勃起を契機に診断に至った慢性骨髄性白血病の1例

市村裕菜, 小野寺晃一, 諸田直哉, 田中悠也, 道又大吾, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第225回日本内科学会東北地方会 WEB
Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae
OS-93-5 Prospective evaluation of alternative donor from unrelated donor and cord blood in adult AL and MDS

Tatsunori Goto, Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yasuyuki Nagata, Shingo Kurahashi, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

第82回日本血液学会学術集会（WEB)
OS-81-1 Randomized phase II study to optimize MPB in untreated multiple myeloma: Final analysis of JCOG1105

Shinsuke Iida, Dai Maruyama, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura, Akira Hangaishi, Takahiro Yamauchi, Takahiko Utsumi, Ishikazu Mizuno, Yasushi Takamatsu, Yasuyuki Nagata, Koichiro Minauchi, Eiichi Otsuka, Ichiro Hanamura, Yasuhiro Suzuki, Shinichiro Yoshida, Satoshi Yamasaki, Youko Suehiro, Yutaro Kamiyama, Yuko Watanabe, Kensei Tobinai, Kunihiro Tsukasaki, Hirokazu Nagai

第82回日本血液学会学術集会（WEB)
OS-76-1 Efficacy and safety of modified BLd therapy for transplantineligible patient with multiple myeloma

Satsuki Murakami, Masaki Ri, Masato Ito, Nobuhiko Nakamura, Senji Kasahara, Yuichiro Inagaki, Junya Kuroda, Makoto Yoshimitsu, Akinao Okamoto, Noriko Fukuhara, Hirofumi Taji, Hirokazu Nagai, Hiroatsu Iida, Ichiro Hanamura, Hideki Tsujimura, Miyuki Okura, Mio Kurata, Yoshiko Atsuta, Shinsuke Iida

第82回日本血液学会学術集会（WEB)
OS-75-5 HLA typing predicts toxicity and response in MPB regimen for Myeloma; an ancillary study of JCOG1105

Masaki Ri, Shinsuke Iida, Dai Maruyama, Aya Sakabe, Ryo Kamei, Takuto Nakashima, Masahiro Tohkin, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

第82回日本血液学会学術集会（WEB)
OS-48-5 Phase 1b study of parsaclisib in Japanese patients with relapsed/refractory B-cell lymphoma

Noriko Fukuhara, Youko Suehiro, Harumi Kato, Shigeru Kusumoto, Cinthya Coronado, Erica Rappold, Wanying Zhao, Jia Li, Koji Izutsu

第82回日本血液学会学術集会（WEB)
OS-48-3 Polatuzumab vedotin with bendamustine and rituximab in r/ r DLBCL (P-DRIVE): A phase 2 study in Japan

Hirohiko Shibayama, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Yasuhito Terui

第82回日本血液学会学術集会（WEB)
OS-48-2 Phase II study of tirabrutinib in Japanese patients with Waldenstrom's macroglobulinemia

Shinya Rai, Naohiro Sekiguchi, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

第82回日本血液学会学術集会（WEB)
OS-48-1 Phase 2 study of E7777 on relapsed or refractory peripheral and cutaneous T-cell lymphoma in Japan

Kazuhito Yamamoto, Kiyoshi Ando, Dai Maruyama, Eiji Kiyohara, Yasuhito Terui, Noriko Fukuhara, Tomomitsu Miyagaki, Hidetsugu Kawai, Yoshiki Tokura, Mamiko Sakata-Yanagimoto, Tadahiko Igarashi, Junya Kuroda, Jiro Fujita, Toshiki Uchida, Takayuki Ishikawa, Kentaro Yonekura, Koji Kato, Tadashi Nakanishi, Kenya Nakai, Risa Matsunaga, Kensei Tobinai

第82回日本血液学会学術集会（WEB)
OS-15-4 Venetoclax plus azacitidine in Japanese patients with newly diagnosed or relapsed/refractory AML

Takahiro Yamauchi, Ilseung Choi, Noriko Fukuhara, Kensuke Usuki, Jalaja Potluri, Paulo Maciag, Ahmed Hamed Salem, Wan-Jen Hong, Hideyuki Honda, Yasuko Nishimura, Sumiko Okubo, Shuichi Taniguchi

第82回日本血液学会学術集会（WEB)
PS-29-4 Two cases of central nervous system PTLD after ATG-based haploidentical HCT

Eijiro Furukawa, Yasushi Onishi, Shinji Nakajima, Koichi Onodera, Kazuki Hashimot, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

第82回日本血液学会学術集会（WEB)
PS-19-3 Three cases of Philadelphia-positive acute leukemia presenting with deep venous thrombosis

Kazuki Hashimoto, Yasushi Onishi, Koichi Onodera, Eijiro Furukawa, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

第82回日本血液学会学術集会（WEB)
PS-14-1 Establishment of SF3B1 mutation screening based on high resolution melting analysis

Chie Suzuki, Tohru Fujiwara, Tetsuro Ochi, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Hideo Harigae

第82回日本血液学会学術集会（WEB)
PS-3-3 Switching from eltrombopag to romiplostim in patients with aplastic anemia: A report of three cases

Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-94-3 Outcomes of allo-HCT using fludarabine-based regimens for Ph+ALL in complete molecular remission

Yasushi Onishi, Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-92-4 The impact of cytomegalovirus reactivation on outcomes in cord blood transplantation

Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Mai Watanabe, Shunsuke Hatta, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kuniaki Meguro, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-56-2 Clinical outcomes of commercial tisagenlecleucel for diffuse large B-cell lymphoma in our center

Kei Saito, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Ken Sagou, Noriaki Tachi, Keiichi Ohashi, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-50-5 The prognosis of FL with a concurrent DLBCL in the population-based lymphoma registry in Miyagi

Shotaro Watanabe, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Yuna Katsuoka, Shunsuke Hatta, Kei Saito, Osamu Sasaki, Yoriko Harazaki, Mayumi Kamata, Yasuo Tomiya, Ryo Ichinohasama, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-49-1 An autopsy case of γδ T cell clonal proliferation early after PD-1 blockade

Koya Ono, Yasushi Onishi, Shotaro Watanabe, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Chie Suzuki, Hirofumi Watanabe, Mariko Oikawa, Yuto Yamazaki, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-27-6 Parameters for distinguishing polycythemia vera from secondary erythrocytosis

Junichi Kameoka, Masahiro Kobayashi, Shori Abe, Jun Nomura, Yoko Okitsu, Shinichiro Takahashi, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-5-2 Impact of ferroptosis in X-linked sideroblastic anemia

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

第82回日本血液学会学術集会（WEB)
OS-5-1 Establishment of congenital sideroblastic anemia model dueto ABCB7 defect

Tohru Fujiwara, Tetsuro Ochi, Chie Suzuki, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

第82回日本血液学会学術集会（WEB)
PS-31-10 Mature γδT-cell leukemia complicated with agranulocytosis

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Tohru Fujiwara, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

第82回日本血液学会学術集会（WEB)
腑帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の一例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

第130回日本血液学会東北地方会秋田
Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Tohru Fujiwara, Chie Suzuki, Tetsuro Ochi, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Chie Suzuki, Tohru Fujiwara, Hiroki Shima, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Koichi, Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, Dai Maruyama, Kosuke Saito, Yoshiro Saito, Satoshi Osaga, Masahiro Tohkin, Naoki Miyata, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Yosuke Minami, Norifumi Tsukamoto, Hideki Tsujimura, Makoto, Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton’s Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory PrimaryPhase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton’s Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary

Motoo Nagane, MD, Yoshitaka Narita, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood

Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, KazutakaOzeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Dai Maruyama, Kiyoshi Ando, Kazuhito Yamamoto, Eiji Kiyohara, Yasuhito Terui, Noriko Fukuhara, Tomomitsu Miyagaki, Hidetsugu Kawai, Yoshiki Tokura, Mamiko Sakata-Yanagimoto, Tadahiko Igarashi, Junya Kuroda, Jiro Fujita, Toshiki Uchida, Takayuki Ishikawa, Kentaro Yonekura, Koji Kato, Tadashi Nakanishi, Kenya Nakai, Risa Matsunaga, Kensei Tobinai

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Masataka Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Tohru Izumi, Yoshihiro Kin, Kunihiro Tsukasaki, Daigo Hashimoto, Masaaki Yuge, Atsumi Yanagisawa, Yachiyo Kuwatsuka, Satoko Shimada, Yasufumi Masaki, Nozomi, Niitsu, Hitoshi Kiyoi, Ritsuro Suzuki, Takashi Tokunaga, Shigeo Nakamura, Tomohiro Kinoshita

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton’s Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, Rai Shinya, Kenshi Suzuki, Hiroshi, Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi, Koji Izutsu

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Clinical Debete1悪性リンパ腫1 ・早期再発濾胞性リンパ腫に対して自家移植の適用はあり？・再発低腫瘍量濾胞性リンパ腫に治療介入は必要？

福原規子

第81回日本血液学会学術集会
Retrospective analysis of anthracycline-induced cardiotoxicity in a single center

Kei Saito, Eijiro Furukawa, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Koichiro Sugimura, Hideo Harigae
Outcome of first alloSCT in adult patients with Phnegative B-ALL

Yasushi Onishi, Koichi Onodera, Yuya Tanaka, Yoonha Lee, Kei Saito, Satoshi Ichikawa, Noriko Fukuhara, Toru Fujiwara, Minami Fujiwara, Hideo Harigae
Establishment of cellular model of X-linked sideroblastic anemia using homology-directed CRISPR/Cas9

Koya Ono, Noriyuki Takahashi, Toru Fujiwara, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae
Role of mitochondrial membrane protein FAM210B during erythroid differentiation

Chie Suzuki, Toru Fujiwara, Kei Saito, Hiroki Shima, Koya Ono, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae
Causes of eosinophilia in Tohoku University Hospital over the past eight years

Junichi Kameoka, Masahiro Kobayashi, Yuko Shirota, Shori Abe, Jun Nomura, Takao Kodera, Yumiko Oka, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hiroshi Fujii, Tomonori Ishii, Shinichiro Takahashi, Hideo Harigae
Three cases of MTX-associated Hodgkin lymphoma treated with brentuximab vedotin-containing regimen

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Tsuyoshi Shirai, Yasushi Onishi, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae
Preemptive therapy for CMV reactivation after daratumumab in patients with RRMM

Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri, Koichi Onodera, Eijiro Furukawa, Sayaka Sano, Kei Saito, Satoshi Ichikawa, Toru Fujiwara, Noriko Fukuhara, Hideo Harigae, Preemptive therapy for CMV reactivation after daratumumab in, patients with RRMM
Japanese iNHL patients receiving lenalidomide/rituximab (R2) from AUGMENT (R/R) and RELEVANCE (1L)

Yasuhito Terui,John, P. Leonard, Nathan H. Fowler, Franck Morschhauser, Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai, Kiyoshi Ando, Hisayuki Yokoyama, Michiaki Koike, Koji Kato, Tomoko Ohtsu, Stacey Kalambakas, Pierre Fustier, Shuichi Midorikawa, Kensei Tobinai
Phase Ib/II study of copanlisib in Japanese patients with relapsed/refractory indolent B-cell NHL

Dai Maruyama, Noriko Fukuhara, Koji Izutsu, Toshiki Uchida, Shigeru Kusumoto, Junya Kuroda, Chisako Iriyama, Masamitsu Yanad, Norifumi Tsukamoto, Yoko Suehiro, Hironobu Minami, Hirokazu Nagai, Shigeo Masuda, Kensei Tobinai
Randomized phase II/III study of R-CHOP vs CHOP with dose-dense rituximab in DLBCL: JCOG0601

Dai Maruyama, Ken Ohmachi, Gakuto Ogawa, Tomohiro Kinoshita, Kensei Tobinai, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Yoko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai
Long-term outcomes and diagnosis-to-treatment interval (DTI) in NK/T-cell lymphoma: NKEA study

Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi, Kana Miyazaki, Senzo Taguchi, Jun Amaki, Takeshi Maeda, Nobuko Kubota, Dai Maruyama, Yasuhito Terui, Nodoka Sekiguchi, Jun Takizawa, Hiroyuki Tsukamoto, Tohru Murayama, Toshihiko Ando, Hiroshi Matsuoka, Masatoshi Hasegawa, Hideho Wada, Rika Sakai, Yoshihiro Kameoka, Norifumi Tsukamoto, Ilseung Choi, Yasufumi Masaki, Kazuyuki Shimada, Noriko Fukuhara, Takahiko Utsumi, Nobuhiko Uoshima, Yoshitoyo Kagami, Naoko Asano, Naoyuki Katayama
Final results from a Japanese phase 2 study of nivolumab in relapsed/refractory Hodgkin lymphoma

Yasuhito Terui, Dai Maruyama, Kazuhito Yamamoto, Noriko Fukuhara, Ilseung Choi, Junya Kuroda, Kiyoshi Ando, Akira Hattori, Kensei Tobinai
Venetoclax combined with azacitidine for Japanese patients with relapsed/refractory AML

Noriko Fukuhara, Ilseung Choi, Kensuke Usuki, Takahiro Yamauchi, Jalaja Potluri, Paulo Maciag, Wan-Jen Hong, Hideyuki Honda, Ahmed Salem, Shuichi Taniguchi
CRISPR/Cas9を用いたALAS2ミスセンス変異導入によるX連鎖性鉄芽球性貧血のモデル細胞

小野浩弥, 高橋昇之, 藤原亨, 細川奈津子, 齋藤慧, 鈴木千恵, 小野寺晃一, 市川聡, 福原規子, 大西康, 張替秀郎

第43回日本鉄バイオサイエンス学会学術集会
B細胞性リンパ腫

福原規子

第59回日本リンパ網内系学会総会モーニングセミナー４　2019/06/28
再発又は難治性のCD30陽性古典的ホジキンリンパ腫/全身性未分化大細胞性リンパ腫に対するBrentuximab Vedotin再治療の安全性及び有効性に関する後方視的検討

山本豪, 福原規子, 辻村秀樹, 張高明, 柴山浩彦, 矢内友子, 渋谷和憲, 伊豆津宏二

第59回日本リンパ網内系学会総会　2019/06/28
エリスロポエチン産生制御と赤血球造血

張替秀郎

第64回日本透析医学会学術集会・総会教育講演３　2019/06/28
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

第59回日本リンパ網内系学会総会　2019/06/28
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

第59回日本リンパ網内系学会総会　2019/06/28
診断・治療に苦慮したメソトレキセート関連ホジキンリンパ腫の１例

岩渕蒼太, 市川聡, 齋藤慧, 小野寺晃一, 白井剛志, 福原規子, 大西康, 藤井博司, 張替秀郎

第217回日本内科学会東北地方会　2019/06/22
MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

第94回日本結核病学会総会シンポジウム１（生涯教育セミナー）“免疫不全に合併したNTM症”S1-5　2019/06/07
Epidemiology and molecular characterization of congenital sideroblastic anamia

Tohru Fujiwara, Kei Saito, Chie Suzuki, Koya Ono, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae
臍帯血移植前に肺真菌症に対する外科的切除が有効であった急性骨髄性白血病3例

中川諒, 大西康, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
成人発症の慢性活動性EBV感染症に対する臍帯血移植の成績

大西康, 小野寺晃一, 中川諒, 佐野沙矢香, 川尻昭寿, 齋藤慧, 市川聡, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
再生不良性貧血に対する同種造血幹細胞移植後にドナー型二次性着不全からAMLへと進展した一例

小野寺晃一, 中川諒, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 市川聡, 福原規子, 大西康, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
Daratumumab併用療法後にCD38陰性化を伴って病勢増悪を来した再発難治性多発性骨髄腫の一例

齋藤慧, 古川瑛次郎, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 市川聡, 大西康, 福原規子, 張替秀郎

第127回日本血液学会東北地方会　2019/02/17
進行期胃癌の診断に先行して認められた骨髄癌腫症の1例

古川瑛次郎, 市川聡, 矢坂健, 星陽介, 齋藤慧, 白井剛志, 福原規子, 大西康, 大内康太, 張替秀郎

第216回日本内科学会東北地方会　2019/02/16
Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Ken Ohmachi, Tomohiro Kinoshita, MD, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Youko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Dai Maruyama, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai

60th ASH Annual Meeting & Exposition San Diego Convention Center,
Generation and Molecular Characterization of Human Ring Sideroblasts

Kei Saito, Tohru Fujiwara, Shunsuke Hatta, Chie Suzuki, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae

60th ASH Annual Meeting & Exposition San Diego Convention Center,
既治療CTCL患者に対するモガムリズマブの国際共同第III相比較試験

飛内賢正, 菅谷誠, 福原規子, 戸倉新樹

第80回日本血液学会学術集会　2018/10/13
再発/難治性の成熟B細胞腫瘍日本人患者に対するibrutinibの第I相試験：最終解析結果

内田俊樹, 飛内賢正, 福原規子, 棟方理, 蒔田真一, 小林美希, 齊藤繁紀, 山口洋平, 西川智章

第80回日本血液学会学術集会　2018/10/13
Aggressive lymphomaに対するDA-EPOCH -/+ Rituximab療法の忍容性と安全性に関する後方視的解析

松田真一朗, 末廣陽子, 富田直人, 伊豆津宏二, 福原規子, 今泉芳孝, 島田和之, 仲里朝周, 吉田功, 高橋勉, 鈴木律朗, 山口素子, 鈴宮淳司

第80回日本血液学会学術集会　2018/10/13
日本人再発難治性MCL患者に対するIbrutinibの第II相試験：最終解析結果

福原規子, 永井宏和, 丸山大, 北野俊行, 石川隆之, 柴山浩彦, 崔日承, 畠清彦, 内田俊樹, 錦織桃子, 木下朝博, 松野吉宏, 西川智章, 飛内賢正

第80回日本血液学会学術集会　2018/10/13
再発または難治性の日本人低悪性度B細胞リンパ腫患者に対するコパンリシブの第Ib相試験

福原規子, 丸山大, 畠清彦, 永井宏和, 亀崎健次郎, 小坂さおり, 飛内賢正

第80回日本血液学会学術集会　2018/10/13
大量化療前導入治療R-CHOP-14とR-CHOP-14/CHASERの比較試験：JCOG0908

丸山大, 鏡味良豊, 柴田, 大朗, 飛内賢正, 山本一仁, 今泉芳孝, 内田俊樹, 島田和之, 皆内康一郎, 福原規子, 小林泰文, 山内寛彦, 辻村秀樹, 半下石明, 富永亮, 末廣陽子, 吉田真一郎, 井上佳子, 鈴木左知子, 得平道英, 楠本茂, 黒田純也, 薬師神芳洋, 高松泰, 久保田寧, 野坂生郷, 森島聡子, 中村栄男, 堀田知光, 森島泰雄, 塚崎邦弘, 永井宏和

第80回日本血液学会学術集会　2018/10/13
初発進行期、末梢性T細胞リンパ腫に対するTHP-COP療法の第II相試験 (THP-3試験)

小椋美知則, 大間知謙, 鈴木律朗, 熱田由子, 伊藤達也, 大屋敷一馬, 矢野真吾, 日高道弘, 安藤潔, 福原規子, 森下剛久, 鈴木孝世, 塚崎邦弘, 小林直樹, 塚本憲史, 小澤幸泰, 山本一仁, 堀田知光, 木下朝博

第80回日本血液学会学術集会　2018/10/13
成熟T細胞性リンパ腫に対する臍帯血移植：10例の報告

佐野沙矢香, 大西康, 古川瑛次郎, 中川諒, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
T-LGL白血病に対するシクロスポリンA治療：単施設の経験

大西康, 藤原実名美, 佐野沙矢香, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
ダラツムマブ投与中にサイトメガロウイルス抗原血症陽性化を示した多発性骨髄腫の2例

小林匡洋, 佐野沙矢香, 大地哲朗, 那須健太郎, 市川聡, 福原規子, 大西康, 亀岡淳一, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
びまん性大細胞型B細胞リンパ腫におけるsIL-2R値の層別化予後因子としての意義

市川聡, 福原規子, 小林匡洋, 沖津庸子, 大西康, 一迫玲, 石澤賢一, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
尿酸66mg/dlを伴う腫瘍崩壊症候群で発症し,救命し得たB細胞リンパ腫の１例

橋本和貴, 佐野沙矢香, 中川諒, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 大西康, 張替秀郎

第215回日本内科学会東北地方会　2018/09/22
IgG4関連疾患の経過中にホジキンリンパ腫を発症した1例

鍋島立秀, 菅野敦, 福原規子, 三浦晋, 滝川哲也, 濱田晋, 粂潔, 菊田和宏, 張替秀郎, 正宗淳

第215回日本内科学会東北地方会　2018/09/22
巨大な膵形質細胞腫を伴った再発難治性多発性骨髄腫の1例

古川瑛次郎, 市川聡, 福原規子, 齋藤慧, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 大西康, 張替秀

第126回日本血液学会東北地方会　2018/09/22
X連鎖性鉄芽球性貧血患者の疾患特異的iPS細胞の樹立

藤原亨, 八田俊介, 齋藤慧, 福原規子, 大西康, 田中徹, 川真田伸, 張替秀郎

第42回日本鉄バイオサイエンス学会学術集会　2018/09/01
全身性に発症した組織球肉腫の1例

佐野沙矢香, 市川聡, 大橋圭一, 大地哲朗, 那須健太郎, 小林匡洋, 沖津庸子, 福原規子, 大西康, 張替秀郎

第214回日本内科学会東北地方会　2018/06/16
多発根神経炎で発症した血管内大細胞型B細胞リンパ腫の一例

奥田健大, 福原規子, 氷室真仁, 市川聡, 沖津庸子, 小林匡洋, 大西康, 黒田宙, 張替秀郎

第115回日本内科学会総会・ことはじめ2018　2018/04/14
全身性エリテマトーデスの経過中に大腿に限局した節外性NK/T細胞リンパ腫を発症した１例

池田正俊, 市川聡, 福原規子, 渡邊正太郎, 沖津庸子, 小林匡洋, 大西康, 石井智徳, 一迫玲, 張替秀郎

第115回日本内科学会総会・ことはじめ2018　2018/04/14
自己免疫性溶血性貧血が先行した卵巣原発びまん性大細胞型B細胞リンパ腫の1例

笹岡麻実, 市川聡, 福原規子, 渡邊正太郎, 沖津庸子, 小林匡洋, 大西康, 張替秀郎

第115回日本内科学会総会・ことはじめ2018　2018/04/14
Dasatinibによる治療を行ったPhiladelphia染色体陽性骨髄異形成症候群

大地哲朗, 大西康, 佐野沙矢香, 大橋圭一, 那須健太郎, 市川聡, 小林匡洋

第125回日本血液学会東北地方会　2018/02/18
慢性リンパ性白血病（ＣＬＬ）に自己免疫性溶血性貧血（ＡＩＨＡ）を合併し、Rituximabが著効した1例

佐野沙矢香, 大西康, 大地哲朗, 那須健太郎, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

第213回日本内科学会東北地方会　2018/02/17
再生不良性貧血に対するFludarabine+Cyclophosphamide+TBI 4Gyを用いた臍帯血移植

大地哲朗, 大西康, 渡邊正太郎, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 福原規子, 張替秀郎

第40回日本造血細胞移植学会総会　2018/02/01
臍帯血移植が奏効したアグレッシブＮＫ細胞白血病の１例

市川聡, 福原規子, 渡邊正太郎, 氷室真仁, 沖津庸子, 大地哲朗, 那須健太郎, 八田俊介, 小林匡洋, 大西康, 張替秀郎

第40回日本造血細胞移植学会総会　2018/02/01
Establishment and Characterization of in Vitro Model of X- Linked Sideroblastic Anemia

Kei Saito, Tohru Fujiwara, Shunsuke Hatta, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Hairgae

ASH59th Annual Meeting&Exposition　2017/12/09
Role of GATA2 in the Maintenance of the Bone Marrow Microenviroment

Shin Hasegawa, Tohru Fujiwara, Yoko Okitsu, Hiroki Kato, Yuki Sato, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

ASH59th Annual Meeting&Exposition　2017/12/09
濾胞性リンパ腫に対する治療戦略

福原規子

第79回日本血液学会学術集会教育講演　2017/10/20
Clinicopathological analysis of primary gastrointestinal T-cell lymphoma

Shunsuke Hatta, Noriko Fukuhara, Satoshi Ichikawa, Masahiro Kobayashi, Yasushi Onishi, Hiroki Kato, Hisayuki Yokoyama, Joji Yamamoto, Sayaka Sano, Koichi Onodera, Shinji Hasegawa, Sinji Nakajima, Mayumi Kamata, Hiroki Katsushima

第79回日本血液学会学術集会　2017/10/20
Generation of induced pluripotent stem cell-derived erythroblasts of X-linked sideroblastic anemia

Shunsuke Hatta, Tohru Fujiwara, Takako Yamamoto, Mayumi Kamata, Noriko Fukuhara, Yasushi Onishi, Yoshiko Tamai, Yukio Nakamura, Shin Kawamata, Hideo Harigae

第79回日本血液学会学術集会　2017/10/20
Bach1 and Bach2 orchestrate erythro-myeloid differentiation responding to environmental changes

Hiroki Kato, Ari Itoh, Mitsuyo Matsumoto, Risa Shibuya, Yuki Sato, Masahiro Kobayashi, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi

第79回日本血液学会学術集会　2017/10/20
Exploring the mechanism of FOG-1-dependent transcriptional regulation in erythroid cells

Tohru Fujiwara, Katsuyuki Sasaki, Kei Saito, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae

第79回日本血液学会学術集会　2017/10/20
血液悪性疾患に対する骨髄内臍帯血移植

村田誠, 前田嘉信, 増子正義, 福原規子, 西田徹也, 寺倉精太郎, 石川裕一, 谷本光音, 柴崎康彦, 鈴木律朗, 小寺良尚, 清井仁, 直江知樹

第76回日本癌学会学術総会　2017/09/28
転写因子Bach1による鉄応答と赤血球造血の調節

五十嵐和彦, 加藤浩貴, 池田正俊, 小林匡洋, 張替秀郎

第41回日本鉄バイオサイエンス学会学術集会　2017/09/23
ALAS2遺伝子変異を認めた大球性鉄芽球性貧血の一例

藤原亨, 福原規子, 猪俣美津恵, 大西康, 古山和道, 張替秀郎

第41回日本鉄バイオサイエンス学会学術集会　2017/09/23
同種造血幹細胞移植後患者における糖化フェリチン測定の有用性

鈴木千恵, 八田俊介, 藤原亨, 小林匡洋, 市川聡, 福原規子, 大西康, 張替秀郎

第41回日本鉄バイオサイエンス学会学術集会　2017/09/23
移植後リンパ増殖性疾患の再発に対して大量化学療法、自家末梢血幹細胞移植を施行し完全寛解を達成した一例

櫻井一貴, 福原規子, 市川聡, 氷室真仁, 沖津庸子, 渡邊正太郎, 大地哲朗, 那須健太郎, 八田俊介, 小林匡洋, 大西康, 張替秀郎

第124回日本血液学会東北地方会　2017/09/09
難治性胃潰瘍を合併した後天性血友病の1例

高橋浩彦, 渡邊正太郎, 市川聡, 沖津庸子, 福原規子, 大地哲朗, 那須健太郎, 小林匡洋, 大西康, 張替秀郎

第212回日本内科学会東北地方会　2017/09/09
腸腰筋膿瘍との鑑別が困難であった未分化大細胞リンパ腫

小山千佳, 大地哲朗, 渡邊正太郎, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 福原規子, 張替秀郎

第212回日本内科学会東北地方会　2017/09/09
EXPLORING THE MECHANISM OF FOG1-DEPENDENT TRANSCRIPTIONAL REGULATION IN ERYTHROID CELLS International-presentation

Tohru Fujiwara, Katsuyuki Sasaki, Kei Saito, Shunsuke Hatta, Satoshi Ichikawa

22nd European Hematology Association　2017/06/22
ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA International-presentation

Kei Saito, Tohru Fujiwara, Masanobu Morita, Yoko Okitsu, Noriko Fukuhara

22nd European Hematology Association　2017/06/22
最重症型再生不良性貧血に対するupfrontの臍帯血移植

渡邊正太郎, 大西康, 小野浩弥, 八田俊介, 氷室真仁, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

第211回日本内科学会東北地方会　2017/06/17
けいれんで発症し著名な血圧高値を認めた大動脈炎症候群の１例

星陽介, 永井泰地, 石井悠翔, 藤田洋子, 白井剛志, 城田祐子, 藤井博司, 石井智徳, 張替秀郎

第211回日本内科学会東北地方会　2017/06/17
GENERATION OF INDUCED PLURIPOTENT STEM CELL-DERIVD ERYTHROBLASTS FROM A PATIENT WITH X-LINKED SIDEROBLASTIC ANEMIA International-presentation

Shunsuke Hatta, Tohru Fujiwara, Takako Yamamoto, Mayumi Kamata, Yoshiko Tamai, Yukio Nakamura, Shin Kawamata, Hideo Harigae

Biennial World Meeting (BioIron 2017)　2017/05/07
再発難治性濾胞性リンパ腫の経過中に初感染と考えられる重症水痘症を発症した一例

櫻井一貴, 市川聡, 氷室真仁, 福原規子, 八田俊介, 小林匡洋, 大西康, 張替秀郎

医学生・研修医の日本内科学会ことはじめ2017 （第114回日本内科学会）　2017/04/15
Outcome of umbilical cord blood transplantation in adult patients with chronic active Epstein-Barr Virus infection. International-presentation

Yasushi Onishi, Masahiro Kobayashi, Shunsuke Hatta, Satoshi Ichikwa, Noriko Fukuhara, Tohru Fujiwara, Minami Yamada Fujiwara, Hideo Harigae

European Society for Blood and Marrow Transplantation 2017　2017/03/26
臍帯血移植にて血液腫瘍に併存した自己免疫疾患の改善を求めた3例

小林匡洋, 大西康, 小野浩弥, 渡邊真威, 八田俊介, 市川聡, 福原規子, 藤原実名美

第39回日本造血細胞移植学会総会　2017/03/02
Up-frontで自家造血幹細胞移植併用大量化学療法を施行したAITL4例の検討

八田俊介, 大西康, 福原規子, 小林匡洋, 市川聡, 那須健太郎, 渡邊真威, 小野浩弥, 藤原亨, 藤原実名美, 張替秀郎

第39回日本造血細胞移植学会総会　2017/03/02
脳病変を伴った皮膚原発CD8陽性劇症型表皮向性細胞障害性T細胞リンパ腫に対して臍帯血移植を施行した一例

市川聡, 福原規子, 八田俊介, 氷室真仁, 那須健太郎, 小野浩弥, 渡邊真威, 猪倉恭子, 小林匡洋, 大西康, 石澤賢一, 一迫玲, 張替秀郎

第123回日本血液学会東北地方会　2017/02/19
皮膚筋炎にびまん性大細胞型B細胞リンパ腫を合併した1例

渡邉正太郎, 市川聡, 福原規子, 八田俊介, 那須健太郎, 小野浩弥, 渡邉真威, 大西康, 藤井博司, 張替秀郎

第210回日本内科学会東北地方会　2017/02/18
GATA2 regulates dendritic cell differentiation

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

第78回日本血液学会学術集会　2016/10/13
Impact of TET2 on iron metabolism in erythroblasts: A potential link to ring sideroblast formation

Kei Saito, Kyoko Inokura, Tohru Fujiwara, Shunsuke Hatta, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Kazuya Shimoda, Hideo Harigae

第78回日本血液学会学術集会　2016/10/13
Identification of a novel mitochondrial protein FAM210B associated with erythroid differentiation

Aiko Kondo, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Kenichi Sawada, Hideo Harigae

第78回日本血液学会学術集会　2016/10/13
Primary duodenal and small-intestinal follicular lymphoma;signal center experience

Satoshi Ichikawa, Noriko Fukuhara, Masahito Himuro, Mai Watanabe, Shunsuke Hatta

第78回日本血液学会学術集会　2016/10/13
Evaluation of glycosylated ferritin in patients after allo-HSCT

Shunsuke Hatta, Chie Suzuki, Yasushi Onishi, Masahhiro Kobayashi, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Minami Fujiwara, Junichi Kameoka, Hideo Harigae

第78回日本血液学会学術集会　2016/10/13
前縦隔腫瘍の経過中に発症した最重症型再生不良性貧血

小野浩弥, 氷室真仁, 渡邉真威, 小林匡洋, 市川聡, 福原規子, 大西康, 張替秀郎

第209回日本内科学会東北地方会　2016/09/10
当科で経験したEBV陽性びまん性大細胞型B細胞リンパ腫の2例

渡邉真威, 小林匡洋, 小野浩弥, 氷室真仁, 那須健太郎, 八田俊介, 市川聡

第122回日本血液学会東北地方会　2016/09/10
脳死肺移植後に発症した移植後リンパ増殖性疾患の一例

石際康平, 市川聡, 福原規子, 小野浩弥, 渡邉真威, 那須健太郎, 八田俊介, 大西康, 松田安史, 岡田克典, 張替秀郎

第122回日本血液学会東北地方会　2016/09/10
腸管上皮細胞モデルにおけるALAの代謝

齋藤慧, 藤原亨, 田中徹, 張替秀郎

第40回日本鉄バイオサイエンス学会　2016/09/10
臍帯血移植後早期に再燃したがGVL効果にて持続的寛解を得られたγδT‐Cell lymphomaの一例

市川聡, 福原規子, 氷室真仁, 大橋圭一, 鈴木琢磨, 沖津庸子, 小林匡洋, 大西康, 一迫玲, 張替秀郎

第56回日本リンパ網内系学会総会　2016/09/01
宮城県内において5年間で新規発症したマントル細胞リンパ腫43例のうちCD5/CD10/CyclinD1に異常発言を呈した7例の検討

勝嶌浩紀, 福原規子, 市川聡, 張替秀郎, 一迫玲

第56回日本リンパ網内系学会総会　2016/09/01

More details Close

誌上発表
The efficacy of radiommunotherapy in patients with relapsed indolent B cell lymphoma in our hospital

氷室真仁ほか

第１４回日本臨床腫瘍学会学術集会　2016/07/28
意識障害を伴う癌性髄膜炎に進展したNK細胞慢性リンパ増殖異常症の１例

永井泰地, 渡邉真威, 氷室真仁, 八田俊介, 市川聡, 福原規子, 大西康, 張替秀郎, 西山修平

第208回日本内科学会東北地方会　2016/07/09
Improvement of Autoimmune Disease after Cord Blood Transplantation for Hematological Malignancies;Two Cases

Masahiro Kobayashi, Yasushi Onishi, Mai Watanabe, Shunsuke Hatta, Noriko Fukuhara, Tohru Fujiwara, Minami Fujiwara, Hideo Harigae

The 7th JSH International Symposium 2016 in Awaji　2016/05/13
Philadelphia染色体陽性ALLに対する同種造血幹細胞移植36例の後方視的解析

小林匡洋, 大西康, 横山寿行, 佐々木治, 突田真紀子, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

第38回日本造血細胞移植学会総会　2016/03/04
急性骨髄性白血病および骨髄異形成症候群に対する臍帯血移植の成績：前処置法と病期の影響

渡邉真威, 大西康, 氷室真仁, 小野寺晃一, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

第38回日本造血細胞移植学会総会　2016/03/04
同種造血幹細胞移植後成人患者における心理状態とスピリチュアリティを含めたQOL評価

門馬香菜江, 大西康, 沖津庸子, 福原規子, 大槻久美, 坂本祐子, 片岡ひとみ, 張替秀郎

第38回日本造血細胞移植学会総会　2016/03/04
癌性髄膜炎併発未分化大細胞リンパ腫に対してBrentuximab Vedotin(BV)療法を施行した一例

第121回日本血液学会東北地方会　2016/02/21
癌性髄膜炎併発未分化大細胞リンパ腫に対してbrentuximab Vedotin (BV)療法を施行した一例

八田俊介, 氷室真仁, 渡邉真威, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 大西康, 張替秀郎

第121回日本血液学会東北地方会　2016/02/21
癌性髄膜炎併発分化大細胞リンパ腫に対してbrentuximab Vedotin(BV)療法を施行した一例

八田俊介, 氷室真仁, 渡邉真威, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 大西康

第121回日本血液学会東北地方会　2016/02/21
早期にrituximabを投与した難治性血栓性血小板減少性紫斑病の１例

市川聡, 氷室真仁, 沖津庸子, 福原規子, 渡邉真威, 突田真紀子, 小林匡洋, 大西康, 張替秀郎, 奈良県立医科大学輸血部, 松本雅則

第207回日本内科学会東北地方会　2016/02/20
Impaired Lysophosphatidic Acid Receptor 3 Signaling in Mesenchymal Stromal Cells Promotes Multiple Myeloma Progression through Cellular Senescence and Transdifferentiation into Tumor-Associated Fibroblasts International-presentation

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Ohnishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

57th ASH Annual Meeting and Exposition　2015/12/05
Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL) International-presentation

Tomohiro Kinoshita, Noriko Fukuhara, Hirokazu Nagai, Koji Izutsu, Yukio Kobayashi, Yusuke Higuchi, Hideo Harigae, Takashi Tokunaga, Henry Adewoye, Michelle Robeson, Shringi Sharma, Masato Fukui, Jie Gao, Christine Christenson, Kensei Tobinai

57th ASH Annual Meeting and Exposition　2015/12/05

More details Close

ONLINE PUBLICATION ONLY Blood 2015 126:5089; published ahead of print December 4, 2015
GATA-2 Regulates Dendritic Cell Differentiation International-presentation

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

57th ASH Annual Meeting and Exposition　2015/12/05
Phase II study of R-High-CHOP/CHASER followed by LEED therapy with ASCT in untreated MCL (JCOG0406)

Dai Maruyama, Kazuhito Yamamoto, Taro Shibata, Kensei Tobinai, Kiyoshi Ando, Mitsutoshi Kurosawa, Hiroshi Gomyo, Naokuni Uike, Norifumi Tsukamoto, Noriko Fukuhara, Tatsu Shimoyama, Masafumi Taniwaki, Kisato Nosaka, Yoshihiro Matsuno, Tomomitsu Hotta, Kunihiro Tsukasaki, Yasuo Morishima、MichinoriOgura

第77回日本血液学会学術集会　2015/10/16
Photodynamic diagnosis of minimal residual disease in multiple myeloma with 5-aminolevulinic acid

Keita Iwaki, Tohru Fujiwara, Takako Ito, Masahiro Kobayashi, Makiko Tsukita, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Minami Fujiwara, Hideto Tamura, Tohru Tanaka, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
R-MVP therapy with whole-brain radiotherapy for primary intraocular lymphoma

Kei Saito, Takuma Suzuki, Keiichi Oohashi, Makiko Tsukita, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Oonishi, Toru Fujiwara, Minami Fujiwara, Junichi Kameoka, Kazuichi Maruyama, Ryo Ichinohasama, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
Effect of anagrelide on human megakaryocyte differentiation

Kazuki Sakurai, Tohru Fujiwara, Masahiro Kobayashi, Makiko Tsukita, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Minami Fujiwara, Ryo Ichinohasama, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
Incidence of hemophagocytic syndrome and level of serum ferritin after cord blood transplantation

Keiichi Ohashi, Yasushi Onishi, Takuma Suzuki, Kei Saito, Kunihiro Kobayashi, Makiko Tsukita, Yoko Okitsu, Noriko Fukuhara, Minami Fujiwara, Toru Fujiwara, Junichi Kameoka, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
Minimal residual disease monitoring by next-generation sequencing in ETP-ALL

Noriko Fukuhara, Xiaoqing Pan, Naoki Nariai, Sakae Saito, Yukuto Sato, Shin Hasegawa、Aiko Kondo, Yoko Okitsu, Masao Nagasaki, Masayuki Yamamoto, Jun, Yasuda, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
siRNA screening reveals GATA-2 upstream transcriptional mechanisms in hematopoietic cells

Yo Saito, Tohru Fujiwara, Masahiro Kobayashi, Makiko Tsukita, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Minami Fujiwara, Kenichi Ishizawa, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16
Completely reversible pulmonary artery hypertension induced by dasatinib after CBT for Ph+ALL

Takuma Suzuki, Noriko Fukuhara, Keiichi Ohashi, Kei Saito, Makiko Tsukita, Masahiro Kobayashi, Yoko Okitsu, Yasushi Onishi, Toru Fujiwara, Minami Fujiwara, Junichi Kameoka, Hideo Harigae

第77回日本血液学会学術集会　2015/10/16

More details Close

誌上発表
自己末梢血幹細胞移植後に発症したEBV関連リンパ増殖性疾患

渡邉真威, 突田真紀子, 鈴木琢磨, 齋藤慧, 氷室真仁, 小野寺晃一, 小林匡洋, 沖津庸子, 福原規子, 大西康, 亀岡淳一, 張替秀郎

第120回日本血液学会東北地方会　2015/10/10
再発急性骨髄性白血病に対して3回目の同種造血幹細胞移植をHLA半合致ドナーかた施行した1例

渡邊正太郎, 大西康, 渡邉真威, 氷室真仁, 小野寺晃一, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

第206回日本内科学会東北地方会　2015/10/10
妊娠中期に発症した急性前骨髄球性白血病に対し化学療法を施行した1例

鈴木琢磨, 沖津庸子, 大橋圭一, 齋藤慧, 突田真紀子, 小林匡洋, 福原規子, 大西康, 亀岡淳一, 張替秀郎

第205回日本内科学会東北地方会　2015/06/20
HIGH- THROUGHPUT siRNA SCREENING REVEALS GATA-2 UPATREAM TRANSCRIPTIONAL MECHANISMS IN HEMATOPOIETIC CELLS International-presentation

Yo Saito, Tohru Fujiwara, Masahiro Kobayashi, Makiko Suzuki, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

20th Congress European Hematology Association　2015/06/11
血液悪性腫瘍の同種造血幹細胞移植後再発に対する2回目同種移植の有効性

大橋圭一, 大西康, 鈴木琢磨, 斎藤慧, 小林匡洋, 突田真紀子, 沖津庸子, 福原規子, 藤原実名美, 藤原亨, 亀岡淳一, 石澤賢一, 張替秀郎

第37回日本造血細胞移植学会総会　2015/03/05
HLA8座一致非血縁者間骨髄移植における抗HLA-DPB1抗体の意義について

鈴木琢磨, 沖津庸子, 大西康, 大橋圭一, 斎藤慧, 突田真紀子, 小林匡洋, 福原規子, 藤原実名美, 藤原亨, 石澤賢一, 亀岡淳一, 張替秀郎

第37回日本造血細胞移植学会総会　2015/03/05
非血縁者間骨髄移植後に汎血球減少が延しリツキシマブ投与を行った成人Wiskott-Aldrich syndromeの一例

齋藤慧, 大西康, 大橋圭一, 鈴木琢磨, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 亀岡淳一, 石澤賢一, 張替秀郎

第37回日本造血細胞移植学会総会　2015/03/05
モガムリズマブ単回投与により完全寛解を達成した非血縁者間骨髄移植後早期再発ATLLの一例

大西康, 斎藤慧, 突田真紀子, 小林匡洋, 鈴木琢磨, 大橋圭一, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 亀岡淳一, 石澤賢一, 張替秀郎

第37回日本造血細胞移植学会総会　2015/03/05
食道孔を合併したびまん性大細胞型Ｂ細胞性リンパ腫の2症例

齋藤慧, 鈴木琢磨, 大橋圭一, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 大西康, 藤原亨, 藤原実名美, 亀岡淳一, 張替秀郎

第119回日本血液学会東北地方会　2015/02/22
難治性下痢症を契機に腸症型Ｔ細胞リンパ腫と診断した1例

大橋圭一, 福原規子, 鈴木琢磨, 沖津庸子, 大西康, 藤原実名美, 藤原亨, 亀岡淳一, 石澤賢一, 張替秀郎

第204回日本内科学会東北地方会　2015/02/21
Impact of TET2 Deficiency on Iron Metabolism in Erythroblasts: A Potential Link to Ring Sideroblast Formation International-presentation

Kyoko Inokura, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi

56th ASH Annual Meeting and Exposition　2014/12/06
Exploring the potential usefulness of 5-aminolevulinic acid (ALA) for sideroblastic anemia.

Niikuni R, Fujiwara T, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Tanaka T, Harigae H

第76回日本血液学会学術集会　2014/10/31
Adult MDS cases diagnosed as MonoMAC syndrome

Nakagawa R, Fukuhara N, Okitsu Y, Takahashi T, Katsuoka Y, Kobayashi M, Onishi Y, Fujiwara T, Sasahara Y, Ishizawa K, Harigae H

第76回日本血液学会学術集会　2014/10/31
FR therapy followed by 90Y-ibritumomab tiuxetan for relapsed indolent B cell lymphoma, phase 1 study

Himuro M, Kamata M, Kameoka Y, Takahashi N, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Hideo H, Ishida Y, Sawada K

第76回日本血液学会学術集会　2014/10/31
The cilinical significance of BACH2 expression in diffuse large B-cell lymphoma

Ichikawa S, Fukuhara N, Katsumata H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H

第76回日本血液学会学術集会　2014/10/31
Whole genome sequencing to identify acquired mutations in MonoMAC syndrome evolving into MDS/AML

Fujiwara T, Fukuhara N, Funayama R, Nariai N, Kamata M, Nagashima T, Kojima K, Onishi Y, Sasahara Y, Ishizawa K, Nagasaki M, Nakayama K, Harigae H

第76回日本血液学会学術集会　2014/10/31
Role of GATA2 in the differentiation of bone marrow-derived mesenchymal stem cell

Kamata M, Okitsu Y, Fujiwara T, Nakajima S, Takahashi T, Inoue A, Fukuhara N, Onishi Y, Ishizawa K, Shimizu R, Yamamoto M, Harigae H

第76回日本血液学会学術集会　2014/10/31
Salvage cord blood transplant in patients with graft failure after myeloabative conditioninig

Onishi Y, Saito K, Suzuki T, Ohashi K, Kondo A, Hasegawa S, Kobayashi M, Okitsu Y, Fukuhara N, Fujiwara T, Fujiwara M, Kameoka J, Ishizawa K, Harigae H

第76回日本血液学会学術集会　2014/10/31
多発脳神経障害で発症し進行性の馬尾病変をきたした原発性神経リンパ腫症の一例

加藤浩貴, 福原規子, 大橋圭一, 近藤愛子, 長谷川慎, 鎌田真弓, 市川聡, 沖津庸子, 大西康, 藤原亨, 藤原実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第54回リンパ網内系学会総会　2014/06/19
GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells International-presentation

M Kamata, Y Okitsu, T Fujiwara, S Nakajima, T Takahashi, A Inoue, N Fukuhara, Y Onishi, K Ishizawa, R Shimizu, M Yamamoto, H Hrigae

19th EHA Congress　2014/06/12
Identification of Acquired mutations by whole-genome sequencing in monomac syndrome evolving into myelodysplasia and acute leukemia International-presentation

T Fujiwara, N Fukuhara, R Funayama, N Nariai, M Kamata, T Nagashima, K Kojima, Y Onishi, Y Sasahara, K Ishizawa, M Nagasaki, K Nakayama, H Harigae

19th EHA Congress　2014/06/12
自家移植後再発びまん性大細胞型B細胞リンパ腫に対する化学療法中に致死的な内臓播種性帯状疱疹ウイルス感染を発症した1例

金美賢, 市川聡, 大西康, 長谷川慎, 近藤愛子, 沖津庸子, 福原規子, 石澤賢一, 張替秀郎

第111回日本内科学会総会・講演会　2014/04/11
本邦における遺伝性鉄芽球性貧血の臨床病理学的特徴

藤原亨, 大場理恵, 古山和道, 福原規子, 大西康, 伊藤悦朗, 小澤敬也, 小島勢二, 小川誠司, 張替秀郎

第111回日本内科学会総会・講演会　2014/04/11
マントル細胞リンパ腫に対し自己末梢血細胞移植治療後に成人T細胞性白血病/リンパ腫を発症したHTLV-1キャリアの一例

大橋圭一, 大西康, 加藤浩貴, 近藤愛子, 長谷川慎, 沖津庸子, 勝岡優奈, 福原規子, 藤原実名美, 藤原亨, 亀岡淳一, 張替秀郎

第３６回日本造血細胞移植学会総会　2014/03/07
T細胞性急性リンパ性白血病/リンパ芽球性リンパ腫に対する造血幹細胞移植13例の後方視的解析

近藤愛子, 大西康, 大橋圭一, 加藤浩貴, 長谷川慎, 沖津庸子, 福原規子, 勝岡優奈, 藤原実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第３６回日本造血細胞移植学会総会　2014/03/07
同種造血幹細胞移植におけるボリコナゾール血中濃度測定とその有用性についての後方視的検討

加藤浩貴, 大西康, 大橋圭一, 近藤愛子, 長谷川慎, 沖津庸子, 勝岡優奈, 福原規子, 藤原亨, 藤原実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第３６回日本造血細胞移植学会総会　2014/03/07
非寛解期血液悪性疾患に対する臍帯血移植の成績：単一施設50例の後方視的検討

第３６回日本造血細胞移植学会総会　2014/03/07
Azacitidine投与により腫瘍崩壊症候群を来した慢性骨髄単球性白血病の1例

長谷川慎, 大西康, 大橋圭一, 近藤愛子, 市川聡, 沖津庸子, 福原規子, 石澤賢一, 張替秀郎

第201回日本内科学会東北地方会　2014/02/15
Exploring The Mechanisms To Reveal The Contribution Of LMO2 To The Transcriptional Regulation In Human Erythroblasts International-presentation

AI Inoue, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

55th ASH® Annual Meeting and Exposition.　2013/12/08
A Low-Molecular-Weight Compound K7174 Represses Hepcidin: Possible Therapeutic Strategy Against Anemia Of Chronic Disease. International-presentation

Tohru Fujiwara, Takashi Ikeda, Yuki Nagasaka, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Naohisa Tomosugi, Hideo Harigae

55th ASH® Annual Meeting and Exposition.　2013/12/07
A long term obserbation of rheumatoid arthritis who developed methotrexate related lymphoproliferative disorders.

Kamogawa Yukiko, Watanabe Ryu, Shirai Tsuyoshi, Fujita Yoko, Shirota Yuko, Fukuhara Noriko, Fujii Hiroshi, Saito Shinichiro, Ishii Tomonori, Harigae Hideo

ACR/ARHP annualmeeting　2013/10/26
Regulation of hepcidin transcription by K-7174

Takashi Ikeda, Tohru Fujiwara, Yuki Nagasaka, Ai Inoue, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

第75回日本血液学会　2013/10/11
The efficacy of consolidation radioimmunotherapy in patients with relapsed indolent B cell lymphoma

Masahito Himuro, Mayumi Kamata, Jun Kimura, Satoshi Ichikawa, Masanori Takagawa, Jouji Yamamoto, Katsura Kohata, Osamu Sasaki, Yasuo Tohmiya, Yoriko Harazaki, Syouji Ine, Masami Fujii, Tomofumi Kimura, Yoshihiro Kameoka, Jun Nomura, Kuniaki Meguro, Izumi Ishikawa, Makiko Suzuki, Shinji Nakajima, Yuna Katsuoka, Tohru fujiwara, Youko Okitsu, Noriko Fukuhara, Yasuhi Onishi, Junichi Kameoka, Kenichi Ishizawa, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Amelioration of pulmonary artery hypertension after cord blood transplantation in an CAEBV patient.

Yasushi Onishi, Koichiro Sugimura, Yoko Okitssu, Yuna Katsuoka, Noriko Fukuhara, Tohru Fujiwara, Junichi Kameoka, Kenichi Ishizawa, Heideo Harigae

第75回日本血液学会学術集会　2013/10/11
Effect of 5-aminolevulinic acid(ALA) on erythroid cells.

Kouji Okamoto, Tohru Fujiwara, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Elucidation of the role of LIM domain only 2 (LMO2) in human primaty erythroblasts.

Ai Inoue, Tohru Fujiwara, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasuchi Onishi, Kenichi Ishizawa, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
A case of B lymphoblastic leukemia/lymphoma with complex karyotype involving t(14;18) (q32;q31).

Aiko Kondoh, Yoko Okitsu, Keiichi Ohashi, Hiroki Kato, Shin Hasegawa, Noriko Fukuhara, Yuuna Katsuoka, Yasushi Onishi, Toru Fujiwara, Junichi Kameoka, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Progressive multifocal leukoencephalopathy by JCV in a PCL patient treated with bor/lem/dex therapy.

Yukiko Kamogawa, Yasuhi Onishi, Makiko Suzuki, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Toru Fujiwara, Junichi Kameoka, Kenichi Ishizawa, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Addition of oral cyclophosphamide is effective for myeloma refractory to lenalidomide/dexamethasone.

Hiroki Kato, Yasuhi Onishi, Keiichi Ohashi, Aiko Kondou, Shin Hasegawa, Youko Okitsu, Yuuna Katsuoka, Noriko Fukuhara, Tohru Fujiwara, Junichi Kameoka, Kenichi Ishizawa, Masanori Takagawa, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Clinicopathological analysis primary adrenal diffuse large B-cell lymphoma

Satoshi Ichikawa, Noriko Fukuhara, Ai Inoue, Hiroki Katsushima, Rie Ohba, Yuna Katsuoka, Yasushi Onishi, Joji Yamamoto, Osamu Sasaki, Jun Nomura, Osamu Fukuhara, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
Monitoring EBV reactibation in Severe Aplastic Anemia treated with rabbit ATG.

Kentaro Nasu, Noriko Fukuhara, Kyoko Inokura, Kouichi Onodera, You Saitou, Shunsuke Hatta, Makiko Suzuki, Shinji Nakajima, Yoko Okitsu, Yuna Katsuoka, Yasushi Onihi, Toru Fujiwara, Katsura Kohata, Joji Yamamoto, Junichi Kameoka, Kenichi Ishizawa, Hideo Harigae

第75回日本血液学会学術集会　2013/10/11
咽頭腫瘤による気道閉塞にて発症したIgD型多発性勝髄種の１例

長谷川慎, 福原規子, 近藤愛子, 沖津庸子, 勝岡優奈, 藤原亨, 大西康, 亀岡淳一, 石澤賢一, 張替秀郎

第２００回日本内科学会東北地方会　2013/08/31
A Clinicopathological analysis of lymphoproliferative disorders in rheumatoid arthritis.

Yukiko Kamogawa, Noriko Fukuhara, Makiko Suzuki, Shinji Nakajima, Yoko Okitsu, Yuna Katsuoka, Yasushi Onishi, Tomonori Ishii, Kenichi Ishizawa, Hideo Harigae

第１１回日本臨床腫瘍学会学術集会　2013/08/29
Tumor Lysis Syndrome in Malignant Lymphoma, A retrospective study

Kentaro Nasu, Noriko Fukuhara, Natsuko Takahashi, Shinji Nakajima, Yoko Okitsu, Yuna Katsuoka, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

第１１回日本臨床腫瘍学会学術集会　2013/08/19
非血縁者間臍帯血移植後、尿閉を契機に診断された仙骨部帯状疱疹の1例

近藤愛子, 大西康, 沖津庸子, 勝岡優奈, 藤原亨, 福原規子, 藤原実名美, 亀岡淳一, 石澤賢一, 張替秀郎

第199回日本内科学会東北地方会　2013/06/15
dasatinib療法2年後に肺高血圧症をきした臍帯血移植後PhALLの１例

那須健太郎, 福原規子, 中嶌真治, 鈴木真紀子, 沖津庸子, 勝岡優奈, 大西康, 石澤賢一, 福本義弘, 張替秀郎

第198回日本内科学会東北地方会　2013/02/16
Induction of Thymic Stromal Lymphopoietin in Mesenchymal Stem Cells by Interaction with Myeloma Cells. International-presentation

Nakajima S, Ohguchi H, Onishi Y, Kamata M, Fujiwara T, Okitsu Y, Fukuhara N, Ishizawa K, Harigae H

54th ASH® Annual Meeting and Exposition.　2012/12/08
Regulation of Erythropoiesis by Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin A(DZNep) International-presentation

Fujiwara T, Saitoh H, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Harigae H

54th ASH® Annual Meeting and Exposition.　2012/12/08
Elucidation of the Role of LMO2 (LIM-only protein 2) in Erythroid Cells

Inoue A, FujiwaraT, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H

54th ASH® Annual Meeting and Exposition.　2012/12/08
Successful treatment for MDS developed from MonoMAC syndrome with GATA2 mutation by RIST

Onodera Koichi, Yo Saito, Shunsuke Hatta, Kyoko Inokura, Yukiko Miura, Katsura Kohata, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Junichi Kameoka, Youji Sasahara, Shigeru Tsuchiya, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
Induction of thymic stromal lymphopoietin in mesenchymal stem cell by interaction with myeloma cell.

Shinji Nakajima, Hiroto Ohguchi, Yasuhi onishi, Mayumi Kamata, Mayuko Tsuji, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
Composite 5q-syndrome and acute lymphoblastic leukemia

Keiichi Ohashi, Shinji Nakajima, Yo Saotp, Kyoko Inokura, Yoko Okitsu, Katsura Kohata, Noriko Fukuhara, Kentaro Nasu, Makiko Suzuki, Yuna Katsuoka, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
A clinicopathological analysis of extranodal NK/T-cell lymphoma in younger adults:MIYAGI study.

Noriko Fukuhara, Satoshi Ichikawa, Makiko Suzuki, Shinji Nakajima, Yoko Okitsu, Yuna Katsuoka, Katsura Kohata, Tohru Fujiwara, Yasushi Onishi, Joji Yamamoto, Hisayuki Yokoyama, Minami Fujiwara, Kuniaki Meguro, Taro Takahashi, Izumi Ishikawa, Kenichi Ishizawa, Junichi Kameoka, Ryo Ichinohasama, Hideo Hariage

第７４回日本血液学会学術集会・総会　2012/10/19
Allogeneic HSCT in adult patients with EBV-associated T/NK-cell LPD, ENKL, and ANKL

Yasuhi Onishi, Kentaro Nasu, Makiko Suzuki, Shinji Nakajima, Yuna Katsuoka, Yoko Okitsu, Tohru Fujiwara, Noriko Fukuhara, Junichi Kameoka, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
Expression profiling for discoering the role of LIM domain only2(LMO2) in erythroid cells.

Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasuhi Onishi, Kenichi Ishizawa, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
Regulation of erythropoiesis by histone methyltransferse EZH2 inhibitor 3 deazaneplanocin A (DZNep)

Haruka Saito, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasuhi Onishi, Kenichi ishizawa, Ryo Ichinohasama, Hideo Harigae

第７４回日本血液学会学術集会・総会　2012/10/19
R-CHOP療法経過中にneurolymphomatosisにて再燃したDLBCLの１例

海野裕一郎, 福原規子, 長谷川慎, 猪倉恭子, 中嶌真治, 沖津庸子, 木幡桂, 大西康, 石澤賢一, 張替秀郎

第197回日本内科学会東北地方会　2012/09/08
同種造血管細胞移植後にBacillus cereus 菌血症を呈した10例の検討

八田俊介, 斎藤陽, 猪倉恭子, 小野寺晃一, 三浦由希子, 勝岡優奈, 木幡桂, 福原規子, 大西康, 徳田浩一, 石澤賢一, 亀岡淳一, 賀来満夫, 張替秀郎

第３４回日本造血幹細胞移植学会総会　2012/02/24
臍帯血移植または非血縁者間骨髄移植を施行された成人急性骨髄性白血病および骨髄異形成症候群の成績：単一施設における比較解析

大西康, 八田俊介, 斎藤陽, 猪倉恭子, 小野寺晃一, 三浦由希子, 木幡桂, 勝岡優奈, 福原規子, 石澤賢一, 亀岡淳一, 張替秀郎

第３４回日本造血幹細胞移植学会総会　2012/02/24
臍帯血移植後早期に非感染性胸水を合併した２例

小野寺晃一, 斎藤陽, 八田俊介, 猪倉恭子, 三浦由希子, 木幡桂, 勝岡優奈, 福原規子, 大西康, 石澤賢一, 亀岡淳一, 張替秀郎

第３４回日本造血幹細胞移植学会総会　2012/02/24
The safety of short-course fludarabine and rituzimab followed by yttrium-90 ibritumomab tiuxetan.

Himuro M, Kamata M, Kimura J, Sasaki T, Kimura T, Takagawa M, Niitu H, Sasaki O, Tohmiya Y, Harazaki Y, Ine S, Nomura J, Meguro K, Yokoyama H, Inokura K, Ohba R, Kohata K, Oonishi Y, Fukuhara N, Katuoka Y, Yamamoto J, Ishizawa K, Kameoka J, Harigae H

第７３回日本血液学会学術集会　2011/10/14
Transcription Factor GATA2 Regulates the Differentiation of Mesenchymal Stem Cells(MSC)

Mayumi Kamata, Yoko Okitsu, Tohru Fujiwara, Rie Ohba, Yuna Katsuoka, Noriko Fukuhara, Katsura Kohata, Hiroto Ohguchi, Yasushi Onishi, Joji Yamamoto, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
Expression profiling of ETO2-regulated genes in erythroid cells.

Yarob Wael Alqadi, Tohru Fujiwara, Yoko Okitsu, Katsura Kohata, Noriko Fukuhara, Yasushi Onishi, Joji Yamamoto, Kenichi Ishizawa, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
Efficacy of 90 ibritumomab tiuxetan for low grade B cell lymphoma:analysis of long term responders.

Kamata M, Kimura J, Niitu H, Kimura T, Sasaki T, Takagawa M, Sasaki O, Harasaki Y, Tohmiya Y, Ine S, Yokoyama H, Nomura J, Kameoka Y, Inokura K, Fukuhara N, Katsuoka Y, Ohba R, Kohata K, Oonishi Y, Yamamoto J, Ishizawa K, Harigae H

第７３回日本血液学会学術集会　2011/10/14
The safety of short-course fludarabine and rituzimab followed by yttrium-90 ibritumomab tiuxetan

Masahito Himuro, Mayumi Kamata, Jyun Kimura, Toru Sasaki, Tomofumi Kimura, Masanori Takagawa, Hidetaka Niitu, Osamu Sasaki, Yasuo Tohmiya, Yoriko Harazaki, Syoji Ine, Jyun Nomura, Kuniaki Meguro, Hisayuki Yokoyama, Kyoko Inokura, Rie Ohba, Katsura Kohata, Yasushi Oonishi, Noriko Fukuhara, Yuna Katuoka, Jyoji Yamamoto, Kenichi Ishizawa, Jyunichi Kameoka, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
Transcription Factor GATA2 Regulates the Differentiation of Mesenchymal Stem Cells(MSC)

Mayumi Kamata, Yoko Okitsu, Tohru Fujiwara, Rie Ohba, Yuna Katsuoka, Noriko Fukuhara, Katsura Kohata, Hiroto Ohguchi, Yasushi Onishi, Joji Yamamoto, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
Expression profiling of ETO2-regulated genes in erythroid cells

Yarob Wael Alqadi, Tohru Fujiwara, Yoko Okitsu, Katsura Kohata, Noriko Fukuhara, Yasushi Onishi, Joji Yamamoto, Kenichi Ishizawa, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
Efficacy of 90 ibritumomab tiuxetan for low grade B cell lymphoma:analysis of long term responders.

Mayumi Kamata, Jun Kimura, Hidetaka Niitu, Tomohumi Kimura, Toru Sasaki, Masanori Takagawa, Osamu Sasaki, Yoriko Harasaki, Yasuo Tohmiya, Syoji Ine, Hisayuki Yokoyama, Jun Nomura, Yoshihiro Kameoka, Kyoko Inokura, Noriko Fukuhara, Yuna Katsuoka, Rie Ohba, Katsura Kohata, Yasushi Oonishi, Joji Yamamoto, Kenichi Ishizawa, Hideo Harigae

第７３回日本血液学会学術集会　2011/10/14
再生不良性貧血に対して免疫抑制療法後、急性骨髄性白血病に移行した１例

山崎有人, 福原規子, 猪倉恭子, 大場理恵, 勝岡優奈, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

第194回日本内科学会東北地方会　2011/09/10
生不良性貧血に対して免疫抑制療法後、急性骨髄性白血病に移行した１例

山崎有人, 福原規子, 猪倉恭子, 大場理恵, 勝岡優奈, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

第194回日本内科学会東北地方会　2011/09/10
ＦＩＳＨ法によるＩｇＨ転座解析を用いた濾胞性リンパ腫骨髄浸潤の検出

木幡桂, 大口裕人, 福原規子, 大場理恵, 勝岡優奈, 大西康, 山本譲司, 石澤賢一, 張替秀郎, 一迫玲, 安久美子, 藤巻慎一, 賀来満夫

第9回日本臨床腫瘍学会学術集会　2011/07/21
Mantle cell lymphoma: a clinicopathological analysis of long-term survivors

福原規子, 原崎頼子, 井根省二, 遠宮靖雄, 佐々木治, 猪倉恭子, 大場理恵, 勝岡優奈, 大口裕人, 大西康, 木幡桂, 山本譲司, 石澤賢一, 一迫玲, 張替秀郎

日本臨床腫瘍学会学術集会　2011/07/21
Flu/CY/ATGの前処置にてATGを先行投与し同種骨髄移植を施行した再生不良性貧血の１例

大場理恵, 猪倉恭子, 勝岡優奈, 沖津庸子, 福原規子, 大口裕人, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

第３３回日本造血細胞移植学会総会　2011/03/09
再発に対して２回目の同系移植を施行した形質細胞性白血病の１例

猪倉恭子, 大場理恵, 勝岡優奈, 沖津庸子, 福原規子, 大口裕人, 木幡桂, 大西康, 山本譲司, 石澤賢一, 峰岸正好, 張替秀郎

第３３回日本造血細胞移植学会総会　2011/03/09
フルダラビン+大量エンドキサン+TBI 4Gyを前処置に用いた臍帯血移植の検討

大西康, 大場理恵, 猪倉恭子, 勝岡優奈, 沖津庸子, 木幡桂, 福原規子, 大口裕人, 山本譲司, 石澤賢一, 張替秀郎

第３３回日本造血細胞移植学会総会　2011/03/09
排尿障害で発症し定位脳生検で診断がついたIVLBCLの症例

吉野優樹, 猪倉恭子, 大口裕人, 大場理恵, 沖津庸子, 木幡桂, 大西康, 福原規子, 山本譲司, 張替秀郎

第193回日本内科学会東北地方会　2011/02/19
Enteropathy-associated T-cell lymphoma:a clinicopathological analysis from MIYAGI study group

福原規子, 鎌田真弓, 山本譲司, 横山寿行, 髙橋太郎, 石川泉, 菅原知広, 高川真徳, 佐々木治, 勝岡優奈, 三浦由紀子, 大場理恵, 沖津庸子, 木幡桂, 大口裕人, 大西康, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

第７２回日本血液学会学術集会　2010/09/24
Safety of 90Y-ibritumomab tiuxetan for refractory/relapsed low grade B cell lymphoma

鎌田真弓, 木村淳, 新津秀孝, 木村朋文, 佐々木徹, 高川真徳, 佐々木治, 原崎頼子, 遠宮靖雄, 井根省二, 横山寿行, 猪倉恭子, 小林匡洋, 沖津庸子, 福原規子, 大場理恵, 木幡桂, 大西康, 山本譲司, 石澤賢一, 亀岡淳一, 張替秀郎

第７２回日本血液学会学術集会　2010/09/24
Allogeneic HSCT following imatinib/dasatinib for patients with CML in accelerated and blastic phase.

Yasushi Onishi, Osamu Sasaki, Yuna Katsuoka, Masahiro Kobayashi, Mayumi Kamata, Rie Ohba, Yoko Okitsu, Katsura Kohata, Hiroto Ohguchi, Noriko Fukuhara, Hisayuki Yokoyama, Joji Yamamoto, Kenichi Ishizawa, Hideo Harigae

第７２回日本血液学会学術集会　2010/09/24
Successful treatment of POEMS syndrome with bortezomib therapy.

Hiroto Ohguchi, Masahiro Kobayashi, Mayumi Kamata, Kyoko Inokura, Yoko Okitsu, Rie Oba, Noriko Fukuhara, Yasushi Onishi, Katsura Kohata, Joji Yamamoto, Kenichi Ishizawa, Hideo Harigae

第７２回日本血液学会学術集会　2010/09/24
慢性骨髄性白血病慢性期に急性前骨髄球性白血病を合併した１例

猪倉恭子, 大場理恵, 福原規子, 沖津庸子, 大口裕人, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

第１９２回日本内科学会東北地方会　2010/09/04
妊娠合併ＩＴＰ症例の後方視的検討

沖津庸子, 亀岡淳一, 鎌田真弓, 小林匡洋, 大場理恵, 福原規子, 大口裕人, 木幡桂, 山本譲司, 横山寿行, 千坂泰, 石澤賢一, 鈴木宗三, 八重樫伸夫, 張替秀郎

第３３回日本血栓止血学会学術集会　2010/04/22
再発・難治低悪性度リンパ腫に対する９０Ｙ－イブリツモマブ・チイウキセタン療法の有効性・安全性の検討

鎌田真弓, 木村淳, 新津秀孝, 木村朋文, 小林匡洋, 沖津庸子, 福原規子, 大場理恵, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

第８回日本臨床腫瘍学会　2010/03/18
Ph染色体異常を有するＢ細胞性白血病の病態解析

鈴木真紀子, 市川聡, 中嶌真治, 大口裕人, 沖津庸子, 木幡桂, 福原規子, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 関正則, 遠宮靖雄, 張替秀郎

第７１回日本血液学会学術集会　2009/10/23
ＦＩＳＨ法によるIgH転座解析を用いた濾胞性リンパ腫骨髄浸潤の検出

木幡桂, 三浦由希子, 大口裕人, 沖津庸子, 福原規子, 大西康, 山本譲司, 石澤賢一, 亀岡淳一, 張替秀郎, 横山寿行, 一迫玲, 安久美子, 賀来満夫

第７１回日本血液学会学術集会　2009/10/23
Bortezomibが著効したIgM型多発性骨髄腫の１例

鎌田真弓, 山本譲司, 市川聡, 中嶌真治, 鈴木真紀子, 小林匡洋, 沖津庸子, 福原規子, 木幡桂, 大西康, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

第７１回日本血液学会学術集会　2009/10/23
フルダラビン、メルファランを用いた造血器腫瘍に対する同腫造血幹細胞移植-当科におけ

山本譲司, 鎌田真弓, 渡部龍, 小林匡洋, 市川聡, 中嶌真治, 鈴木真紀子, 井上あい, 三浦由希子, 沖津庸子, 木幡桂, 福原規子, 大西康, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第７１回日本血液学会学術集会　2009/10/23
宮城県における悪性リンパ腫の臨床および病理学的特徴

三浦由希子, 鎌田真弓, 小林匡洋, 中嶌真治, 市川聡, 鈴木真紀子, 井上あい, 沖津庸子, 大口裕人, 福原規子, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

第７１回日本血液学会学術集会　2009/10/23
診断に難渋し、bortezomibが奏効した形質細胞性白血病の一例

中嶌真治, 市川聡, 鈴木真紀子, 沖津庸子, 木幡桂, 福原規子, 大西康, 山本譲司, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎, 一迫玲

第107回日本血液学会東北地方会　2009/02/22
東北大学グループで施行した寛解期Philadelphia染色体陽性急性リンパ性白血病に対する同種臍帯血移植成績―非血縁者間同種骨髄移植との比較

市川聡, 中嶌真治, 鈴木真紀子, 高橋太郎, 井上あい, 沖津庸子, 木幡桂, 藤原亨, 福原規子, 大西康, 山本譲司, 山田実名美, 石澤賢一, 佐々木治, 遠宮靖雄, 原崎頼子, 奥田光崇, 亀岡淳一, 張替秀郎

第31回日本造血幹細胞移植学会総会　2009/02/05
東北大学病院における慢性期CMLに対するimatinibの治療成績

山本譲司, 市川聡, 白井剛志, 中嶌真治, 鈴木真紀子, 高橋太郎, 田島結実, 井上あい, 三浦由紀子, 沖津庸子, 木幡桂, 藤原亨, 福原規子, 大西康, 山田実名美, 石澤賢一亀岡淳一, 張替秀郎

第１５回日本遺伝子診療学会大会　2008/08/01
歩行時息切れを契機に診断された多発性筋炎を伴う慢性ＧＶＨＤの1例

高橋太郎, 井根省二, 鈴木真紀子, 井上あい, 大口裕人, 藤原亨, 阿部正理, 大西康, 福原規子, 山本譲司, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第30回日本造血細胞移植学会総会　2008/02/29
T-cell prolymphocytic leukemia(T-PLL) の4例

鈴木真紀子, 井上あい, 高橋太郎, 福原規子, 大口裕人, 沖津庸子, 阿部正理, 山本譲司, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

第104回日本血液学会・第49回日本臨床血液学会合同東北地方会　2007/09/01
完全房室ブロックを契機に診断に至ったびまん性大細胞型B細胞リンパ腫心臓浸潤の1例

木葉大地, 市川聡, 道満剛之, 田中悠也, 猪倉恭子, 福原規子, 横山寿行, 鈴木秀明, 安田聡, 張替秀郎

第224回日本内科学会東北地方会 WEB
同種造血幹細胞移植後の菌血症に対しバック法で採取した顆粒球輸血を行った 2 症例

横山寿行, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 島貫美和子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第 119 回日本輸血・細胞治療学会東北支部例会 WEB
CD45かつCD30陽性のため悪性リンパ腫と鑑別を要した未分化神経内分泌腫瘍の1例

諸田直哉, 小野寺晃一, 齋藤良太, 道又大吾, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第223回日本内科学会東北地方会 WEB
血球貪食症候群を伴い発症したTCR陰性末梢性T細胞リンパ腫、非特定型の一例

澤田拓実, 諸田直哉, 小野浩弥, 道又大吾, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
CRAB症候にて発症した骨髄原発B細胞リンパ腫の一例

道満剛之, 市川聡, 猪倉恭子, 櫻井一貴, 木葉大地, 田中悠也, 福原規子, 横山寿行, 小野寺晃一, 大西康, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
BCR-ABL1陽性急性骨髄性白血病（AML with BCR-ABLの2例

櫻井一貴, 勝岡優奈, 横山寿行, 斎藤慧, 八田俊介, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 大西康, 和泉透, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
移植後早期再発した急性巨核芽球性白血病に対して臍帯血移植を行い長期寛解を達成した一例

櫻井一貴, 市川聡, 齋藤慧, 猪倉恭子, 福原規子, 横山寿行, 小野寺晃一, 大西康, 藤原亨, 亀岡淳一, 張替秀郎

第131回日本血液学会東北地方会（WEB)
再発難治性浸潤性胸腺腫に併発した赤芽球癆に対してシクロスポリンが著効した1例

橋本和貴, 市川聡, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 高橋昌宏, 張替秀郎

第222回日本内科学会東北地方会 WEB
気道感染を契機に重篤な出血症状を伴って発症した後天性第X因子欠乏の1例

八木櫻子, 市川聡, 齋藤慧, 福原規子, 小野寺晃一, 大西康, 横山寿行, 藤原実名美, 張替秀郎

第221回日本内科学会東北地方会
SAA に対するuBMT 後に、肝多発腫瘤で発症しR-EPOCH 療法が有効であったPTLD の1 例

中川諒, 大西康, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 藤原亨, 福原規子, 横山寿行, 藤原実名美, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
直接作用型抗ウイルス薬治療後のHCV 再活性化を認めた急性骨髄性白血病に対する臍帯血移植の一例

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
Comparison of the outcomes between cord blood transplantation and BMT/PBSCT from young or elderly donors
臍帯血移植後の末梢血単球絶対数が移植成績に及ぼす影響

小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
｢成人難治性血液悪性腫瘍に対する非血縁者間臍帯血移植の有効性に関する研究（臨床第Ⅱ相試験）｣（C-SHOT 0601）

澤正史, 寺倉精太郎, 西田徹也, 加藤智則, 宮尾康太郎, 小澤幸泰, 河野彰夫, 大西康, 福原規子, 笠井雅信, 藤井伸治, 横山寿行, 飯田浩充, 兼村信宏, 藤枝敦史, 吾郷浩厚, 堤豊, 中村文彦, 野吾和宏, 森内幸美, 太田秀一, 大橋春彦, 柳澤昌実, 鈴木律朗, 鍬塚八千代, 熱田由子, 宮村耕一, 村田誠

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
急性骨髄性白血病においてHLA-DR の発現が同種移植の予後に与える影響についての検討

李尹河, 田中悠也, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
節外性NK/T 細胞リンパ腫の同種移植後早期再発に対して短期L-asparaginase 投与が著効した一例

市川聡, 福原規子, 齋藤慧, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

第129回日本血液学会東北地方会
ルキソリチニブ投与中に低悪性度B細胞性リンパ腫を発症した原発性骨髄線維症の1例

戒能明, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第219回日本内科学会東北地方会
MelDex療法にて臓器障害が改善し安全に自家末梢血幹細胞移植を施行し得た全身性ALアミロイドーシスの1例

山口知暁, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第218回日本内科学会東北地方会　2019/09/28

Show all Show first 5

Research Projects 4

濾胞性リンパ腫の新規予後予測モデルの開発

福原規子, 一迫玲

Offer Organization: 日本学術振興会

System: 科学研究費助成事業

Category: 基盤研究(C)

Institution: 東北大学

2022/04/01 - 2025/03/31
未治療低腫瘍量濾胞性リンパ腫に対するリツキシマブ早期介入に関するランダム化比較第III相試験

石澤賢一, 福原規子, 丸山大, 前島亜希子, 亀岡吉弘, 蒔田真一, 山本一仁, 島田和之, 宮崎香奈, 古林勉, 口分田貴裕, 田村志宣, ほか

Offer Organization: 国立研究開発法人日本医療研究開発機構

System: 日本医療研究開発機構研究費

Category: 革新的がん医療実用化研究事業

Institution: 山形大学、東北大学、公益財団法人がん研究会有明病院、国立がん研究センター中央病院、秋田大学ほか

2021/04 - 2024/03
眼内悪性リンパ腫に対するブルトンキナーゼ阻害剤を用いた中枢再発予防法による医師主導多施設共同治験

田岡和城, 黒川峰夫, 遠山和博, 田中理恵, 蕪城俊克, 橋本大吾, 新田文彦, 福原規子ほか

Offer Organization: 国立研究開発法人日本医療研究開発機構

System: 日本医療研究開発機構研究費

Category: 革新的がん医療実用化研究事業

Institution: 東京大学、自治医科大学附属さいたま医療センター、北海道大学、東北大学ほか

2020/11 - 2022/03
高齢者多発性骨髄腫患者に対する至適な分子標的療法の確立と治療効果および有害事象を予測するバイオマーカーの探索的研究

Offer Organization: 国立研究開発法人日本医療研究開発機構

System: 革新的がん医療実用化研究事業

2014/04 - 2017/03